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ABSTRACT 
 
Peripheral biomarkers of cumulative exposure to n-hexane and predictive of its neurotoxicity 
were investigated through an analytical and a toxicological approach. 
Synthesis and identification of the standard pyrroles, dimethylpyrrole norleucine (DMPN), 
cysteine-pyrrole conjugate (DMPN NAC) and glutathione-pyrrole conjugate (DMPN GSH) was 
performed by LC-MS/MS and their identification was determined in urine of rats treated with 
2,5-hexanedione (2,5-HD), the main neurotoxic metabolite of n-hexane. 
Two in vivo assays were performed to investigate the toxicological meaning of excretion of 
DMPN and DMPN NAC and to study the protector/toxicity binomium induced by NAC on 2,5-
HD neurotoxicity. Wistar rats were treated with 4 doses of: 400 mg 2,5-HD/kg (Group I), 400 
mg 2,5-HD/kg + 200 mg NAC/kg (Group II), 200 mg NAC/kg (Group III) and with saline 
(Group IV) and the correlation between the changes on motor activity and the levels of urinary 
DMPN, DMPN NAC, and free 2,5-HD was performed. The results show a significant decrease 
(p<0.01) in urinary DMPN and free 2,5-HD, a significant increase (p<0.01) in DMPN NAC 
excretion and a significant recovery (p<0.01) on motor activity in rats co-treated with 2,5-
HD+NAC, as compared with rats treated with 2,5-HD alone. 
A second in vivo assay, was performed to deeper investigate the interference of NAC on 2,5-HD 
bioactivity co-treating the rats with 12 doses of 2,5-HD+NAC. Our results confirm that until the 
4
th
 dose NAC protects against 2,5-HD neurotoxicity, however, after that dose, there is a 
progressive increase of rats motor activity dysfunctions. Brain GSH levels were determined and 
the highest GSH/GSSG ratio was found in co-treated rats, indicating that NAC induces GSH 
brain recovery, nevertheless, this effect was not accompanied by the recovery of motor activities. 
A preliminary study, was implemented in humans, where were identified 2,5-HD and DMPN in 
urine of an healthy and on a neurodegenerative disease population. Finally, the results suggest 
that DMPN is a sensitive and specific biomarker of 2,5-HD exposure and NAC interacts with 
2,5-HD in a biphasic manner: initially protecting against its neurotoxicity and progressively 
attenuating this effect, and at higher doses inducing toxicity in rats co-treated with 2,5-
HD+NAC. 
Keywords: 2,5-HD; Neurotoxicity; NAC; Pyrrole compounds; Urinary biomarkers; Behavioral 
assays; LC-MS/MS. 
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RESUMO 
 
O trabalho apresentado nesta tese está inserido na área de Toxicologia, e pretende ser uma 
contribuição para a selecção de biomarcadores específicos a serem aplicados no controle e 
prevenção da neurotoxicidade em populações de risco, utilizando uma abordagem analítica e 
uma toxicológica para o seu desenvolvimento.  
Sendo o controlo e prevenção da exposição humana a produtos químicos neurotóxicos uma área 
importante de pesquisa que certamente contribui para a promoção da saúde pública, pretende-se 
contribuir para a implementação de medidas de modo a controlar e prevenir a neurotoxicidade 
induzida pela 2,5-hexanodiona (2,5-HD) estudando alternativas de biomarcadores de exposição e 
efeito. 
Introdução: A exposição crónica ao n-hexano induz neuropatias periféricas classificadas 
como atrofia axonal no sistema nervoso periférico (SNP) e sistema nervoso central (SNC) tanto 
em seres humanos como em animais. Estudos in vivo e in vitro demonstraram que o metabolito 
responsável pela sua neurotoxicidade é a 2,5-HD. A via metabólica de destoxificação deste 
solvente também conduz à formação de 4,5-dihidroxi-2-hexanona que é excretada através da 
urina na forma de conjugado glucorónico. Deste modo, a 2,5-HD e o composto 4,5-dihidroxi-2-
hexanona excretados através da urina foram utilizados em análises de rotina como 
biomarcadores de exposição ocupacional ao n-hexano, sendo a soma dos seus níveis denominada 
2,5-HD Total. Em 2001 a Conferência Americana de Higienistas Industriais Governamentais, 
alterou o Índice de Exposição Biológica ao n-hexano para apenas 2,5-HD, recomendando a 
determinação de 2,5-HD Livre em vez da Total. Na verdade, a 2,5-HD Livre pode ser 
considerado um bom biomarcador analítico que nos permite avaliar a quantidade de 2,5-HD que 
escapa ao processo de destoxificação sendo portanto um melhor indicador preditivo do risco de 
neurotoxicidade. Estudos mecanísticos mostraram que a administração de 2,5-HD, uma γ-
dicetona, a animais experimentais, leva à formação de 2,5-DMP (2,5-dimetilpirrol). A formação 
destes aductos pirrol é originada através da ligação selectiva da 2,5-HD a grupos ɛ-amino das 
lisinas existentes nas proteínas de determinados neurofilamentos do citoesqueleto axonal. Após 
este passo, ocorrem reacções de autoxidação secundárias do 2,5-DMP que originam 
intermediários electrofílicos pirrolil-metilo. Estes, por sua vez, reagem com pirróis ainda não 
autoxidados, formando-se dímeros que produzem ligações cruzadas intra e intermoleculares nas 
proteínas dos neurofilamentos axonais. De facto, alterações na expressão das proteínas por γ-
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dicetonas podem provocar danos a nível da estrutura/membrana e refletir mudanças na síntese de 
proteínas e/ou na degradação após modificações pós-tradução, possivelmente devido à formação 
dos aductos com a γ-dicetona e reacções de crosslinking (polimerização). Vários autores 
consideram este conjunto de eventos, o responsável pela indução de disfunções motoras 
sensoriais, observadas em seres humanos e animais experimentais. Os efeitos neurotóxicos 
provocados pela exposição ao n-hexano, reflectem alterações comportamentais, que podem ser 
medidas e utilizadas para rastrear o desenvolvimento progressivo da neurotoxicidade durante a 
exposição a longo prazo. Estes testes são bastante sensíveis, permitindo detectar alterações 
progressivas a nível das disfunções motoras em função do tempo de exposição ao n-hexano ou à 
2,5-HD.  
Além das reacções anteriores, podem ainda ocorrer reacções de dimerização do 2,5-DMP em 
cadeia, devido à presença de radicais livres. Se estas reacções ocorrerem na presença de 
nucleófilos biológicos como a N-acetil-L-cisteína (NAC) e glutationa reduzida (GSH), estes 
antioxidantes podem directa ou indirectamente afectar estas reacções de dimerização, levando à 
inibição deste processo. Sendo a NAC um precursor da L-cisteína, é uma excelente fonte de 
grupos sulfidrilo (SH) que estimula e restaura a glutationa reduzida celular (GSH), aumentando o 
seu aporte no organismo. O papel da NAC para a protecção do SNC foi investigado por 
Banaclocha (2001), que propôs um mecanismo de acção potencial para a NAC baseado no 
pressuposto de que a NAC pode atravessar a barreira hemato-encefálica e exercer os seus efeitos 
benéficos a nível do SNC. Estudos in vitro mostraram a formação de aductos pirrólicos 
secundários estáveis com os grupos sulfidrilo da cisteína, os quais podem inibir a reacção de 
crosslinking pirrol-pirrol. Ao formarem estes aductos pirrólicos secundários, podem 
provavelmente inibir o processo responsável pela neurotoxicidade da 2,5-HD. No entanto, a 
formação dos vários aductos pirrólicos pode igualmente ser associada a certas patologias 
neurodegenerativas, como a doença de Alzheimer, devido à peroxidação lipídica. Assim, torna-
se importante o estudo de agentes protectores e/ou antagonistas que possam interferir no 
mecanismo de formação desses aductos pirrólicos. 
Metodologia: Para atingir este objectivo foi realizada inicialmente a síntese de compostos 
pirrólicos padrão: DMPN (dimetilpirrol norleucina), DMPN NAC (conjugado da DMPN com a 
N-acetil-L-cisteína, NAC) e DMPN GSH (conjugado da DMPN com a glutationa, GSH). A sua 
síntese foi confirmada pelo seu estudo por ESI-LC-MS/MS. A identificação destes derivados 
pirrólicos na urina de ratos expostos à 2,5-HD, pretendeu permitir selecionar um biomarcador 
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periférico preditivo adequado à neurotoxicidade desta. Assim, a análise dos derivados pirrólicos 
na urina de ratos, foi feita através de um estudo in vivo: ratos tratados, por via ip, com 2,5-HD 
(400 mg/kg de peso corporal/48-h) permitindo pela primeira vez a identificação dos vários 
compostos pirrólicos, nomeadamente DMPN, DMPN NAC, DMPN GSH e 2,5-DMP. Procedeu-
se também à quantificação de DMPN e DMPN NAC. Considerando que é importante controlar a 
exposição a agentes neurotóxicos estudando agentes protectores e/ou antagonistas que podem 
reduzir as patologias devidas à exposição ambiental/ocupacional, a interferência da NAC na 
neurotoxicidade da 2,5-HD foi avaliada através de outro estudo in vivo. Trataram-se ratos Wistar 
com 4 doses de 400 mg de 2,5-HD/kg de peso corporal/48-h (Grupo I), 400 mg de 2,5-HD/kg de 
peso corporal/48-h + 200 mg NAC/kg de peso corporal (Grupo II), 200 mg NAC/kg de peso 
corporal (Grupo III) e com solução salina, via ip (Grupo IV). A 2,5 HD foi administrada aos 
animais por via ip e a NAC por via oral, na água bebível. Procedeu-se a ensaios 
comportamentais (ambulation e rearing) e à análise na urina dos valores urinários de DMPN e 
DMPN NAC por ESI-LC-MS/MS. Também se efectuou a detecção e análise da 2,5-HD urinária 
por GC-MS e quantificou-se a 2,5-HD Livre e Total. Para avaliar o binómio protector/toxicidade 
induzido pela NAC na neurotoxicidade da 2,5-HD procedeu-se a um novo ensaio in vivo. Este 
estudo foi realizado aumentando o tempo de exposição, tratando-se agora os ratos com 12 doses 
de 2,5-HD. Durante este estudo determinou-se as alterações nos biomarcadores urinários 
seleccionados, DMPN, DMPN NAC e 2,5-HD Livre, assim como alterações no desempenho da 
actividade motora. No final da experiência foi estudado o mecanismo de interferência da NAC 
na neurotoxicidade da 2,5-HD quantificando a L-cisteína e a GSH no cérebro de rato. Foi 
igualmente investigado se seria possível identificar os biomarcadores seleccionados, 2,5-HD, 
DMPN e DMPN NAC na urina de uma população saudável e na de pacientes com doenças 
neurodegenerativas.  
Resultados: através do estudo dos padrões sintetizados e utilizando como técnica analítica 
ESI-LC-MS/MS, foi possível identificar e confirmar pela primeira vez, a presença dos 
compostos pirrólicos DMPN, DMPN NAC, DMPN GSH e 2,5-DMP na urina dos animais 
expostos à 2,5-HD (400 mg/kg de peso corporal/48h). Os compostos 2,5-HD e DMPN 
apresentaram os níveis urinários mais elevados de todos os compostos analisados na urina de 
ratos expostos. A comparação entre a excreção de DMPN e de DMPN NAC evidenciou a 
elevada excreção urinária de DMPN relativamente ao DMPN NAC urinário, e a correlação linear 
entre os níveis urinários de DMPN ou DMPN NAC e as doses administradas. Relativamente ao 
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estudo in vivo em que os ratos foram tratados com 4 doses de 2,5-HD e co-tratados com 2,5-
HD+NAC, os resultados mostraram uma diminuição significativa (p<0,01) da DMPN urinária e 
2,5-HD Livre e um aumento significativo (p<0,01) na excreção da DMPN NAC e 2,5-HD Total. 
Verificou-se igualmente uma recuperação significativa (p<0,01) da actividade motora (estudo do 
andamento na horizontal, e estudo da colocação na posição vertical dos animais) nos ratos do 
Grupo II, quando comparada com os ratos do Grupo I. Estes resultados indicam que a NAC 
poderá ter um efeito protector na neurotoxicidade da 2,5-HD. Após o estudo in vivo em que se 
pretendia avaliar o binómio protector/toxicidade induzido pela NAC, na neurotoxicidade da 2,5-
HD, aumentado-se para isso o tempo de exposição, e tratando-se agora os ratos com 12 doses de 
2,5-HD, os resultados obtidos mostraram que os animais tratados com 2,5-HD (Grupo I) e co-
tratados com 2,5-HD+NAC (Grupo II), têm uma diminuição significativa (p<0,01) dos seus 
pesos corporais e apresentam disfunções significativas na sua actividade motora. Há também 
uma diminuição significativa (p<0,01) da DMPN urinária e da 2,5-HD Livre. No entanto esta 
diminuição apenas é verificada até às 8 doses. Verificou-se um aumento significativo (p<0,01) 
na excreção da DMPN NAC para todas as doses. Assim, os resultados por nós obtidos mostram 
que depois de 4 doses, há uma redução progressiva do efeito de protecção da NAC e um ligeiro 
aumento de neurotoxicidade no Grupo II. Relativamente aos níveis de GSSG no cérebro dos 
animais, os animais dos Grupos II, III e IV apresentam perto de 10, 15,4 e 15,0% do valor de 
GSH Total, respectivamente, sendo as maiores concentrações de GSSG cerebrais encontradas 
nos animais tratados apenas com 2,5-HD (Grupo I), aproximadamente 42% da GSH Total. 
Ambos os Grupos I e II têm um valor inferior para a L-cisteína. A maior proporção de 
GSH/GSSG é observada no Grupo II, o que demonstra o papel antioxidante da NAC de modo a 
garantir a redução da GSSG. O Grupo I é o que apresenta menor valor para a razão GSH/GSSG. 
Sobre o estudo em pessoas saudáveis e pessoas com doenças neurodegenerativas, os nossos 
resultados mostraram que a 2,5-HD e o composto pirrólico DMPN foram identificados na urina 
de todos os indivíduos saudáveis assim como na urina dos pacientes. Verificou-se ainda a 
presença de vestígios de DMPN NAC, mas apenas na urina dos pacientes.  
Discussão e Conclusões: sugerimos que a fonte de DMPN nos animais apenas tratados com 
2,5-HD é devida à formação de aductos primários amino-pirrol (N-acetil-lisina pirrolizados), e a 
fonte de conjugados de cisteína é devida à formação de conjugados de cisteína pirrolizados, 
DMPN NAC, ou seja, aductos tiol-pirrol. Estes dois tipos de aductos podem ocorrer na maioria 
das proteínas, mas os resultados obtidos confirmam que os aductos de amino-pirrol são formados 
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em quantidades muito mais elevadas, o que pode ser explicado pelo baixo nível de tióis livres 
presentes na maior parte das proteínas. Relativamente ao conjugado DMPN GSH e ao composto 
pirrólico 2,5-DMP estes pirróis foram detectados, mas os seus níveis estavam abaixo do limite de 
quantificação do método analítico utilizado (52,6 nmol/mL). Em conclusão, DMPN é um forte 
candidato a ser proposto como um novo biomarcador de exposição à 2,5-HD. No 2º estudo in 
vivo a correlação entre os níveis de 2,5-HD, DMPN, DMPN NAC e DMPN GSH urinários e o 
desempenho da atividade motora nos ratos dos Grupos I e II foram determinados para clarificar a 
sua utilização como biomarcadores e investigar o papel da NAC na protecção perante a 
neurotoxicidade da 2,5-HD. A interferência da NAC na neurotoxicidade da 2,5-HD foi 
evidenciada por uma diminuição significativa nos níveis de 2,5-HD e DMPN urinários, um 
aumento significativo dos níveis de DMPN NAC urinários e uma recuperação significativa das 
atividades motoras neurocomportamentais nos animais do Grupo II, quando comparados com os 
seus valores em ratos tratados com a 2,5-HD (Grupo I). A escolha dos endpoints 
comportamentais para prever a neurotoxicidade da 2,5-HD foi baseada no seu uso frequente para 
identificar alterações induzidas por produtos químicos nas funções do sistema nervoso, uma vez 
que são habitualmente utilizados como indicadores sensíveis da diminuição da actividade motora 
provocada pela 2,5-HD. Esta constatação preliminar indica que, para as quatro doses 
administradas de 2,5-HD, a NAC tem um papel protector perante a neurotoxicidade da 2,5-HD. 
Com base no mecanismo de neurotoxicidade desta molécula, em que esta reage com grupos 
amino da lisina, formando os aductos pirrólicos, estes resultados podem ser explicados 
considerando que a formação de DMPN depende directamente da reacção entre a γ-dicetona e o 
grupo ε-amino da lisina nas proteínas. Efectivamente, os nossos resultados mostraram que em 
ratos co-tratados com 2,5-HD+NAC (Grupo II) observa-se uma diminuição significativa da 2,5-
HD Livre urinária em relação aos seus níveis urinários em ratos do Grupo I. Este facto está de 
acordo com a recuperação nas funções da atividade motora no Grupo II. Na verdade, é a 2,5-HD 
Livre que pode atingir os órgãos-alvo e ser responsável pela sua toxicidade. Uma diminuição de 
níveis de 2,5-HD Livre provavelmente explica a diminuição dos seus níveis urinários assim 
como dos nívei do DMPN, indicando também a redução da sua neurotoxicidade. A hipótese por 
nós colocada é que, nos animais do Grupo II, a 2,5-HD Livre pode reagir em parte com os 
resíduos tiol (SH) de cisteína da NAC ou com grupos sulfidrilo da GSH, antes de atingir os 
grupos ε-amino de resíduos da lisina nos neurofilamentos axonais. Níveis de 2,5-HD Total 
encontrados nos animais co-tratados foram mais elevados que os encontrados no Grupo I. Este 
RESUME 
xliii 
resultado pode ser explicado considerando que a 2,5-HD Total, corresponde essencialmente a 
produtos conjugados de biotransformação, sugerindo que a NAC pode contribuir para a 
destoxificação da 2,5-HD. Também se verificou que os ratos do Grupo II mostraram um 
aumento significativo da concentração de DMPN NAC, em comparação com os seus níveis em 
ratos do Grupo I. Este aumento dos níveis de DMPN NAC pode ser associada à inibição da 
autoxidação dos pirróis, permanecendo o DMPN livre para se ligar à NAC ou à GSH. De facto, 
uma vez que a formação dos pirróis não é suficiente para causar neuropatia, sugere-se que a 
NAC induz o aumento de tióis biológicos, os quais podem contribuir indirectamente para 
impedir a progressão da neuropatia induzida pela 2,5-HD, por promover a desintoxicação de 
ROS, reduzindo a probabilidade de autoxidação dos pirróis, a subsequente reacção de 
crosslinking pirrolil-pirrol e o desenvolvimento de neuropatias. Esta hipótese pode explicar a 
recuperação das atividades motoras nos ratos do Grupo II. Estes resultados sugerem que nas 
condições estudadas a NAC protege contra a neurotoxicidade da 2,5-HD. No 3º estudo in vivo 
em que se pretendeu estudar o binómio protecção/toxicidade induzido pela NAC na 
neurotoxicidade da 2,5-HD, esta interferência foi evidenciado por uma diminuição significativa 
nos níveis urinários da 2,5-HD Livre e do DMPN até às 8 doses no Grupo II em relação ao 
Grupo I. No entanto, esta diminuição deixou de ser significativa após as 12 doses de tratamento. 
Verificou-se igualmente um aumento significativo do DMPN NAC urinário no Grupo II em 
relação ao Grupo I para todas as doses administradas. Os dados comportamentais referidos no 
estudo anterior foram confirmados porque ocorreu uma recuperação significativa do desempenho 
da atividade motora no Grupo II, até às 4 doses. No entanto, também foi evidente que esse efeito 
protector diminuiu progressivamente ao longo do tempo de co-tratamento e a partir da 8ª dose 
não houve qualquer diferença significativa no desempenho comportamental entre os Grupos I e 
II. Além disso, para a 12ª dose verificou-se que houve uma inversão do efeito protector da NAC 
passando provavelmente a produzir efeitos tóxicos. O DMPN NAC, é um composto mais estável 
do que os outros compostos resultantes da acção da 2,5-HD sobre aminoácidos, peptídeos e 
proteínas, tendo sido referido recentemente, que devido à sua grande estabilidade, os aductos 
formados entre o eletrófilo DMPN e os grupos sulfidrilo tiolato podem ser irreversíveis. Neste 
contexto, sabendo que DMPN NAC, é um composto mais estável do que DMPN, talvez ele se 
possa acumular no sistema nervoso, induzindo toxicidade retardada nos animais co-tratados do 
Grupo II. Consequentemente, outra hipótese é que o neurotóxico eletrofílico DMPN, aducte 
seletivamente a tiolatos-receptor (como o NO) em tríades catalíticas o que resulta em perda de 
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neurotransmissão, com implicações substanciais para a função da proteína e toxicidade pré-
sináptica subsequente. LoPachin e Barber (2006), referem que um grande número de produtos 
químicos estruturalmente electrófilos causam disfunção sináptica por mecanismos 
desconhecidos. Grupos tiolato cisteína altamente nucleofílicos, dentro de proteínas sinápticas 
constituem alvos para neurotóxicos eletrófilos que compartilham a capacidade de aductar ou 
modificar grupos sulfidrilo nucleofílicos. Assim, neurotóxicos electrófilos podem produzir 
toxicidade sináptica, modificando esses tióis já que a maioria das proteínas contém resíduos de 
cisteína. Estes locais sulfidril-tiolato permitem regular a atividade de proteínas, desempenhando 
um papel direto no processo catalítico enzimático e num amplo espectro de actividades 
sinápticas, actuando como receptores de óxido nítrico (NO), e outros moduladores redox (H2O2) 
que transitoriamente permitem regular funções enzimáticas. Como conclusão, referimos que a 
hipótese de que o co-tratamento de ratos com 2,5-HD+NAC tem um efeito oposto dependente da 
dose: em primeiro lugar, inibindo a formação de ligações cruzadas DMPN em neurofilamentos 
axionais e protegendo contra a neurotoxicidade da 2,5-HD, em segundo lugar acumulando os 
aductos formados DMPN NAC (persistentes), que depois de atingir um valor limite induzem 
neurotoxicidade por mecanismos desconhecidos. Relativamente ao mecanismo de interacção da 
NAC na neurotoxicidade da 2,5-HD através da determinação dos níveis de GSH do cérebro e de 
cisteína em ratos tratados com 12 doses de (2,5-HD+NAC), há que referir que o cérebro tem uma 
potencial capacidade oxidativa, no entanto limitada para compensar o stresse oxidativo. Dentro 
da célula, as espécies reactivas de oxigénio (ROS) em condições normais estão fisiologicamente 
presentes em concentrações mínimas, havendo um equilíbrio no estado estacionário entre pró-
oxidantes e antioxidantes, o que é necessário para assegurar a eficiência óptima de defesas 
antioxidantes.  No entanto, quando a taxa de geração de radicais livres exceder a capacidade de 
defesa antioxidante, o stress oxidativo segue com consequentes danos graves para as proteínas e 
lípidos (Calabrese et al., 2008), e tem sido implicada em mecanismos que conduzem à lesão 
neuronal em vários estados patológicos do cérebro, incluindo doenças neurodegenerativas. De 
acordo com Stipanuk et al., (2006), o fígado de mamíferos regula a quantidade de cisteína, 
mesmo quando a ingestão de aminoácidos de enxofre é deficiente ou excessiva. Ao manter os 
níveis de cisteína dentro de um intervalo restrito e através da regulação da síntese de glutationa, a 
qual serve como um reservatório de cisteína, o fígado permite resolver quer a necessidade de ter 
a cisteína adequada para suportar o metabolismo normal, quer a necessidade de manter os níveis 
de cisteína abaixo do limite de toxicidade. Este regulação pode em parte explicar os valores mais 
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baixos de cisteína no cérebro de animais co-tratados, Grupo II e Grupo III, em comparação com 
os Grupos I e IV. Além disso, o aumento dos níveis de cisteína em tecidos nos grupos (2,5-
HD+NAC) e NAC pode levar à sua autoxidação formando cistina e ROS, levando assim à 
diminuição de conteúdo cerebral de L-cisteína. Estudos clínicos preliminares mostraram alguns 
benefícios na administração sistémica de NAC em algumas doenças neurológicas degenerativas, 
sendo que as concentrações de GSH aumentaram no plasma após administração crónica de NAC, 
podendo aumentar as concentrações de GSH no cérebro o que teria um efeito benéfico a nível do 
SNC. Vários autores referem que a glutationa encontrada em células de mamíferos existe 
principalmente na forma reduzida (GSH), sendo a GSSG < 5-10% da GSH Total sob condições 
fisiológicas normais. Os valores por nós obtidos para os Grupos II, III, e IV estão de acordo com 
estes valores encontrados por outros autores. Apenas no Grupo I apresentam uma GSSG de 42% 
da GSH Total. Também é para este grupo que se encontra o valor de GSH/GSSG mais baixo. 
Como é para o Grupo II que se observa o valor mais elevado de GSH/GSSG, podemos concluir o 
efectivo papel antioxidadante da NAC na redução da GSSG. Em conclusão, podemos dizer que 
os nossos resultados não esclarecem como a NAC interfere na taxa de neurotoxicidade da 2,5-
HD à medida que a relacão GSH/GSSG aumenta no cérebro em ratos co-tratados com 12 doses, 
(Grupo II), confirmando a sua função antioxidante no cérebro. No entanto, este aumento não está 
correlacionada com o aumento observado das disfunções neurocomportamentais nos mesmos 
ratos (Grupo II), o que significa que suas propriedades antioxidantes após 12 doses de tratamento 
não provocam efeitos protetores contra a neurotoxicidade da 2,5-HD. Relativamente ao estudo 
preliminar em adultos saudáveis e com doenças neurodegenerativas a presença de 2,5-HD na 
urina pode ser explicada pela exposição involuntária ao n-hexano pela população em geral, tanto 
como um micropoluente ubíquo, como por produção endógena de n-hexano e 2,5-HD, através de 
reacções do metabolismo e/ou peroxidação lipídica no corpo humano, tal como referido por 
vários autores. Ambas as hipóteses podem explicar o aparecimento de níveis de 2,5-HD em todas 
as amostras de urina analisadas. No que diz respeito ao DMPN urinário identificado em todas as 
amostras de urina, a sua origem é, provavelmente, devida à produção endógena de 2,5-HD e sua 
subsequente reacção com grupos amino da lisina. No entanto, será efectivamente preciso realizar 
um novo estudo com uma população saudável maior, onde serão quantificados tanto a 2,5-HD 
como o DMPN para confirmar estes resultados preliminares. O outro pirrol alvo, DMPN NAC, 
não foi detectado em amostras de urina controlo. Este resultado é interessante, considerando que 
nos Grupo III e IV também não foi possível quantificar DMPN NAC. No entanto, em todas as 
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nove amostras de urina de pacientes foi detectado DMPN NAC em quantidades vestigiais. No 
entanto, é muito difícil de interpretar a origem de DMPN NAC encontrado em algumas amostras 
de pacientes com diferentes doenças neurodegenerativas. Estudos do cérebro humano sugerem 
que o stresse oxidativo tem um papel importante na degeneração neuronal em pacientes mais 
velhos, e uma convergência de vários fatores (genética, idade e poluição ambiental) inicia uma 
cascata fisiopatológica comum que envolve stresse oxidativo, peroxidação lipídica e a 
consequente geração de produtos em regiões cerebrais específicas (LoPachin et al., 2008a,b): por 
exemplo, no hipocampo e neocortex cerebral nos pacientes com doença de Alzheimer. Assim, o 
aumento de produtos electrofílicos resultantes da peroxidação lipídica em indivíduos idosos pode 
produzir sinaptotoxicidade através da sua aducção a proteínas com grupos sulfidrilo 
nucleofílicos, que têm a função de mediadores intermediários de sinaptotoxicidade em muitas 
doenças neurodegenerativas. Em conclusão, é provável que, em parte, o DMPN urinário e 
DMPN NAC, detectados em pacientes possam ser devidos ao aumento da formação de aductos 
de pirrol com os grupos amino e sulfidrilo de proteínas que podem contribuir para os efeitos 
neurológicos observados em doenças neurodegenerativas. 
 
Palavras chave: 2,5-HD; Neurotoxicidade; NAC; Compostos pirrólicos; Biomarcadores 
urinários; Estudos comportamentais; LC-MS/MS.  
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1.1 n-HEXANE 
 
n-Hexane is one of the aliphatics hydrocarbon solvents with significant interest in occupational 
and environmental health because the repeated human exposure to this solvent may result in 
neurological disease (Spencer and Schaumburg, 1985). n-hexane (CAS Rnº 110-54-3) is a 
solvent that has many uses in the chemical and food industries, either in pure form or as a 
component of commercial hexane (US EPA/635/R-03/012). 
 
Hexane typically is present in mixed solvents products and may be found as pollutant at 
hazardous waste sites (Spencer and Schaumburg, 1985). The chemical is colorless, low-
molecular-weight liquid, relatively volatile, with a characteristic odor, and only slightly soluble 
water.  
It is a common component in lacquers, glues and glue thinner, and is widely used in numerous 
industrial processes, including cements, inks and adhesives, painting and coating products, 
laminating plastics, press proofing chemicals and cleaning agents (Fedtke and Bolt, 1986b; 
DeCaprio, 2000). This solvent is also used for manufacturing and processing leather and 
furniture, shoe manufacturing, as well as vulcanization of rubber and in dilution and extraction 
solvents in chemical laboratories (Damstra, 1978; Spencer et al., 1980). It is also used to extract 
vegetable oils for human consumption, as a benzene substitute in solvent applications (IPCS 122, 
1991; Arlien-Søborg, 1992; Huang, 2008; Tshala-Katumbay et al., 2009a) and as a solvent for 
the extraction of oils from seeds, such as cottonseed and sunflower seed (Stanley, 2002). 
The chemical is a minor constituent of crude oil and natural gas and, therefore, represents a 
variable proportion of different petroleum distillates. For example, n-hexane comprises about 
11.6% of unleaded gasoline and about 2% of aviation fuel (ATSDR, 1993a,b; US EPA/635/R-
03/012). The presence of n-hexane and its isomers in gasoline and fuels makes this solvent a 
ubiquitous pollutant to which the general population may be exposed (Brugnone et al., 1991; 
Perbellini et al., 1993; Bavazzano et al., 1998; Manini et al., 1998).  
n-Hexane is rapidly absorbed via inhalation in experimental animals and humans, and widely 
distributed to lipid rich tissues and organs such as the liver, spleen, kidneys, peripheral nerves 
brain and adrenal glands, with the latter three organs showing the highest levels (DeCaprio, 
2000; Huang, 2008). 
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Chronic exposure to n-hexane is one of the well-known causes of multiple disorders of the 
nervous system, defined as polyneuropathy, and has been reported in several cases of 
occupational exposure with inadequate ventilation. Japanese workers of small polyethylene 
laminating factories, in Nagoya, were reported as the first cases of n-hexane polyneuropathy in 
the world (Spencer et al., 1980; Iwata et al., 1983; Chang et al., 1993; Takeuchi, 2006). The 
workers suffered from muscle weakness and impaired sensory function of the hands and feet. 
Biopsy examination of nerves in leg muscles of the exposed workers showed loss of myelin and 
degeneration of axons. However, the symptoms of polyneuropathy were reversible with 
recovery, taking several years, after exposure was ended (Stanley, 2002). 
Awareness of this neurotoxic agent and implementation of preventive measures have increased 
in most industrialized countries, however occasional outbreaks continue (Baldasseroni et al., 
2003; Huang, 2008; Neghab et al., 2012). Because of the euphoric effects of n-hexane, teenagers 
are easily addicted to glue-sniffing (Damstra, 1978; Smith and Albers, 1997). Therefore glue-
sniffing neuropathy, also known as huffer’s neuropathy, after inhalation of glue vapors became a 
familiar neurological disease in 70’s (Goto et al., 1974; Spencer and Schaumburg, 1975, 1985; 
Fedtke and Bolt, 1986b). 
 
 
1.1.1 TOXICOKINETICS OF n-HEXANE (ADME) 
 
1.1.1.1 Absorption 
 
n-Hexane is a volatile lipophilic solvent that may be absorbed through inhalatory, oral, or by 
dermic route. Occupational exposure is mainly via inhalation, representing the skin a minor via 
of n-hexane absorption. 
 
Pulmonary retention in humans varies from 15%-30% over a wide range of exposure 
concentrations (DeCaprio, 2000). According to Mutti et al., (1984) alveolar retention is about 
25% of the inhaled n-hexane corresponding to a lung uptake of about 17%. The post exposure 
alveolar excretion was about 10% of the total uptake. The molecule of n-hexane crosses easily 
the alveolar-capillary membrane and enters the bloodstream (Brugnone et al., 1978; Veulemans 
et al., 1982). Thus, inhalation is the most rapid route of absorption. However, the inhalatory 
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uptake of n-hexane is dependent of several factors as the alveolar uptake, is greater in obese 
individuals, as well as during physical exercise, since total uptake of n-hexane increased slightly, 
due to the higher lung ventilation rate (IPCS 122, 1991).  
Previous work also demonstrated that the alveolar air concentrations of n-hexane are correlated 
with blood concentrations in industrial workers exposed to commercial hexane (Brugnone et al., 
1978; Mutti et al., 1984; Perbellini et al., 1986). 
 
In vivo toxicokinetics experiments were performed in male rats (F-344), exposed via inhalation 
to two concentrations (1000 ppm and 10000 ppm) of n-hexane. The absorption was rapid, 
reaching the plateau levels within 30 min in blood and within 2 h in the other tissues examined 
(liver, kidney, lungs, testis, brain, and sciatic nerve) (IPCS 122, 1991). 
 
Concerning n-hexane dermal exposure, the absorption is poor. In guinea-pigs Jakobson et al., 
(1982) and Tsuruta (1982) measured its penetration through excised rat skin and came to a 
similar conclusion. However, some case reports of percutaneous absorption of n-hexane, referred 
this solvent as the responsible of peripheral neuropathy in humans (IPCS 122, 1991; DeCaprio, 
2000).  
 
Finally it must be considered that, the absorption of n-hexane, or its metabolite 2,5-HD, may be 
enhanced by co-exposure to other solvents (Iwata et al., 1983a; Ladefoged and Perbellini, 1986; 
Ahonen and Schimberg, 1988; Ladefoged et al., 1989, 1994; Cardona et al., 1993, 1996). 
 
Several inhalation studies in humans and animals demonstrate the distribution of n-hexane, 
showing its great affinity to tissues higher lipid content (Perbellini et al., 1986). 
In female albino rats exposed to n-hexane levels of 17 000 mg/m
3
 (50 000 ppm) for up to 10 h, 
kidney, adrenal, blood, brain, and spleen levels of hexane reached a steady state after 
approximately 5 h exposure. However, its concentration in the liver increased linearly with time 
and did not reach saturation at 10 hours. This finding was related to a direct proportionality 
between the tissue saturation of n-hexane and the lipid content of the tissues examined, 
particularly its lipid accumulation in the liver, may be due to its high lipid content, which could 
account for the non-saturability of liver for hexane. In another study, steady-state n-hexane 
concentrations were observed in tissues, including liver, from rats exposed to 500 - 10 000 ppm 
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n-hexane for 6-h. Steady-state concentrations in blood, sciatic nerve, liver, and lung were 
directly proportional to the exposure level, however there was some evidence of saturation in the 
kidney, brain, and testis (IPCS 122, 1991; DeCaprio, 2000).  
In two separated studies, sciatic nerve was found to have the highest levels, following a 6-h 
inhalation exposure in rats (Baker and Rickert, 1981; Bus et al., 1982). 
n-hexane has also been detected in rat fetuses following inhalation exposure of pregnant females 
and the concentration in total fetal tissue was similar to that in maternal blood (IPCS 122, 1991; 
DeCaprio, 2000). 
 
The average half-life for n-hexane in human blood was 1.5-2 hours (US EPA/635/R-03/012) and 
the thermodynamic distribution coefficient of n-hexane between the human organism and the 
atmosphere was calculated to be 12 (Filser et al., 1987). 
 
1.1.1.2 Metabolism 
 
Numerous studies in laboratory animals and humans have examined the metabolism of n-hexane. 
The metabolic pathway, although complex, involve a sequence of hydroxylation and 
dehydrogenation reactions (Fig. 1.1). 
 
At the first step n-hexane is metabolized through hydroxylation reaction that occurs primarily via 
cytochrome P-450-mediated transformation, while cytoplasmic dehydrogenases reversibly 
oxidize hydroxylated metabolites to the corresponding ketones. The major metabolites of n-
hexane are 2-hexanol, methyl n-butyl ketone, 4,5-dihydroxy-2-hexanone and 2,5-hexanedione 
(Graham et al., 1999; Manini et al., 1998, 1999; DeCaprio, 2000).  
 
The carbons 1, 2 and 3 of n-hexane are hydroxylated and form hexanols in different proportions 
(in all species of animals). Detoxification pathway originates 1-hexanol and 3-hexanol that are 
less toxic metabolites. The former is oxidized to hexanoic acid, which undergoes the usual lipid 
metabolism. 
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Figure 1.1 Biotransformation and macromolecular binding reactions of n-hexane and 2,5-HD in 
mammalians systems. Dashed arrows indicate uncertainty in the actual pathway of formation. R-NH2 
represents protein amine side chain. (Adapted from DeCaprio In: Spencer, P.S., Schaumburg H.H., 
Ludolph A.C. (eds); Experimental and Clinical Neurotoxicology. 2
nd
 ed. Oxford University Press, 2000). 
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Finally, 2-hexanol through a bioactivation pathway is converted in an oxidation reaction, to 2-
hexanone and in 2,5-hexanediol through a second hydroxylation. Both of these metabolites are 
then further metabolized to 5-hydroxy-2-hexanone and 4,5-dihydroxy-2-hexanone. By oxidation 
of these two compounds 2,5-hexanedione is formed. This diketone is believed to be the major 
toxic metabolite produced in humans (Perbellini et al., 1980, 1981a; Manini et al., 1998, 1999). 
Several P-450 isozyimes are implicated in n-hexane metabolism, with CYP-IIB1 mediating the 
critical activation pathway from n-hexane to 2-hexanol (Toftgård et al., 1986). 
 
Evidence that the liver is the primary location for the initial hydroxylation step for bioactivation 
of n-hexane comes from the measurement of hydroxylating activity in isolated microsomes from 
liver, lung, brain, and skeletal muscles. Microsomes were incubated with n-hexane in the 
presence of reduced nicotinamide adenine dinucleotide phosphate (NADPH) and the rates of 
production of the primary alcohols, 1-, 2-, and 3-hexanol, were compared.  
Liver microsomes produced significantly more 2-hexanol than microsomes from lung, brain, and 
skeletal muscles (soleus and extensor digitorum longus). Similarly, in liver microsomes, 2-
hexanol production occurred at a much faster rate than that of 1- or 3-hexanol (Toftgård et al., 
1986; Crosbie et al., 1997; US EPA/635/R-03/012).  
 
However, in this process are also generated other secondary metabolites, such as 2,5-
dimethylfuran, γ-valerolactone, 2-amino-1-hexanoic acid, pentanone, 2,5-dimethyl-2,3- 
dihydrofuran and urea. Most of the hydroxylated products are excreted in urine as glucuronides 
and, possibly, sulfate esters whereas 2-hexanone and 2,5-hexanedione are also present in urine as 
‘free’ metabolites (Perbellini et al., 1981b, 1982; Fedtke and Bolt, 1987b; Spencer et al., 2000).  
 
In vivo assays performed in rats demonstrated that 2-hexanol is the major metabolite of n-hexane 
following inhalation exposure. The authors collected urine samples during and after exposure. 
The formation of n-hexane metabolites was dependent on exposure concentrations (up to 
approximately 300 ppm). Formation of 1-, 2-, and 3-hexanol and 2-hexanone was evident during 
exposure, nevertheless had ceased by 8 hours post exposure. Levels of 2,5-hexanedione and 4,5-
dihydroxy-2-hexanone were initially low and the metabolism of n-hexane to these metabolites 
had ceased by 16 and 40 hours post exposure, respectively. The primary metabolite formed in 
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rats following inhalation exposure was 2-hexanol (approximately twice all other metabolites 
observed), followed by 4,5-dihydroxy-2-hexanone. These metabolites together accounted for 
about 90% of the total metabolites formed. The level of 4,5-dihydroxy-2-hexanone was 
approximately 10 times higher than 2,5-hexanedione (calculated by subtraction of the 
concentration of free 2,5-hexanedione measured without acid hydrolysis from the concentration 
of 2,5-hexanedione measured following complete acid hydrolysis) (Fedtke and Bolt, 1987b). 
 
Bus and collaborators (in 1979) observed the metabolism of n-hexane in the fetus and maternal 
tissues of pregnant F344 rats and found that 2,5-hexanedione was the major metabolite observed 
in all maternal tissues evaluated and in the fetus, so they concluded that the metabolism of n-
hexane to 2,5-hexanedione and 2-hexanone was rapid and their levels reached peak 
concentrations in these tissues at 4 hours post exposure (US EPA/635/R-03/012). 
 
1.1.1.3 Excretion 
 
Several human inhalation studies have provided evidence for the elimination of n-hexane and 
metabolites following occupational and voluntary exposures to n-hexane (Imbriani et al., 1984; 
Mutti et al., 1984, 1993; Saito et al., 1991; Cardona et al., 1993; Mayan et al., 2001, 2002; 
Hamelin et al., 2004).  
Elimination of n-hexane occurs via exhalation of unmetabolized agent, volatile metabolites and 
CO2, and by urinary excretion of conjugated and unconjugated metabolites. Some differences 
among species are apparent in the proportion of various metabolites excreted by different routes 
of administration (Perbellini et al., 1982). 
 
In rat, elimination from several adult tissues, including sciatic nerve and liver, and from fetal 
tissue was rapid, however was slower from the kidneys (half-life, 6 h).  
In the guinea-pig, biphasic elimination of n-hexane from blood, have half-lives of 0.5 h and 4 h, 
and from rat blood and brain the elimination was found to be rapid and multiphasic, with initial 
half-lives of 2 - 4 and 7 min and a subsequent half-life of 1 - 2 h (White et al., 1979; Howd et al., 
1982). 
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In rats, the major urinary metabolites of n-hexane are 2-hexanol, 4,5-dihydroxy-2-hexanone, and 
2,5-HD (in that order), although in humans, the latter two compounds predominate (Fedtke and 
Bolt 1987a,b).  
 
Several human studies support the assertion that 2,5-hexanedione levels in urine are the best 
estimate of n-hexane exposure in the workplace. However, Hamelin and collaborators (2004) in 
their study, with five volunteers (three women, two men) that were exposed to n-hexane in an 
exposure chamber for 2 non-consecutive weeks (7 h/day, 1
st
 week/50 ppm, 2
nd
 week/ 25 ppm), 
refer that an important fraction of inhaled n-hexane (approximately 73%) was expired unchanged 
in alveolar air, meaning that only 27% was absorbed by the volunteers. This value agrees with 
those reported in previous studies, which ranged from 15% to 25% (Brugnone et al., 1978; 
Veulemans et al., 1982; Mutti et al., 1984). The results also show that there was no significant 
difference between n-hexane concentrations measured in alveolar air between days of the week, 
which suggests that n-hexane does not accumulate in blood during a normal week.  
 
Urinary levels of 2,5-HD are used as a routine biomarker of exposure to n-hexane, since it is 
correlated to that of airborne n-hexane (Perbellini et al., 1981a; IPCS 122, 1991; Andreoli et al., 
1998). 
 
 
1.2 HEXANEDIONE TOXICITY 
 
It is well known that 2,5-HD induces neurotoxic effects. However, the reproductive and the 
ocular system may be also a target of this toxic metabolite. 
 
 
1.2.1 NEUROTOXICITY  
 
It is well known that nowadays, it is well stablished, that neuropathies induced by n-hexane are 
mediated by its main neurotoxic metabolite 2,5-HD. 
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1.2.1.1 Neurological effects  
 
2,5-Hexanedione induces a central and peripheral distal axonopathy characterized primarily by 
axonal atrophy in large motor and sensory nerve fibers in experimental animal models (Lehning 
et al., 1995, 2000; DeCaprio et al., 2009).  
 
An observation consistently made between species, adult and immature members of the same 
species, and within individual humans and animals, was that longer axons in the PNS and CNS 
were more vulnerable to the toxic effects of n-hexane and its metabolite, than shorter axons.  
Observations in humans and investigations in animals have characterized this ataxia and skeletal 
muscle weakness as a distal sensorimotor neuropathy, specifically a distal axonopathy (dying-
back) type (Spencer et al., 1980; Costa, 1996).  
 
LoPachin et al., (2000) conducted an in vivo study to determine which neurological test or 
combination of tests could provide sufficient functional information to compliment biochemical 
or morphological endpoints in mechanistic studies of toxic axonopathies. 
 
Rats were exposed to two daily dosing rates (HD, 175 or 400 mg/kg per day, via po) and 
neurological endpoints were determined. Specific tests included observations of spontaneous 
locomotion in an open field, and measurements of hind limb landing foot splay, forelimb and 
hind limb grip strength and the hind limb extensor thrust response.  
 
2,5-HD intoxicated rats exhibited hind limb muscle weakness as indicated by a gait abnormality 
(dropped hocks) and decreases in grip strength and the extensor thrust response. However, hind 
limb landing foot spread was not affected by 2,5-HD exposure. For this neurotoxicant, gait 
changes preceded or coincided with alterations in other neurologic indices.  
 
The results suggest that observations of spontaneous behavior in an open field represent a 
practical approach to assessing temporal development and extent of neurological dysfunction 
induced by axonopathic toxicants such as 2,5-HD (LoPachin et al., 2000; Mateus et al., 2002).  
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Peripheral nervous system (PNS) effects 
The clinical manifestation of n-hexane is known as central-peripheral distal axonopathy or 
“dying-back neuropathy” (Huang et al., 1989). The onset is usually subacute or chronic, and the 
course is progressive with initial symptoms of numbness and burning sensation in the toes and 
fingers, followed by distal limb muscle weakness (Schaumburg and Spencer, 1976).  
The symptoms of polyneuropathy are usually symmetrical (Sanagi et al., 1980; Klassen 2013). 
Sensory impairments include reduced sensation of temperature, pin-prick, light touch, and 
vibration as well as position senses in the distal limbs (Schaumburg and Spencer, 1976). The 
muscle wasting usually occurs in the intrinsic hand and foot muscles, and muscle weakness often 
involves the extensor and flexor muscles of the legs and forearms. The extensor muscles are 
usually affected more severely than the flexor muscles in the fore arms and legs (Chang, 1990).  
 
In severely intoxicated patients, proximal muscles may become weak. Tendons reflexes are 
usually absent in ankle jerks and decreased in knee jerks and biceps (Schaumburg and Spencer, 
1976). Autonomic dysfunctions in glue sniffers often include nausea, vomiting, abdominal pain, 
impotence and skin changes such as coldness, sweating, and exfoliation. Cranial neuropathy 
includes blurred vision, impaired color vision, retinal or macular changes, decreased corneal 
reflexes and facial numbness (Dick et al., 2000; Klassen, 2013). 
 
Central nervous system (CNS) effects 
The neurotoxic effects on CNS after intoxication by n-hexane or 2,5-HD include headache, sleep 
disturbance, irritability, mental impairments and spastic gait (DeCaprio, 2000). Acute exposure 
to high n-hexane concentrations may induce narcosis, euphoria, hallucination, dizziness, 
giddiness, and headache (Chang, 1987). Severely intoxicated patients may develop respiratory 
depression, convulsion, coma, and even death. The acute effects are more common in glue 
sniffers than in industrial workers (Chang, 1987; DeCaprio, 2000). 
Hyper reflexes with spasticity are usually observed in polyneuropathic patients several months 
after recovery of the peripheral neuropathy. The sequelae of spasticity may persist for several 
years, even after cessation of n-hexane exposure. Extrapyramidal symptoms including rigidity, 
bradykinesia and tremor are not found. There are no cerebellar signs of nystagmus, tremor, 
ataxia, or sphincter disturbance (Huang, 2008). 
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1.2.1.2 Neuropathologic effects 
 
As mentioned above, ultrastructural studies indicate that nervous system toxicity induced by n-
hexane and 2,5-HD may be the result of a sequence of events leading to degeneration of the 
axons in CNS and PNS (Schaumburg and Spencer, 1976; Spencer and Schaumburg, 1977a).  
 
Internodal swelling and axonal atrophy, retraction of myelin from nodes of Ranvier, segmental 
demyelination, and distal axonal Wallerian-type degeneration are the major neuropathologic 
lesions (Fig. 1.2) (Graham et al., 1995; DeCaprio et al., 1997; Jortner, 2000; Lehning et al., 
2000; LoPachin, 2000.).  
 
The earliest pathological indicator of peripheral nerve axonal degeneration was axonal swelling 
in the distal nonterminal region of the large myelinated fibers. These axonal swellings appeared 
first proximal to the nodes of Ranvier and ascended the nerve with further exposure (i.e., facing 
paranodes and internodal loci).  
 
 
Figure 1.2 The most distally located neurofilaments exhibits the highest pyrrole adducts density, as a 
consequence of the slow migration of neurofilaments along the axon. This is also the site where the 
degeneration of the axon is initiated and from where the damage transgresses to more proximal sites 
(Adapted from: Mateus M.L.; Avaliação e Prevenção do Risco de Exposição a Misturas com n-Hexano: 
Parâmetros Bioquímicos e Comportamentais. Faculdade de Farmácia, Universidade de Lisboa, Lisboa, 
2002 and Boelsterli, Urs A., Mechanistic toxicology: the molecular basis of how chemicals disrupt 
biological targets. 1
st
 ed., Taylor & Francis, London, 2003). 
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Paranodal swelling was accompanied by shrinkage and corrugation of the adjacent distal 
internode. Paranodal myelin sheaths split and retracted leaving giant axonal swellings near the 
nodes of Ranvier. Schaumburg and Spencer (1976), and Spencer and Schaumburg (1977a), 
suggested that Schwann cells may become associated with these denuded regions and 
remyelinate short segments.  
 
The axonal swellings, that initially occurred proximal to nodes of Ranvier in the most distal 
internodes of the longest axons, were filled with disorganized masses of NFs. Thus, Graham et 
al., (1995) postulated that during repeated exposures to n-hexane the resulting metabolite 2,5-HD 
resulted in progressive derivatization of protein lysyl amino groups to form pyrrolyl adducts. 
Oxidation of the pyrrole rings to electrophiles lead to increasing levels of cross-linking of NFs 
during the proximo-distal transport of axoplasm (Tshala-Katumbay et al., 2005; 2009a).  
 
The observations suggested that the constriction of axonal diameter at nodes of Ranvier 
contributed to the formation of axonal swelling at these locations by presenting obstructions to 
the transport of the growing masses of NFs.  
Additionally, no obstructing masses of NFs could be successfully transported to the synapse for 
proteolysis. Since the rate of NF transport is 1 mm/day (Griffin et al., 1984; DeCaprio, 2000), 
axonal length can be seen to determine the period of time during which sufficient NF cross-
linking must occur, to produce the threshold masses necessary to occlude transport and result in 
axonal swellings, secondary myelin retraction and demyelination, and distal axonal degeneration 
(Tshala-Katumbay et al., 2005). 
 
Consequently, neurofilamentous swellings have been the focus of substantial mechanistic 
research. However, the pathophysiological relevance of axonal swelling to γ-diketone 
neurotoxicity has not been demonstrated directly, and in fact, there is now evidence to suggest 
that swelling is a nonessential phenomenon exclusively related to long-term or low dose-rate 
intoxication.  
 
The axonal swelling that might not be relevant to the induction of hexacarbon neurotoxicity was 
first indicated by early studies of Krasavage et al., (1980). These investigators showed that the 
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frequency of giant axonal swellings in tibial nerve did not correlate with 2,5-HD concentration 
and was instead related to length of hexacarbon exposure (LoPachin and DeCaprio, 2004).  
The relative frequency of swollen axons was inversely related to the serum concentrations of 2,5-
HD and to the induction of neurotoxicity. This indicates dissociation between the manifestation 
of axonal swelling and the development of neurological toxicity. 
 
 
Figure 1.3 Possible putative mechanisms by which nerve fibers (axons) undergo degeneration: result of 
changes in the proteins, interfering with the ability of mobile NF proteins, interaction with the polymeric 
cytoskeleton to cause NF accumulation and nerve degeneration. (Adapted from LoPachin and DeCaprio, 
2005). 
 
 
In conclusion, the axon is the site of genesis of γ-diketone axonopathy (Tshala-Katumbay et al., 
2005, 2009b), nevertheless the mechanisms by which changes in axonal proteins lead to 
axonopathy and/or nerve fiber degeneration have yet to be understood (Tshala-Katumbay et al., 
2009a). Analytical studies on the γ-diketone susceptibility of selected proteins that are 
commonly targeted by 2,5-HD and investigations on the time course of proteomic changes as 
shown in recent studies (Song et al., 2008; Wang et al., 2008) and may provide new insights into 
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mechanisms by which nerve fibers (axons) undergo degeneration (Fig. 1.3) (Tshala-Katumbay et 
al., 2009a). 
 
1.2.1.3 Physiological and biochemical effects 
 
Substantial physiological and biochemical studies have explored the mechanism by which 2,5-
HD binds to and cross-links proteins. For example, DeCaprio et al., (1982) studied the covalent 
binding of 2,5-HD to amino acids and polypeptides in vitro.  
 
Studies in vivo showed that exposure of laboratory animals to 2,5-HD produces axon atrophy in 
peripheral nervous system (PNS) and central nervous system (CNS) (Lehning et al., 1995, 2000; 
LoPachin et al., 1994, 2003; LoPachin and DeCaprio, 2004). 
 
Changes in the expression of structural/membrane proteins by γ-diketones may reflect changes in 
protein synthesis and/or degradation after posttranslational modifications possibly by γ-diketo-
adduction and crosslinking (polymerization) (DeCaprio, 1985; Spencer et al., 2002; LoPachin 
and DeCaprio, 2005). The increase in the expression levels of enzymes involved in energy 
metabolism, except for glycogen phosphorylase (GLPH), possibly represents a stress response 
involving unbalanced protein turnover associated with protein degradation and/or chemical 
attack by γ-diketones. Whether the change in the expression levels of these enzymes is 
accompanied by a production of deleterious species such as free radicals is not known and needs 
to be investigated (Genova et al., 2004; Tshala-Katumbay et al., 2009a). Reduction in the 
expression levels of GLPH suggest that impaired glucose metabolism may contribute to the 
pathogenesis of γ-diketone neurotoxicity. 
 
Atrophy induced changes in axonal cable properties (e.g., decreased unit area) and associated 
electrophysiological consequences, such as reduced conduction velocity (Yuan et al., 2009), 
could be responsible for the characteristic neurological deficits that accompany γ-diketone 
neuropathy.  
Their global proteomic approach has allowed the identification of several proteins of interest in 
the pathogenesis of γ-diketone axonopathy. 2,5-HD reduce the expression level of proteins 
involved in maintaining the physical integrity of axons or assisting redox/folding mechanisms. 
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1.2.1.4 Cytotoxic effects  
 
In vitro assays demonstrate that neurons are vulnerable to both n-hexane and 2,5-HD, causing 
loss of neurons (Selkoe et al., 1978; Cui et al., 2007; Kim et al., 2009). 
 
In vivo assays demonstrated that high doses of 2,5-HD (400mg/kg) could induce significant 
changes of both anti-apoptosis and pro-apoptosis proteins, which indicates that apoptosis might 
be involved in 2,5-HD neurotoxicity (Cui et al., 2007). Nevertheless, according to Kim et al., 
(2009), the effects of lower doses of 2,5-HD, (50 mg/kg), also decreased neurogenesis,  
increasing ROS formation by approximately 60% relative to controls. These results indicate that 
2,5-HD also affects adult hippocampal neurogenesis via oxidative stress.  
 
Many evidences demonstrate that 2,5-HD directly induces cell body modifications of neurons 
(Moretto et al., 1991). Almost all proteins essential for the normal function of axon are 
synthesized within the perikaryon and subsequently delivered into the axon by axonal transport. 
According with Cui et al., (2007), neuronal cell body functions critically act in axon maintenance 
and repair. Since approximately 99% of total neurons exist in CNS, has been reported that 2,5-
HD, impairs the spatial memory, mediate some cognitive effect (Carney et al., 2002). 
 
1.2.1.5 Molecular mechanism of 2,5-HD neurotoxicity 
 
Adduct Chemistry: HS/AB Theory 
In the field of toxicology, the irreversible covalent interaction of a toxic electrophile and its 
cognate nucleophilic target is recognized as a basic reaction mediating chemical-induced cell 
injury. It is now understood that electrophile/nucleophile reactions exhibit a significant degree of 
selectivity. In that, a given electrophile preferentially reacts with specific nucleophiles of 
comparable softness or hardness. This selectivity is based on electronic and structural 
characteristics that constitute the soft and hard classifications of the HSAB theory (Pearson, 
1968a,b, 1987). 
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The significant degree of selectivity that occurs in electrophile ─ nucleophile interactions is 
predicted by Pearson's Hard and Soft, Acids and Bases  theory (HSAB) (Pearson, 1990; 
Chattaraj, 2001; LoPachin et al., 2008, 2012).  
This theory classifies reacting species as either relatively “hard” or “soft”, based on 
polarizability. In this classification, reactive molecules such electrophiles and nucleophiles are 
classified as either soft (relatively polarizable) or hard (relatively non polarizable). A useful 
theorem stemming from this principle is that toxic electrophiles react preferentially with 
biological targets of similar hardness or softness (LoPachin and DeCaprio, 2005).  
 
Relative hardness and softness are clearly important characteristics for covalent bond formation 
in biological systems. This concept utilizes the inherent electronic characteristic of polarizability 
(a characteristic of electron distribution in atoms or molecules) to define, for example, reacting 
electrophiles and nucleophiles as either hard or soft, being polarizability the ease with which 
electron density can be displaced or delocalized to form new covalent bonds. Toxicant 
interactions will be either irreversible (covalent adduction) or, at least, slowly reversible (ionic) 
depending upon the respective chemical characteristics (LoPachin and Barber, 2006). 
 
These HSAB definitions have been successfully applied to chemical-induced toxicity in 
biological systems. Whereas exceptions exist, most toxic chemicals are electrophiles that 
produce toxicity by interacting with biological nucleophiles, and therefore, the HSAB concepts 
should have broad applicability to the field of molecular toxicology in discerning plausible 
biological targets and molecular mechanisms of toxicity (LoPachin et al., 2012). 
 
The interaction of a soft electrophile with a nucleophile and covalent bond formation is governed 
and can be described by the shape, property and energy of the respective outermost frontier 
molecular orbitals. These orbital energies for most chemicals can be calculated, and starting 
these values and using quantum mechanical models, it is possible to quantify the HSAB 
parameters. Consequently, the propensity of these chemicals to form adducts can be defined by 
quantum mechanical parameters: relative softness (σ), hardness (η) of electrophiles or 
nucleophiles, even as the electrophilic index (ω), the index of nucleophilicity (ω─) and chemical 
potential (µ). The softness also reflect the rate of adduct formation. On this account is considered 
the ease with which electron redistribution takes place during covalent bonding and thus, the 
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softer the electrophile, more readily it will form an adduct by accepting outer shell electrons 
from a soft nucleophile. Differences in µ, the ability of a nucleophilic species to transfer 
electrons, or more precisely, electron density to the electrophile, could determine protein targets 
of these chemicals. Values of µ are independent of pH and reflect the inherent electronic nature 
of the structural moiety of molecular species (Pearson, 1968a,b; Pearson et al., 1990; Chattaraj et 
al., 2006; LoPachin et al., 2007b). 
 
These parameters can be used to predict the toxic potential of electrophilic xenobiotic chemicals 
and facilitate the identification of corresponding nucleophilic molecular sites of action. They are 
a useful tool in the search for macromolecular targets, converting this information into useful 
indices of reactivity, and subsequent elucidation of molecular mechanisms of toxicity (Schultz et 
al., 2006; LoPachin et al., 2008, 2009b, 2012).  
 
According to several authors the neurotoxic n-hexane metabolite, 2,5-HD is a hard electrophile 
that preferentially forms adducts with harder nucleophiles such as nitrogen atoms on the ε-amino 
group of lysine residues (Fig. 1.4) (LoPachin et al., 2012). However, according Tshala-
Katumbay (2005, 2008, 2009a), aliphatic γ-diketones can react with ε-amino- or sulfyhydryl 
(SH)-groups of neuroproteins. 
 
Sulfur has a large atomic radius so that its valence electrons are relatively far from the nucleus 
and, as such, are highly polarizable and soft. Upon ionization of the thiol (i.e., SH→S-), the 
consequent expansion of the anionic cloud yields the relatively soft (most easily polarizable) 
thiolate nucleophile and cysteine thiolate could be the softest nucleophile in biological systems 
(Table 1.1) (Hinson and Roberts, 1992; LoPachin and DeCaprio, 2005; LoPachin et al., 2008a, 
2012).  
 
In contrast nitrogens of amino groups on lysine or histidine residues are also nucleophiles 
nevertheless they have relatively small atomic radii and, accordingly, their electron clouds are 
less readily distorted. Consequently, such compounds are less polarizable and so much harder 
nucleophiles (e.g., the primary nitrogen of the amino acid lysine) (LoPachin and DeCaprio, 
2005). 2,5-HD is a relatively hard, however weak electrophile that forms lysine adducts very 
slowly (Tabel 1.1) (DeCaprio et al., 1982; Zhang et al., 2010).  
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Table 1.1 Specific nucleophilic sites in amino-acid polymers and electrophilic neurotoxicants 
(metabolites) ordered by increasing hardness. (Adapted from Schultz et al., 2006 and LoPachin et al., 
2012). 
Specific nucleophilic sites in amino acid sites 
1) thiol group of Cys 
2) S-atoms of methionine 
3) primary amino groups of lysine, arginine and guanine 
4) secondary amino-group of histidine 
 
Electrophilic neurotoxicants compounds (or metabolites) 
1) 4-hidroxi-2-nonenal 
2) acrolein 
3) acrilamide 
4) 2,5-hexanedione 
5) glycidamide 
 
 
This theory could explain what mechanistic studies showed. This γ-diketone, when administered 
to experimental animals, can form adducts with numerous proteins, in a selective manner, 
binding to ε-amino groups of lysine in axonal cytoskeletal proteins and forming 2,5-DMP (2,5-
dimethylpyrrole) primary adducts, within specific regions of neurofilaments (NFs) (DeCaprio et 
al., 1982, 1987; Graham et al., 1982; DeCaprio and Fowke, 1992; DeCaprio et al., 1997; Zhang 
et al., 2010). The higher affinity exists between the hard nucleophiles, ε-amino groups of lysine 
in neurofilaments, and the hard electrophile, 2,5-HD (Fig 1.4).  
 
Relative hardness and softness are clearly important characteristics for covalent bond formation 
in biological systems. However, protein adduction is dependent not only upon the 
physiochemical nature of the electrophile, also upon the microenvironment of the nucleophilic 
center, which can vary significantly even among centers of the same elemental type (e.g., sulfur 
or amino groups) (LoPachin and DeCaprio, 2005).  
Thus, nucleophilic reactivity among free sulfhydryl groups on polythiol proteins can be diverse 
and, consequently, soft electrophilic chemicals will adduct the more reactive thiol groups on a 
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given protein (Vogel and Nivard, 1994). This diversity in nucleophilic reactivity is a function of 
both steric and electronic factors mediated primarily by protein tertiary structure (LoPachin and 
DeCaprio, 2005).  
 
Formation of Pyrrole Compounds 
Several studies showed that 2,5-HD could react directly with axonal protein by the formation of 
N-substituted 2,5-DMP adducts at ε-amine nitrogen of the lysine residues of neurofilaments (Fig. 
1.2) (DeCaprio, 1985; Pyle et al., 1992; Graham et al., 1995; Decaprio et al., 1997).  
 
However, only ketones classified as gamma diketones are able to cause this neurotoxic effect. 
Considerable data support the conclusion that the gamma spacing of the two carbonyl 
compounds in 2,5-HD is critical to the generation of neurofilamentous axonopathy (DeCaprio, 
2000; Tshala-Katumbay et al., 2005; Llorens, 2013). 
Secondary oxidation of the pyrrole ring to an electrophile (soft electrophile) reacted with 
nucleophiles (in neurofilaments) resulting in intra- and intermolecular protein cross-linking (A, 
B and C in Fig. 1.4), and this was considered to be the determinant event in 2,5-HD neuropathy 
(Graham et al., 1982; Zhu et al., 1994). 
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Figure 1.4 Molecular mechanisms of protein cross-linking in the neurofilaments neuropathies. 2,5-
Hexanedione is capable of cross-linking proteins. Pyrrole formation from 2,5-HD is followed by 
oxidation and reaction with adjacent protein nucleophiles (Adapted from Moser et al., In Casarett and 
Doull’s Toxicology: The Basic Science of Poisons. 8th ed. McGraw-Hill, New York, 2013, and Mateus 
M.L.; Avaliação e Prevenção do Risco de Exposição a Misturas com n-Hexano: Parâmetros Bioquímicos 
e Comportamentais. Faculdade de Farmácia, Universidade de Lisboa, Lisboa, 2002). 
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1.2.2 REPRODUTIVE TOXICS EFFECTS 
 
In vivo n-hexane exposure, beyond to induce peripheral polyneuropathy, result in testicular germ 
cell loss through the action of its toxic metabolite that causes irreversible testicular atrophy 
(Krasavage et al., 1980; Boekelheide and Hall, 1991; Allard et al., 1995).  
 
During in vivo exposure to 2,5-HD, pyrroles form and accumulate on tissue proteins as a 
required step in the induction of both testicular and nervous system injuries (DeCaprio et al., 
1982; Sayre et al., 1986; Genter et al., 1987). The earliest detectable change was an increase in 
the polymerization rate of testis tubulin, which occurs primarily in Sertoli cells, the supportive 
cell of the seminiferous epithelium (Boekelheide and Hall, 1991; Horimoto et al., 2000).  
After exposure, Sertoli cell microtubules are altered, followed by a decrease in seminiferous 
tubule fluid secretion and subsequent germ cell loss, since 2,5-HD targets Sertoli cells, resulting 
in germ cell apoptosis and testicular atrophy. Considering that these cells have axon-like 
characteristics, tubulin was considered an attractive molecular target in testicular injury 
(Boekelheide et al., 2003). 
 
In 2,5-HD-induced testicular atrophy a time delay between administration of the toxicant and the 
development of testicular injury is evident, and the length and dose rate of exposure determine 
the magnitude of germ cell loss. 2,5-Hexadione exposure alters testicular microtubule assembly, 
and the extent of this assembly abnormality correlates with testicular injury as measured by 
testicular weight loss and histopathology (Boekelheide and Eveleth, 1988; Boekelheide and Hall, 
1991). After exposure to 2,5-HD (1% drinking water solution, for 5 weeks), peak germ cell loss 
occurred 7 weeks later (Boekelheide, 1988; Boekelheide et al., 2003; Moffit et al., 2007), 
suggesting a time delay between exposure and testicular injury. Germ cell loss persisted up to 75 
weeks after 2,5-HD exposure (Boekelheide and Hall, 1991;  Allard et al., 1995), indicating that 
the injury was irreversible. 
 
In the rat, testicular atrophy associated with 2,5-HD exposure can occur at cumulative exposure 
levels below those that produce clinical neurotoxicity. High-level exposure for relatively brief 
periods produced testicular injury without clinical evidence of distal polyneuropathy 
(Boekelheide, 1988), whereas chronic low-level exposure produced clinical evidence of distal 
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polyneuropathy without testicular injury (Boekelheide and Eveleth, 1988). In fact, the testicular 
injury was dose-rate sensitive, whereas the extent of nervous system toxicity was related to the 
total dose over a range of dose-rates (Krasavage et al., 1980).  
 
These tissue-selective pharmacokinetic effects may, in part, explain the predominance of 
neurotoxicity in human exposures to 2,5-HD precursors. In addition, the clinical manifestations 
of neurotoxicity are obvious, whereas those of testicular injury are subtle (Boekelheide et al., 
2003; Moffit et al., 2007). 
According with Boekelheide et al., (2003) a proposed pathogenic sequence for 2,5-HD-induced 
testicular injury is as follows: 2,5-HD-induced cross-linking of tubulin leads to altered 
microtubule assembly, which results in altered microtubule-dependent transport, in Sertoli cells. 
This altered microtubule-dependent transport is manifested as decreased seminiferous tubule 
fluid formation and a failure to provide adequate support to germ cells causing them to undergo 
apoptosis. 
 
One of the most common morphological responses of the Sertoli cell to injury is vacuolation. 
Vacuoles have been described as an early event with 2,5-HD exposure. In some cases the 
vacuoles are large and discrete, while in others microvacuolation of the basal Sertoli cell 
cytoplasm is seen. Subsequent to the vacuolation and/or swelling, germ cell degeneration, 
disorganization or exfoliation is generally seen. The characteristics of the germ cell changes can 
vary with different toxicants and are related with the nature of the functional disturbance within 
the Sertoli cell. In the case of 2,5-HD, which require prolonged exposure to elicit toxicity, there 
is a gradual, multifocal degeneration of germ cells with the frequent formation of multinucleate 
spermatid aggregates (Creasy, 2001; Moffit et al., 2007; Bryant et al., 2008). 
 
Other reproductive toxics effects that can be observed in the animals are the percentage of motile 
sperm and sperm count, and have been used as principal parameters for detecting potential 
effects on spermatozoa. For the males treated with 2,5-HD, which affects sperm indirectly by 
damage to the Sertoli cell, decreased sperm motion was observed despite the absence of a 
marked change in testicular weight, epididymal weight or sperm count. Velocity parameters, that 
directly express sperm motion (swimming speed), average path velocity (VAP), straight line 
velocity (VSL), and curvilinear velocity (VCL), responded sensitively to abnormal sperm motion 
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in the 2,5-HD studies (Horimoto et al., 2000). Its administration also induced changes in one 
histopathology endpoint, spermatid head retention. The presence of retained spermatids along the 
basement compartment of the seminiferous tubule epithelium was identified as a sensitive 
measure of 2,5-HD-induced testicular injury being retained spermatid heads (RSH) considered as 
a sensitive histopathological marker of testicular toxicity for subacute 2,5-HD exposure (Moffit 
et al., 2007; Bryant et al., 2008). 
 
Most commonly used endpoints for male reproductive toxicity are defined as reproductive 
organs (testis, epididymis and prostate), weight, their morphological changes, and sperm analysis 
such as sperm count, sperm mobility and viability (EPA, 1996; Creasy, 2001; Yamamoto et al., 
2005). It is usually better to study several because generally no individual endpoint is singularly 
capable of identifying testicular injury (Moffit et al., 2007). 
 
An interesting aspect of 2,5-HD-induced testicular toxicity is that despite the survival of 
spermatogonia, the lesion is largely irreversible. However, recovery can occur if an agonist is 
administered (Leuprolide). This appears to function by normalizing the expression of stem cell 
factor (a growth factor secreted by the Sertoli cell), which is altered by 2,5-HD treatment. This in 
turn stimulates the dividing spermatogonia to continue through spermatogenesis (Creasy, 2001). 
Treatment with a gonadotropin releasing hormone (GnRH) agonist can successfully reverse the 
“irreversible” 2,5-HD-induced testicular atrophy.  
 
1.2.3 RETINA AND VISUAL TOXICS EFFECTS 
 
Animal studies on n-hexane exposure also indicate that 2,5-HD could provoke premature or 
accelerated deterioration in vision (Spencer et al, 1978; Bäckström, 1998; Carelli et al., 2007). 
Dose-response color vision loss (acquired dyschromatopsia) and decreases in the contrast 
sensitivity function occur in workers exposed to n-hexane and adverse effects usually occur only 
at concentrations above the occupational exposure limits (Mergler et al., 1987, 1991; Moser et 
al., 2013).  
 
Large percentage of workers in paint manufacturing facilities, adhesive bandage factory and 
vegetable oils extraction workers, who were exposed to concentrations of solvents that exceeded 
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the threshold limit values, had acquired dyschromatopsia as assessed by the Lanthony 
desaturated panel D-15, color vision test (Eguchi et al., 1995; Bull, 2007).  
 
Several workers had no observable clinical abnormalities as assessed by biomicroscopy, 
funduscopy, and peripheral visual field tests. The color vision losses were mainly blue-yellow 
losses, although more severe red-green losses were reported (Mergler et al., 1987; Moser et al., 
2013). As a rule, acquired blue-yellow losses generally result from lens opacification or outer 
retinal alterations, whereas red-green losses are associated with inner retinal, retrobular, or 
central visual pathway alterations (Issever et al., 2002). Moreover, these occupationally exposed 
workers also exhibited lower contrast sensitivity at intermediate spatial frequencies, which likely 
reflects alterations in neural function (Lacerda et al., 2011). The data from the Mergler et al., 
(1987, 1991), studies appear to show gender differences in these adverse visual effects.  
 
A study of female workers, where the Lanthony D-15 desaturated test was used to assess color 
vision, showed a trend toward increased prevalence of color vision impairment.  
Blue-yellow deficits as well as macular changes were observed in workers exposed to n-hexane 
for 5 to 21 years (Bäckström, 1999; Ballantyne, 2009). These findings correlate with the rod and 
cone degeneration observed in rats exposed to 2,5-HD (Bäckström et al., 1993; Klaassen, 2013).  
 
Regarding mechanisms, chemically-induced dyschromatopsia has be claimed to be an early sign 
of more serious neurotoxicity, since it may occurs at levels lower than those producing other 
neurotoxic effects (Bull, 2007). 
Dyschromatopsia associated to organic solvents intoxication has been attributed to 
maculopathies caused by damage in cone photoreceptors, ganglion cells and optic nerve 
demielinization (Issever et al., 2002). Blain and Mergler, (1986), suggested that solvent 
intoxication led to blue-yellow color vision losses and later may develop to red-green color 
vision loss. It reflects progressive degeneration from outer retina to optic nerve (Eguchi et al., 
1995; Lacerda et al., 2011). Grant and Schuman (1993) suggest that this type of visual loss 
indicates a beginning process of optical neuropathy after exposure to methanol, styrene, toluene, 
trichloroethylene and organic solvents mixtures.  
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1.3 CONTROL AND PREVENTION OF OCCUPATIONAL EXPOSURE TO 
SOLVENTS 
 
During the industrial revolution occupational and industrial diseases became common. There are 
now many thousands of chemical substances used in industry ranging from metals and other 
inorganic compounds to complex organic chemicals, and since a man spends on average one-
third of his life at work, the environment in that workplace can be a major factor in determining 
his health.  
 
An estimated 10 million people are potentially exposed to organic solvents in the workplace. 
Many of the most severe exposures to solvents have occurred as a result of their use in confined 
spaces with inadequate ventilation (Bruckner et al., 2013). 
Although the working environment has improved immeasurably over the last century, some 
occupations are still hazardous despite legislation and efforts to improve conditions.  
 
Occupational Toxicology is a specific area of Toxicology that was developed to control and 
prevent the risk of diseases induced by exposure of workers to chemicals. To achieve this goal 
research was performed to establish environmental and biological threshold limit values of 
chemicals below which no risk of disease may occur (Grandjean and Landrigan, 2006). 
Workplace exposure limits exist for chemical, biological, and physical agents and are 
recommended as guidelines or promulgated as standards in order to promote worker health and 
safety. In the most major industrialized nations there is legislation which sets limits on the levels 
of toxic substances in the workplace. 
 
This involves setting exposure levels based on the results of human epidemiological data and on 
the results of animal toxicity studies. It requires monitoring of the occupational environment for 
compliance. The experimental evidence of toxic effects usually includes the determination of a 
dose-response relationship and no-effect levels in experimental animals.  
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1.3.1 OCCUPATIONAL EXPOSURE LIMITS 
 
Occupational Exposure Limits (OELs) are established as standards by regulatory agencies or as 
guidelines by research groups or trade organizations (Topping, 2001; Jakubowski and Trzcinka-
Ochocka, 2005; Bolt and Thier, 2006).  
 
The European Commission has established legally enforceable Binding Occupational Exposure 
Limit Values (BOELV) and Biological Limit Values (BLV) for the protection of health and 
safety in the workplace. Socioeconomic and technical feasibility factors are also considered in 
setting these values. The OELs are established based on recommendations of the Scientific 
Committee on Occupational Exposure Limits (SCOEL), which evaluates published scientific 
data on hazardous compounds for regulation and provides assessment of exposure limits that “it 
believes will protect workers from chemical risks” (2006/15/EC; Huang, 2008). 
 
In the United Kingdom compliance with occupational exposure limits (OELs), for airborne 
substances, is required by the Control of Substances Hazardous to Health Regulations (COSHH), 
established under the Health and Safety at Work Act 1974. Under the regulations, OELs are used 
to define adequacy of control by inhalation (HSE, 1997). There are two types, the occupational 
exposure standard (OES) and the maximum exposure limit (MEL) (Topping et al., 1998). 
 
In the United States, the Occupational Safety and Health Administration (OSHA) promulgate 
legally enforceable standards known as Permissible Exposure Limits (PELs). These standards 
are determined and supported by the best scientific evidence available and assure “to the extent  
feasible that no employee will suffer material impairment of health or functional capacity” with 
regular exposure “for the period of his working life”. OSHA has defined an 8-hour Time-
Weighted Average (TWA) PEL as the “employee’s average airborne exposure in any 8-hour 
work shift of a 40-hour work week which shall not be exceeded”. The TWA PEL is established 
as the highest level of exposure to which an employee may be exposed without incurring the risk 
of adverse health effects (OSHA, 2005).  
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The American Conference of Governmental Industrial Hygienists (ACGIH) is a trade 
organization that publishes OELs for chemicals and for physical agents. These take the form of 
threshold limit values (TLVs) and biological exposure indices (BEIs).  
 
They are frequently revisited and generally reflect current knowledge in occupational toxicology 
and industrial hygiene (Table 1.2).  
 
Table 1.2 Occupational Exposure Limits (OELs) that are established as standards by regulatory agencies 
or as guidelines by research groups or trade organizations. 
 
 
 
EC  
SCOEL, Scientific Committee on Occupational Exposure Limits, 
 OEL Occupational Exposure Limits  
 BOELV Binding Occupational Exposure Limit Values  
 BLV Biological Limit Values  
USA 
OSHA, Occupational Safety and Health Administration,  
 PEL Permissible Exposure Limits  
 TWA  Time-Weighted Average  
USA 
ACGIH, American Conference of Governmental Industrial Hygienists, 
 OEL Occupational Exposure Limits  
 TLV Threshold Limit Value  
 BEI Biological Exposure Indices  
UK 
COSHH, Control of Substances Hazardous to Health and HSC, Health and Safety 
Commission,  
 OES Occupational Exposure Standard  
 MEL Maximum Exposure Limit  
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These parameters were developed as guidelines and are not enforceable standards. However, 
many industries adopt TLVs and BEIs as internal OELs. As stated by the ACGIH, “The TLVs 
and BEIs represent conditions under which ACGIH believes that nearly all workers may be 
repeatedly exposed without adverse health effects” (ACGIH, 2003; OSHA, 2005; Huang, 2008). 
 
BEIs are guidelines for biological monitoring and represent levels “most likely to be observed in 
specimens collected from healthy workers who have been exposed to chemicals to the same 
extent as workers with inhalation exposure at the Threshold Limit Value” (Mutti, 1999; ACGIH, 
2003). BEIs are recommended for analysis of urine, blood, and exhaled air. While hair, 
fingernails, and other specimens are used in research and forensic toxicology, there are no BEIs 
for these biological samples. 
 
To protect against the onset of subclinical and clinical neuropathological symptoms of n-hexane 
exposure, ACGIH proposes a BEI of 0.4 mg/L as an acceptable concentration of free 2,5-HD in 
urine (non-acid hydrolyzed samples) and a BEI of 5 mg/g creatinine of total 2,5-HD (acid 
hydrolyzed samples) at the end of shift on the last day of a workweek, Table 1.3 (ACGIH, 2003; 
Huang, 2008).  
 
 
Table 1.3 Limit values and biological indices, for n-hexane and 2,5-HD.  
Substance   Value  Agency 
 
n-hexane  
Europe TLV-TWA 50 ppm, 180 mg/m3 SCOEL 
USA TLV-TWA 
PEL 
50 ppm, 180 mg/m3 
500 ppm 
 ACGIH, 2005 
OSHA  
 
2,5-hexanedione 
 
 
USA 
 
BEI 
 
0,4 mg/L urine (a) 
5 mg/g creatinine (b) 
  
ACGIH, 2005  
    
 
TLV-TWA, Threshold Limit Values, Time-Weighted Average; SCOEL, Scientific Committee on Occupational 
Exposure Limits; PEL, Permissible Exposure Limits; ACGIH, American Conference of Governmental Industrial 
Hygienists; OSHA, Occupational Safety and Health Administration; BEI, Biological Exposure Indices. 
(a) non-acid hydrolyzed samples; 
(b) acid hydrolyzed samples. 
 
1.3.2 BIOMONITORING n-HEXANE EXPOSURE 
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1.3.2.1 Biomarkers as tools in biomonitoring chemicals exposure 
 
Biomonitoring consists of the measurement of toxicants, their metabolites, or molecular 
signatures of effect in specimens from humans or animals, including urine, blood, feces, exhaled 
breath, hair, finger or toenails, bronchial lavage, breast milk, and adipose tissue (Thorne, 2013).  
 
These biological indicators are also called biomarkers, and are defined as “any substance, 
structure or process that can be measured in the body or its products and influence or predict the 
incidence of outcome or disease” (IPCS 222, 2001).  
 
Depending on their use, biomarkers can be classified as markers of exposure, effect and 
susceptibility and can be applied to get insights on the multi-stage and multi-factor process that 
is thought to link exposure to long-term outcomes, as shown in Figure 1.5 (NRC, 1987). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Simplified flow chart with classes of biological markers: continuum of events between 
exposure and disease. Solid horizontal arrows indicate progression, if it occurs. Individual susceptibility 
influences the rates of progression. Biological markers represent a continuum of changes, and the 
classification of change may not always be distinct. (Adapted from: NRC, 1987; Manini et al., 2007). 
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An ideal biomarker of exposure should be specific for the exposure of interest, detectable in 
trace levels, measurable by non-invasive techniques, inexpensive, associated with prior exposure 
and provide a predictive value to a specific health status.  
In occupational toxicology, the major focus of interest has long been, to clarify if biomarkers of 
exposure can provide reliable measurements of internal doses, which are useful to assess dose–
response relationships (Manini et al., 2004). 
External exposure is the sum of the xenobiotic material presented to an organism, whereas 
internal dose is the amount of the xenobiotic compound that is actually absorbed into the 
organism. Biological markers of internal dose may include pharmacokinetic data, such as half-
life, circulating peak, or cumulative dose. Biologically effective dose is the amount of material 
interacting with critical subcellular, cellular, and tissue targets or with an established surrogate 
(NCR, 1987). 
 
In fact, when a dose–response relationship is known, an appropriate biomarker of internal dose 
may be sufficient to assess the risk of adverse effects. Urine and blood are the most used 
biological samples for the determination of parent compounds and/or their metabolites and for its 
non-invasiveness, however, when possible, urine is preferable due to its non-invasiveness. Blood 
is needed for the determination of macromolecular adducts, which are considered biomarkers of 
biologically effective dose.  
 
A biological marker of an effect or response can be any change that is qualitatively or 
quantitatively predictive of health impairment or potential impairment resulting from exposure. 
An effect is defined as “an health impairment or (by general consensus) recognized disease; an 
early precursor of a disease process that indicates a potential for impairment of health; or an 
event peripheral to any disease process correlated with it and thus predictive of development of 
impaired health”.  
 
It is important to realize, however, that these markers represent points on a continuum evolution, 
whose boundaries may change as knowledge increases. 
Early biological responses may include alterations in the functions of the target tissue shortly 
after exposure. Organs or tissues that are not directly involved in the disease process may also 
exhibit a response proportional to the biologically effective dose. 
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The ideal biomarkers should be predictive of effect, should be detected early and be able to show 
adverse effects before they are irreversible. They are particularly useful in the evaluation of 
progressive diseases ranging symptoms that occur sometime after the initial exposure to 
chemicals. In such cases, traditional early warning symptoms of developing disease may be 
lacking. At the same time, the disease, once clinically apparent, may be essentially irreversible.  
 
Those are the most studied biomarkers and they include modifications in some parameters of 
blood composition, alterations of specific enzyme activities, the appearance of DNA or protein 
adducts, localized mRNA and protein increases and the appearance of specific antibodies 
(autoantibodies) against a xenobiotic or a particular cellular fraction (Gil and Pla, 2001). 
 
1.3.2.2 Biomarkers of Exposure 
 
Exposure to n-hexane in occupationally exposed workers has been mostly assessed by 
determination of urinary levels of the toxic metabolite 2,5-hexanedione (Kawai et al., 1991b; 
Saito et al., 1991). However, this measurement reflects only recent exposure, in the order of a 
few hours to a few days, due to its rapid elimination. 
 
2,5-Hexanedione which metabolic pathway of detoxification leads to the formation of 4,5-
dihydroxy-2-hexanone is also excreted in urine as a glucuronide conjugated form (Fedtke and 
Bolt 1987a,b; DeCaprio et al., 1983; Zhu et al., 1993). Therefore, urinary levels of total 2,5-HD 
(free 2,5-HD + 4,5-dihydroxi-2-hexanone + 5-hydroxy-2-hexanone) have been used in routine 
analysis as a biomarker of occupational exposure to n-hexane (Perbellini et al., 1990a). 
Furthermore, the amount of 2,5-HD detected in urine varies more than tenfold, depending on the 
pretreatment of urine (at acid pH) prior to analysis (Fedtke and Bolt 1986a,b, 1987a). In 2001, 
the American Conference of Governmental Industrial Hygienists modified the biological 
exposure index (BEI) for n-hexane and suggested measuring free urinary 2,5-HD (without 
hydrolysis), as 0.4 mg/g creatinine (or 3.5µmol/L), instead of total 2,5-HD (acid hydrolysis), 
corresponding to a Threshold Weight Average, (TWA), of 50 ppm (American Conference of 
Governmental Industrial Hygienists, 2004). This modification is justified, since the treatment of 
urine with acid hydrolysis converts other n-hexane metabolites (4,5-dihydroxy-2-hexanone and 
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5-hydroxy-2-hexanone) into 2,5-HD. These other n-hexane metabolites are not neurotoxic and 
are conjugated to glucuronic acid and, therefore, easily excreted in urine. Moreover, the 
hydrolysis of urine is not a necessary step in the measurement of 2,5-HD, since it is excreted 
unbound in urine (Fedtke and Bolt 1987b; Manini et al., 1999). 
In fact, “free” 2,5-HD is a good analytical and biological biomarker of n-hexane exposure, that 
may indicate the amount of 2,5-HD that escapes to the detoxification process, and might 
provoke, neurotoxicity, being a better predictor of the neurotoxic risk than the conjugated 
metabolites that are rapidly excreted in urine (Manini et al., 1999, 2004, 2006; Mateus et al., 
2001).  
 
According to Manini et al. (2006), the reappraisal of n-hexane metabolism allowed to draw 
important conclusions in occupational field: “free” 2,5-HD is both suitable from an analytical 
point of view and meaningful for biological monitoring purposes, since the neurotoxic risk 
arising from conjugated metabolites is negligible. Thus, since “free” 2,5-HD corresponds to the 
main metabolite responsible for the neurotoxicity of n-hexane, its determination is a good 
indicator of neurotoxicity.  
However, there are limitations in its analytical determination resulting from the low levels found 
in individuals exposed (false negatives) and because this compound was detected in urinary 
concentrations, for total 2,5-HD, in the order 0.2 to 0.8 mg/L, in individuals not exposed to n-
hexane (Fedtke and Bolt 1986b; Bavazzano et al., 1998). This 2,5-HD, also called endogenous, 
could be due to environmental pollutants, to the process of lipid peroxidation, or to intermediates 
resulting from the metabolism of carbohydrates in the body (Filser et al., 1983; Perbellini et al., 
1993; Manini et al., 1998). 
 
Other biomarkers could alternatively be used for the biological monitoring of n-hexane, for 
instance, the measurement of n-hexane in blood can be used (Brugnone et al., 1978; Veulemans 
et al., 1982; Perbellini et al., 1986). However, this measurement is invasive, and the difficulty in 
measurement is complicated by the fact that n-hexane is highly volatile. On the other hand, the 
measurement of unchanged n-hexane in alveolar air was recommended by the ACGIH in the past 
as a confirmatory test of exposure to n-hexane. This measurement could be useful for biological 
monitoring purposes because of its simplicity and high specificity and also because it is related 
to the concentration of n-hexane in blood. However, few studies have examined this indicator 
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(Filser et al., 1987; Brugnone et al., 1991; Periago et al., 1993; Cardona et al., 1996; Hamelin et 
al., 2004) and they couldn’t reach a conclusion since the used methodology was different in the 
referred studies. 
 
Hamelin and collaborators (2004) characterized, for 5 consecutive days, the relationship between 
n-hexane exposure (25 ppm and 50 ppm) and n-hexane excretion in alveolar air, and urinary 2,5-
HD excretion in human volunteers. Through their study they conclude that both free urinary 2,5-
HD and n-hexane in alveolar air measurements could be used for the biological monitoring of 
exposure to n-hexane. These authors consider that between these two indicators, n-hexane in 
alveolar air is less variable than 2,5-HD in urine, nevertheless the sampling time is more critical. 
After doing the study they suggest that biological monitoring of n-hexane based on the 
measurement of free urinary 2,5-HD is preferable to n-hexane in alveolar air.  
 
1.3.2.3 Biomarkers of Susceptibility 
 
Both the host and external environment factors affect many toxicant-induced health impairments 
and diseases and the metabolic enzyme gene polymorphisms on individual susceptibility to n-
hexane-induced peripheral nerve damage, may be associated with a possible marker of 
susceptibility. 
 
The differences in individual expressions of toxicity have become a hot point in toxicology 
because, although epidemiological studies have shown that occupational exposure is a major risk 
factor for n-hexane neuropathy, only a small fraction of workers exposed to n-hexane develop 
neuropathy (Zhang et al., 2006).  
 
A marker of susceptibility could be a genetic factor such as the variants of metabolic genes for n-
hexane that are involved in the procession of n-hexane neuropathy, as CYP2E1, and 
consequently individual susceptibility to peripheral nerve damage (Chang et al., 1993; Jenner, 
1998). Metabolic interferences arising from habits and genetic polymorphisms should be 
carefully considered in order to explain inter- and intra-individual variability, even as biological 
conditions as sex, age, fatty mass, diseases and chronobiological factors (Mutti, 2001). Inter-
individual differences in absorption, bioavailability, excretion and DNA repair should be taken 
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into account. Moreover, intra-individual differences, as a consequence of particular 
physiopathological alterations occurring in a specific period of time, also should be considered 
(Gil and Pla, 2001). 
 
The CYP2E1 enzyme is responsible for metabolism of various aliphatic and aromatic 
hydrocarbons, solvents, and industrial monomers, including n-hexane and acetone. This 
isoenzyme is associated with free radical production and formation of endogenous toxins. 
Selectively localized in nigral dopamine-containing cells, CYP2E1 metabolizes n-hexane leading 
to the formation of its neurotoxic metabolite 2,5-HD (Jenner, 1998).  
 
Iba and col. (2000) demonstrated that 2,5-HD formation following n-hexane exposure occurs 
more extensively in wild-type mice that in their CYPE21-deficient counterparts, indicating a 
requirement for CYP2E1 for 2,5-HD formation in the mouse. They also indicate that 
detoxification of metabolite may be more extensive in this species than in rat. The results suggest 
that overall formation of the γ-diketone may be higher in the rat than in the mouse. 
According with Zhang and coworkers (2006), also polymorphism of CYP1A1 and GST genes 
are involved in the formation of 2,5-HD from n-hexane as well as in the elimination of 2,5-HD-
formed electrophile.  
In addition, differences in the development and maturity of phase I and phase II metabolic 
enzymes (specifically CYP2E1) between adults and children have been shown in several studies 
(Johnsrud et al., 2003; Ginsberg et al., 2002). Taken together, these data suggest that differences 
in metabolism of n-hexane may exist within the human population and between adults and 
children (Howd et al., 1983; US EPA/635/R-03/012). 
 
Several authors concluded that CYP2E1 is highly polymorphic in the general population, could 
possibly lead to interindividual differences in the toxicity of chemicals metabolized. The 
polymorphism of this enzyme may be a susceptibility gene to n-hexane-induced peripheral nerve 
system dysfunction (Iba et al., 2000; Bolt et al., 2003; Zhang et al., 2006). 
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1.3.2.4 Biomarkers of Effect 
 
Considering that the mechanism of toxicity of neurotoxicants is often very complex several 
biomarkers of neurotoxicity and of oxidative stress are used alone or in combination to evaluate 
their neurotoxic effects. 
 
Biomarkers of neurotoxicity 
The complexity of the nervous system and its distinctive peculiarities, together with the 
problems associated with determination of precise targets for neurotoxic action, does not allow a 
rapid and easy development of sensitive, specific and reliable biomarkers for neurotoxicity. 
Neurochemical measurements for detecting neurotoxicity in humans are limited by the 
inaccessibility of target tissue. The search for neurochemical parameters in peripheral tissues that 
are obtained easily and ethically in humans is the necessary approach for identifying and 
characterizing neurotoxicity, and could represent a marker for the same parameters in nerve 
tissue (Costa and Manzo, 1995). 
As example we could refer the MAO-B activity. It is used clinically as a marker of 
pharmacological effects of MAO inhibitors, such as in the treatment of Parkinson’s disease. The 
MAO-B activity in platelets has been used as a biomarker of the effects of styrene and 
perchloroethylene occupational exposures, which are known to cause dopamine depletion. 
Changes in MAO-B could represent an adaptive response to dopamine depletion and, 
alternatively, styrene or its metabolite(s) might exert a direct inhibitory effect on the enzyme (Gil 
and Pla, 2001).  
 
Biomarkers of neurotoxicity were recently investigated by our research team, and Santos et al., 
(2012, 2013) selected AChE as a target of Mn in the CNS that may trigger or contribute to the 
development of oxidative stress suggesting that AChE activity may be an early biomarker of Mn 
neurotoxicity and risk assessment in populations exposed to this metal. 
Neurotoxic metals were also studied by Andrade et al., (2013) who performed an in vivo study 
and tested delta-ALA-U and other biomarkers, as exposure and/or neurotoxicity biomarker in 
response to Pb, As or Mn treatments, as well as to a mixture of these 3 metals and they suggested 
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that delta-ALA-U levels may be used as a sensitive peripheral biomarker of exposure and 
neurotoxicity upon exposure to a mixture of Pb, As and Mn. 
 
Biomarkers of oxidative stress  
Industrial solvents such as n-hexane are capable of causing oxidative damage, especially through 
free radicals. In response to oxidative stress, there may be adaptive responses of the antioxidant 
systems, modification of cellular macromolecules and tissue damage.  
Changes in the antioxidant systems and modified macromolecules can serve as biomarkers for a 
variety of xenobiotics. The protective systems include oxidized glutathione/reduced glutathione, 
glutathione reductase, catalase, superoxide dismutase and peroxidase activities. Macromolecules 
that may be affected by free-radical damage include lipids, proteins and nucleic acids (Gil and 
Pla, 2001). 
 
With respect to the lipids, lipid peroxidation is started by the capture of a hydrogen from a fatty 
acid by an oxygen radicalar followed by the formation of hydroperoxides. The degradation of 
these hydroperoxides results in a series of derivatives with various compounds including 
carbonyl groups (Yin and Chen, 2005). The main compounds resulting from lipid peroxidation 
are aldehydes α,β-unsaturated as malondialdehyde (MDA), acrolein and HNE (4-Hydroxy-2 (E)-
nonenal, and γ-ketoaldehydes as Isoketals (IsoKs) and Neuroketals (Picklo et al., 2002; Davies et 
al., 2004). 
 
Lipid peroxidation of arachidonic acid mediated by free radicals, gives rise to H2-Isoprostanes 
(H2-IsoPs isomers of Prostaglandin H2), which in turn lead to the formation of highly reactive γ-
ketoaldehyde called "Isoketals" (IsoKs). The H2-Isoprostanes can still suffer a non-enzymatic 
rearrangement giving rise to the F2-Isoprostanes (F2-IsoPs). 
The quantification of the levels of F2-IsoPs in plasma and urine has been used in studies of 
biomarkers of oxidative stress (Davies et al., 2007). According Sonnen et al., (2007) F2-
Isoprostanes have received considerable attention due to its chemical stability and minimal 
metabolism in situ, making them candidate biomarkers of lipid peroxidation. 
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The γ-ketoaldehydes are highly reactive and form covalent adducts with lysine residues and 
cross-linking with proteins at rates greater than HNE speed. Form Schiff bases adducts lactams 
and stable yielding hidrolactams (Picklo et al., 2002). 
 
Studies have suggested the chemical basis for the extreme reactivity of IsoKs. The products of 
lipid peroxidation, such as HNE, acrolein and other carbonyls α,β-unsaturated, primarily react 
with proteins via Michael addition. Subsequently, these aldehydes generally adduct with Cys and 
to a lesser extent with lysine or histidine residues of proteins (Davies et al., 2004). The carbonyls 
α,β-unsaturated react with lysine to form the adduct hemiaminal, then dehydrate to form an 
imine. Both reactions are highly reversible, so we are in equilibrium in bulk form carbonyl. In 
contrast to the α,β-unsaturated, the γ-dicarbonyls, such as 2,5-HD, react rapidly to form the 
adduct hemiaminal (Fig. 1.6). The carbonyl group of hemiaminal can suffer intramolecular 
nucleophilic attack by the amine yielding a highly unstable pyrrolidine adduct.  
A methyl 2,5-HD substitution increases the rate of formation of the pyrrole-adduct 10 times, 
probably through dialkyl effect. As IsoK is similar to dimethyl-2,5-hexanedione in relation to 
dialkyl substitution, is expected a rapid formation of pyrroles to IsoKs (Fig. 1.7) (Roberts et al., 
1999; Davies et al., 2004, 2007). 
 
Another important aspect concerning the alkyl substitution for γ-dicarbonyls is the impact of the 
oxidability of pyrrole adducts. The increased electron density of pyrroles formed from 3,4-
dimethyl-2,5-hexanedione compared with those formed by 2,5-HD enables rapid oxidation in the 
presence of molecular oxygen. The oxidation of pyrrole leads to further cross-linking probably 
via formation of an electrophile which undergoes nucleophilic attack. The ability of γ-
dicarbonyls substituted undergo cross-linking with proteins appears to be directly related to their 
susceptibility to oxidation. 
The pyrrolidine then undergoes rapid dehydration to form the pyrrole adduct. These fast 
reactions are essentially irreversible, and quickly originate free γ-dicarbonyls pyrrole adducts.  
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Figure 1.6 Proposed mechanism for imine and pyrrole adduct formation from isoketal reaction with 
lysine (Adapted from: Davies et al., 2004). 
 
 
 
 
 
 
Figure 1.7 IsoK reacts with lysyl residues of proteins to form imine, pyrrole, lactam, hydroxylactam and 
crosslinked adducts (Adapted from: Davies et al., 2007). 
 
GENERAL INTRODUCTION 
41 
The pyrroles formed by IsoKs should be more easily oxidized than those formed from dimethyl-
2,5-hexanedione, due to the presence of an additional double bond in the pyrrole ring that may 
undergo conjugation (Davies et al., 2004, 2007). 
 
Biomarkers of 2,5-HD neurotoxic effects 
There isn’t any validated biomarker of 2,5-HD neurotoxicity, however several studies have 
investigated endpoints of 2,5-HD toxicity to be selected as biomarkers of effect. 
Experiments in rats exposed to γ-diketones have shown that formation of 2,5-HD-hemoglobin 
adducts is proportional to both: time and dose (Anthony et al., 1988; Costa, 1996). As the 
formation of adducts has been shown to be causally related to the development of neuropathy, 
hemoglobin may be seen as a surrogate for neurofilaments during in vivo exposure. As such, 
measurements of hemoglobin pyrrole adducts in the case of n-hexane are more than a biomarker 
of exposure and can be seen as a biomarker of effect. In this regard, more detailed dose-response 
studies in animals, as well as studies in humans, may be useful to arrive at a better quantitative 
assessment of neurotoxic risk linked to exposure to n-hexane or other γ-diketone precursors. As 
the cross-linking of neurofilaments is essential for neurofilament-filled axonal swellings 
(Graham et al., 1995), the ability to measure protein cross-linking in an accessible tissue would 
provide an additional means of assessing exposure to and health effects of n-hexane.  
 
A protein present in erythrocytes, spectrin, has proved to be useful in this regard. The α and β 
subunits of spectrin are closely associated on the cytoplasmic side of the red blood cell 
membrane. Cross-linking compounds yield α,β-heterodimers that can be identified (in SDS 
polyacrylamide gels). Neurotoxic γ-diketones have been indeed shown to cause spectrin 
dimerization, while administration of nontoxic diketones does not cause spectrin cross-linking 
(Anthony et al., 1983; Genter et al., 1987, 1988; Costa, 1996). Erythrocytes are a source of stable 
proteins, and cross-linked spectrin can be detected in rats receiving daily ip injections of 2,5-HD. 
 
Based on the mechanism of toxic action of 2,5-HD, some authors have proposed (Graham et al., 
1995; Costa, 1996) the determination of adducts formed between pyrrole 2,5-HD and 
endogenous proteins as biomarkers of cumulative exposure to n-hexane, which reflects the 
amount of free 2,5-HD available to react with the target proteins. Thus, assessment of pyrrole 
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derivatives in serum and in urine (Mateus et al., 2002; Yin et al., 2014) may reflect the formation 
of pyrrole adducts, and be potential predictive biomarkers for neurotoxic effects. 
However, these derivatives can either be present in the body due to exposure to certain 
xenobiotics, or due to genetic factors that determine changes in the physiological processes that 
induce the development of certain diseases (Landrigan et al., 2005; Sonnen et al., 2007).  
 
The pyrrolization of proteins was observed in various diseases such as diabetes, Parkinson's 
disease, Alzheimer's disease, atherosclerosis, kidney disease, senile macular degeneration 
(Hidalgo et al., 1998; Martínez-Cruz et al., 2002) being pyrrole adducts formed as consequence 
of lipid peroxidation (Manini et al., 1998; Hidalgo et al., 2001; Gu et al., 2003; Davies et al., 
2004).  
The detection and characterization of these pyrroles may well be an index of the stress exerted 
by the cell in the body (Hidalgo et al., 1998), leading to the knowledge of the origin and the 
pathogenesis of some diseases, including neurodegenerative, even as a preventive warning 
system in order to facilitate timely therapeutic intervention in certain diseases (Gu et al., 2003). 
 
 
1.3.2.5 Analytical methods to determine biomarkers of exposure  
 
Analytical methods for routine analysis of biomarkers of exposure are mainly based on 
chromatographic techniques, both gas chromatography (GC) and liquid chromatography (LC) 
coupled with different kinds of detectors. GC is used for the determination of unchanged organic 
solvents present in exhaled air, blood, and urine. Identification of polar metabolites by gas 
chromatography-mass spectrometry (GC-MS) is not difficult, if these products tend to be 
relatively volatile and thermally stable (Manini et al., 2004). According with Manini et al., 
(2004, 2006), although the application of LC-MS in biomarker research is relatively young, 
recent studies clearly showed the potential of this technique in the determination of traditional 
biomarkers of exposure, as well as in the metabolism studies aimed at investigating minor 
metabolic routes.  
Polar metabolites are molecules suitable for determination by LC. Efficient chromatography of 
acidic metabolites is obtained by using phosphate buffers, whereas retention of conjugated 
metabolites was obtained by ion-pair reversed phase (RP) chromatography.  
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Limitations due to the scarce sensitivity and selectivity of UV detection have been overcome by 
proper sample preparation: extensive sample clean up limits interferences from the matrix. 
Sample pre-concentration, derivatization with UV-chromophores or fluorescent reagents have 
been proposed to improve the characteristics of routinary used LC methods. 
 
Exposure to n-hexane in occupationally exposed workers has been mostly assessed by 
determination of urinary levels of the toxic metabolite 2,5-hexanedione (Saito et al., 1991), being 
the urinary excretion of 2,5-HD an established biomarker of exposure to n-hexane and a suitable 
predictor of neurotoxic effects (IPCS 122, 1991; Mutti et al., 1984; Kawai et al., 1991b). Since 
most n-hexane metabolites are excreted only after conjugation with glucuronic acid, their 
determination by GC or HPLC requires preliminary hydrolysis (enzymatic and/or acid) followed 
by liquid–liquid extraction (Perbellini et al., 1981b; Fedtke and Bolt, 1987a,b; Perbellini et al., 
1990a; Kawai et al., 1990, 1991a). 
 
In the Table 1.4 is indicated the analytical/instrumental techniques used to detect biomarker 2,5-
HD as well as the detection of pyrrole compounds in urine of animals exposed to n-hexane or 
2,5-HD. 
 
Throughout our work we use as analytical techniques, the spectrophotometric method of Ehrlich, 
GC-MS and ESI-LC-MS/MS techniques. 
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Table 1.4 Analytical/instrumental techniques used to detect biomarker 2,5-HD or pyrrole compounds in 
urine of animals exposed to n-hexane or 2,5-HD. 
Parent 
compound 
Biomarker Method 
Sample 
preparation 
Internal 
standard 
Reference 
n-Hexane 2,5-HD GC-FID Yes Yes Saito et al., 
1991  
n-Hexane 2,5-HD LC-APCI-MS Direct 
injection 
None Andreoli et al., 
1998 
n-Hexane 2,5-HD GC-MS  
ESI-LC/MS(MS) 
Yes  
Direct 
injection 
Yes 
 None 
Manini et al., 
1998 
n-Hexane PLS UV-Vis Spectrom. 
Ehrlich Method 
Yes None Mattocks and 
White, 1970 
2,5-HD PE UV-Vis Spectrom. 
Ehrlich Method 
Yes None  Mateus et al., 
2000 
2,5-HD DMPN LC-MS/MS Direct 
injection 
None Torres et al., 
2014 
PLS: Pyrrole-like substances; PE: Pyrrole equivalents; DMPN: dimethylpyrrolenorleucine 
 
 
1.4 MECHANISM OF TOXICITY OF PYRROLE COMPOUNDS 
 
1.4.1 DIMETHYLPYRROLE ADDUCTS 
 
Several studies showed that 2,5-HD could react directly with axonal protein by the formation of 
N-substituted 2,5-dimethylpyrrole adducts at ε-amine nitrogen of the lysine residues of 
neurofilaments (Fig. 1.8) (Pyle et al., 1992; Graham et al., 1995; DeCaprio et al., 1997).  
Secondary oxidation of the pyrrole ring to an electrophile reacted with neurofilament 
nucleophiles resulting in intra- and intermolecular protein cross-linking, and this was considered 
to be the determinant event in 2,5-HD neuropathy (Graham et al., 1982; DeCaprio, 1986; Sayre 
et al., 1986; Genter et al., 1988; DeCaprio et al., 1988; Zhu et al., 1994). 
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Figure 1.8 Sequential covalent binding of the electrophile 2,5-hexanedione to lysine residues of axonal 
proteins results in the formation of a 2,5-dimethylpyrrole adduct. (Adapted from: Boelsterli, Urs A., 
Mechanistic toxicology: the molecular basis of how chemicals disrupt biological targets. 1
st
 ed., Taylor & 
Francis, London, 2003). 
 
 
According to LoPachin and DeCaprio, (2004) pyrrole adduct formation in NF proteins has been 
proposed to result in physicochemical changes in the proteins sufficient to interfere with the 
ability of mobile NF proteins to interact with the polymeric cytoskeleton and to cause NF 
accumulation and nerve degeneration (Fig. 1.2). As a result, the adducted subunit remains 
attached to the kinesin transport vector which, in the absence of compensatory changes in gene 
expression or synthesis, promotes a loss of NF protein content per unit area of axon. 
 
Pyrrolylated proteins are susceptible to attack by molecular oxygen and most of alkylpyrroles 
undergo the same reaction (DeCaprio and O’Neill, 1985). 
It was observed that autoxidation of alkylpyrrole adducts in vivo (DeCaprio 1986; Lapadula et 
al., 1986; Carden et al., 1986) and in vitro (DeCaprio et al., 1982; Zhu et al., 1993) leads to the 
cross-linking of numerous proteins, including NF proteins. Pyrrole oxidation-mediated covalent 
cross-linking of NF proteins has been proposed as the second obligatory step in γ-diketone 
neuropathy (Graham et al., 1982; Genter et al., 1988; Zhu et al., 1995). 
 
Zhu and coworkers (1993, 1994) showed that 2,5-dimethyl-N-alkylpyrroles are chemically 
reactive in aqueous solutions at physiologic temperature and undergo spontaneous and rapid 
autoxidation to form pyrrole dimers and trimmers (Fig. 1.9 B). A clear understanding of the 
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reaction of autoxidation of N-substituted 2,5-dimethylpyrroles is a prerequisite for the 
elucidation of a role for protein cross-linking in 2,5-HD neurotoxicity. 
 
The oligomers compounds obtained from autoxidation reaction of 2,5-dimethyl-N-alkylpyrroles 
contain methylene bridges between C-2 of one pyrrole ring and C-3 of a second ring (Zhu et al., 
1994, 1995). The same autoxidative dimerization occurred when NAL or lysine containing 
dipeptides are incubated with 2,5-HD. 
The secondary autoxidative phenomena following gamma-diketone-treated protein that 
originates pyrrole adduct formation proceed free radical-mediated mechanisms (DeCaprio, 
1986). 
 
Thus, pyrrole-to-pyrrole linkages mediate by 2,5-HD-derived protein cross-linking and 
autoxidative pyrrole-pyrrole dimerization may involve free radical chain reaction (Zhu et al., 
1993, 1994, 1995). In addition to autoxidative dimerization of pyrrole compound, alternative 
cross-linking reactions may involve oxidized pyrrole rings and protein nucleophiles, such as 
thiols and amines (Fig. 1.9 A and C) (Tshala-Katumbay, 2005, 2008, 2009a). 
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Figure 1.9 Autoxidative dimerization of pyrrole compound (B) and alternative cross-linking reactions 
involving pyrrole rings and protein nucleophiles, such as thiols (A) and amines (C). (Adapted from Moser 
et al., In Casarett and Doull’s Toxicology: The Basic Science of Poisons. 8th ed. McGraw-Hill, New 
York, 2013, and Mateus M.L.; Avaliação e Prevenção do Risco de Exposição a Misturas com n-Hexano: 
Parâmetros Bioquímicos e Comportamentais. Faculdade de Farmácia, Universidade de Lisboa, Lisboa, 
2002). 
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1.4.2 PYRROLE COMPOUNDS AND FREE RADICALS 
 
Pyrrole dimerization may involve free radical chain reactions, and biological nucleophiles 
namely NAC and reduced glutathione (GSH) could directly or indirectly affect the formation of 
pyrrole dimers by inhibiting this process (Amarnath, et al., 1994; Zhu et al., 1995).  
Free radicals promote oxidation, because contain one or more unpaired electrons, act as electron 
acceptors and essentially “steal” electrons from other molecules. They are referred to as 
oxidizing agents because they tend to induce other molecules to donate their electrons.  
 
Figure 1.10 Proposed mechanism of formation of thiol conjugated adducts, via Thiol-to-Pyrrole 
conjugation and direct antioxidation action, and formation of pyrrole dimers, via autoxidative Pyrrole-to-
Pyrrole Cross-linking (Adapted from Zhu et al., 1995). 
 
 
We are constantly exposed to free radicals created by electromagnetic radiation from the 
environment, both natural (e.g., radon, cosmic radiation) and man-made, and by internal cellular 
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metabolism. The most common cellular free radicals are hydroxyl radical (OH●), superoxide 
radical (O2-●), and nitric oxide (NO●). Other molecules, such as hydrogen peroxide (H2O2) and 
peroxynitrate (ONOO), are not free radicals, nevertheless can lead to their generation through 
various chemical reactions. Free radicals and related molecules are often classified together as 
reactive oxygen species (ROS) to signify their ability to promote oxidative changes and 
oxidative stress within the cell (Gilgun-Sherki, 2001). 
 
The presence of free radicals promotes the formation of crosslinked adducts (Amarnath, et al., 
1994; Zhu et al., 1995). In fact secondary autoxidative reactions of the formed alkylpyrroles 
leads to electrophilic pyrrolylmethyl intermediates followed by their capture by unoxidized 
second pyrroles, forming pyrrole dimers which produce intra and intermolecular cross-linking in 
neurofilaments (NF) proteins. If, as has been proposed, covalent cross-linking of NF proteins is 
critical to the mechanism, it is conceivable that biological thiols could exert protective effects 
against γ-diketone neuropathy by interrupting the cross-linking process (Fig. 1.10). Alternatively, 
a lack of effect of GSH would be consistent with the hypothesis that pyrrole formation itself is 
sufficient to cause neuropathy.  
 
 
1.4.3 ENDOGENOUS PRODUCTION OF PYRROLE COMPOUNDS 
 
The presence of 2,5-HD in subjects who have not been occupationally exposed to n-hexane (or 
methyl-n-butyl ketone) is referred by several authors and is important to determine its origin in 
the human body (Brugnone et al., 1991; Mutti et al., 1993;  Bavazzano et al., 1998).  
 
Canesi et al. (2003) found in urine samples of persons not exposed to n-hexane 372±47 μg/mL of 
2,5-HD, and Kessler et al., (1990), reported that 2,5-HD originates pyrrole substances that were 
identified and defined as PLS “pyrrole-like substances”. In addition, pyrrolic compounds not 
originated from 2,5-hexanedione, e.g. urobilinogen, are normal constituents of urine and can be 
detected by Ehrlich's reagent.  
 
In people not exposed to n-hexane, 2,5-HD and 4,5-dihydroxy-2-hexanone are products mainly 
deriving from intermediate metabolism in the human body. Only a minimal part may derive from 
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n-hexane as a ubiquitious micropollutant. The presence of n-hexane and its isomers in gasoline 
and fuels (6%) makes this solvent a ubiquitous pollutant for which reference biological levels in 
the general population need to be defined. Such trace amounts might originate from atmospheric 
contamination or endogenous production of hexane, e.g. by lipid peroxidation (Perbellini et al., 
1993; Manini et al., 1998). According with Brugnone et al., (1991), despite the possibility of this 
endogenous production of aliphatic short-chain hydrocarbons, seems reasonable they conclude 
that urinary 2,5-HD found in the general population should be considered to have derived from 
inhaled n-hexane rather than from an endogenous production. 
 
 
1.5 PYRROLE COMPOUNDS AND NEURODEGENERATIVE DISEASES 
 
Epidemiological studies and basic molecular research have led to the supposition that exposure 
to chemicals in the environment contributes to the onset and development of human 
neurodegenerative diseases (Eisen, 1995; Landrigan et al., 2005; LoPachin et al., 2008a,b). 
These diseases result from the gradual and progressive loss of neural cells, leading to nervous 
system dysfunction. Known risk factors for neurodegenerative disease include certain genetic 
polymorphisms and increasing age. Other possible causes may include gender, poor education, 
endocrine conditions, oxidative stress, inflammation, stroke, hypertension, diabetes, smoking, 
head trauma, depression, infection, tumors, vitamin deficiencies, immune and metabolic 
conditions, and chemical exposure (Brown et al., 2005).  
 
A number of studies have examined the relationship between exposure to environmental agents 
and neurologic outcomes, since exposure to numerous structurally diverse chemicals can cause 
significant morphological and functional damage to nerve cells in the CNS and PNS (Brown et 
al., 2005; LoPachin and DeCaprio, 2005). Table 1.5 summarizes the clinical features of some of 
the major neurodegenerative diseases (Singh et al., 2004). 
 
Because the pathogenesis of many of these diseases remains unknown, we must consider the role 
of environmental factors in these diseases. 
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Despite significant research, the pathophysiological and molecular mechanisms for many 
neurotoxicants remains poorly defined. However, a common mechanistic theme in the 
toxicological sciences has been the formation of chemical adducts with macromolecules.  
Presumably cell toxicity occurs when adduct formation disrupts the structure and/or function of 
macromolecules (Fig. 1.2) (Nelson and Pearson, 1990; Hinson and Roberts, 1992). Since many 
neurotoxicants and their metabolites are electrophiles, it is possible that adduct formation is also 
a critical step in the neuropathogenic processes initiated by exposure to these chemicals 
(LoPachin and DeCaprio, 2005; LoPachin et al., 2008). 
 
Table 1.5 Characteristics feature of a few neurodegenerative (NDG) diseases.  
NDG diseases  Clinical features  Neuropathology 
Alzheimer’s 
Disease (AD) 
 Dementia, progressive deterioration 
of thought, judgment, language 
skills, visual-spatial perception and 
mood 
 Generalized cortical atrophy with 
shrinkage of the amygdala and 
hippocampus. Selective dysfunction 
and death of neocortex, 
hippocampus, amygdala, basal 
forebrain, and brainstem. 
The senile plaque, an extracellular 
deposit of amyloid, composed of Ab 
peptide derived from amyloid 
precursor protein. 
     
Amyotrophic 
Lateral Sclerosis 
(ALS) 
 Progressive weakness and atrophy 
of skeletal muscles. Weakness of 
chest muscles and diaphragm and 
muscle dysfunction in the larynx 
and pharynx lead to respiratory 
problems and death with 
bronchopneumonia. 
 End stage disease is characterized by 
loss of primary motor neurons in the 
neocortex. 
Motor neurons have abnormal 
phosphorylated neurofilaments. 
     
Parkinson’s 
Disease (PD) 
 Slowness of voluntary movement 
(bradykinesia), rigidity, and tremor. 
Cognitive deficits (dementia), i.e., 
post encephalitic parkinsonism. A 
mitochondrial toxin called MPTP 
induces parkinsonism. 
 Neuronal degeneration due to the 
loss of the pigmented neurons in the 
substantia nigra (pars compacta). The 
toxic metabolite MPP
+
 derived from 
MPTP, inhibits the mitochondrial 
complex I leading to ATP depletion 
and generation of toxic oxygen free 
radicals. 
(Adapted from: Singh et al., 2005). 
CHAPTER 1 
52 
 
The protein adduct formation could result in toxic neuropathies as adduct formation could 
negatively impact the tertiary structure and/or function of these proteins and thereby interfere 
with, for example, energy metabolism, axonal transport or presynaptic neurotransmitter release. 
It is also possible, for electrophilic neurotoxicants to produce specific effects by reacting with 
functionally critical nucleophilic centers on proteins that regulate cellular pathways or processes. 
Understanding the chemistry and pathophysiological consequences of adduct formation could 
not only benefit neurotoxicology, as yet might also provide insight into mechanisms of human 
neurodegenerative diseases. 
 
The compounds originated by the reactions resulting from the action of the reactive oxygen 
species are also associated with various neurodegenerative diseases. 
For Alzheimer's disease (AD), high levels of HNE were found in brains and cerebrospinal fluid 
(CSF) of AD patients. Also in cerebrospinal fluid products resulting from the action of free 
radicals in carbohydrates, was found. It was also found high levels of acrolein in the amygdala 
area. Also in hippocampus and inferior parietal lobule, products generated by oxidation by 
hydroxyl radical, the amino acid side chains or derived by the alkylation of multifunctional 
products such as acrolein and HNE were found (Picklo et al., 2002). 
 
1.5.1 ALZHEIMER’S DISEASE 
 
Alzheimer’s disease represents the most common form of dementia in the elderly, characterized 
by progressive loss of memory and cognitive capacity severe enough to interfere with daily 
functioning and the quality of life. The disease is characterized by extracellular amyloid deposits 
or plaques and by the presence of intraneuronal neurofibrillary tangles composed of aggregates 
of hyperphosphorylated tau protein (Migliore and Coppedè, 2009).  
The neurodegeneration associated with Alzheimer’s disease (AD) appears to involve oxidative 
damage characterized by protein oxidation (Hensley et al., 1995; LoPachin and DeCaprio, 2005), 
increased expression of antioxidant enzymes (Pappolla et al., 1998), and elevated lipid 
peroxidation (Sayre et al., 1997). Evidence suggests that the AD process involves several factors 
(genetic, age-related, and environmental) that converge to initiate neuronal oxidative stress and a 
subsequent pathophysiological cascade. Lipid peroxidation, a major consequence of oxidative 
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stress, is the free-radical driven fragmentation of polyunsaturated fatty acids and is a biochemical 
hallmark of AD (Arlt et al., 2002; Keller and Mattson, 1998; Montine et al., 2002; Zarkovic, 
2003; LoPachin et al., 2008). 
 
As we have referred, lipid peroxidation produces several α,β-unsaturated aldehydes (e.g., 
acrolein, malondialdehyde, 4-hydroxy-2-nonenal) among which, acrolein has the highest 
nucleophilic reactivity (Picklo et al., 2002; LoPachin and DeCaprio, 2005). Acrolein-protein 
adducts have been detected in brains of AD patients, and are considered to be a biomarker of the 
accompanying oxidative stress (Uchida et al., 1998). In addition, it has been hypothesized that 
acrolein adduct formation with lysine residues on tau proteins might play a role in the 
development of neurofibrillary tangles that are a pathological hallmark of AD (Calingasan et al., 
1999; Picklo et al., 2002).  
It is interesting to note that acrolein is a ubiquitous environmental pollutant (LoPachin and 
DeCaprio, 2005). Thus, the pathophysiology of AD could involve protein adduct formation 
mediated by both endogenous and exogenous neurotoxic components. 
 
The contribution of adducts formed between IsoKs and proteins to cellular dysfunction also 
remains an area of considerable interest because initial findings suggested that these adducts 
contribute to the mechanism of Alzheimer's disease. Exogenous IsoKs inhibit the mitosis and 
microtubule aggregation, break the blood-brain barrier and induce necrosis in tissues of the brain 
(Davies et al., 2007). 
 
1.5.2 PARKINSON’S DISEASE  
 
The growing scientific consensus is that Parkinson’s Disease (PD) is not a single disorder, 
however instead reflects a common pathological endpoint resulting from the interaction of 
various environmental and genetic risk factors. Thus, the risk attributable to any single factor is 
likely to be small and to differ depending on specific population characteristics. 
Although genomic screening studies are steadily producing more data relating genes to PD 
(Martin et al., 2001; Scott et al., 2001; Moore et al., 2005), there is evidence that also 
environmental factors are involved (Tanner et al., 1999), and the generally accepted hypothesis 
is that the disease is the result of an interaction between the two components. 
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It has been suggested that individuals with particular genotypes may have difficulty in 
metabolizing one or more environmental neurotoxicants and that this “poor metabolizer” status 
could make them susceptible to developing PD following exposure to such neurotoxins (Pezzoli 
et al., 1995; Canesi et al., 2003). 
Toxin accumulation could produce selective neurodegeneration in the substantia nigra through 
mechanisms involving oxidative stress (Moore et al., 2005). 
Hydrocarbon-solvents are environmental toxins that appear to be involved in the pathogenesis of 
PD. Prolonged exposure to these substances has been associated with PD in a number of case 
reports (Gralewicz and Dyzma, 2005). 
 
Moreover, a large study in PD patients has recently shown that chronic exposure to hydrocarbon-
solvents contributes towards earlier onset of PD and more severe disease throughout its course 
(Pezzoli et al., 2000; Canesi et al., 2003). One of the compounds involved was n-hexane, which 
is a neurotoxin that can induce a very well described peripheral neuropathy and also cause 
damage to the central nervous system (IPCS 122, 1991). 
As we already have referred, n-hexane and its derivatives are common environmental 
contaminants, and they are also present in the human body independently of environmental 
micropollution as by-products of lipid peroxidation (Fedtke and Bolt 1986a; Vaz and Coon, 
1987).  
Canesi et al., (2003) show that advancing age and PD are both associated with a reduction in 2,5-
HD and 2,5-DMP urinary levels. The lower 2,5-HD blood and urinary levels could be due either 
to reduced conversion of n-hexane to 2,5-HD or to an increase in the catabolization of 2,5-HD. 
The finding of lower urinary levels of 2,5-DMP, which is a metabolite of 2,5-HD, rules out an 
increase in the catabolism of 2,5-HD, suggesting that the conversion of n-hexane to 2,5-HD is 
reduced in PD patients and elderly controls (Vanacore et al., 2000). 
The reduction in the catabolisation of n-hexane was related to age and the incidence of PD 
increases with age (Canesi et al., 2003). The characteristic Lewy bodies found in the brain of 
patients with PD or Lewy Body Disease and in about 10% of elderly patients contain ubiquitin- 
positive protein conjugates. These are present also in the intermediate filament aggregates found 
in the peripheral and central nervous system of rats exposed to n-hexane (Savica et al., 2010). 
Thus, aging and PD may be associated with a reduction in the capacity to eliminate the 
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hydrocarbon n-hexane. This metabolic alteration may play a role in the pathogenesis of PD 
(Vanacore et al., 2000). 
 
1.6 PROTECTION AGAINST n-HEXANE NEUROTOXICITY 
 
Occupational exposure 
The best way to avoid outbreaks is to use a cleaning solvent with very low n-hexane content, or 
better still, to find a non-toxic substitute for n-hexane. Short of this, safety regulations and 
guidelines in handling n-hexane must be strictly adhered to. Workers should be periodically 
screened for the development of toxicity (Chang et al., 1993).  
 
Table 1.6 shows a list that is not exhaustive, rather gives an indication of the likely intensity of 
exposure in a range of occupations. The actual solvent exposure is determined by a number of 
factors including which solvent is used, in what concentration, the method of use, adequacy of 
ventilation, and the personal protective equipment employed. For example, a house painter 
applying water based paint by brush in a well-ventilated room will have considerably lower 
exposure than one spray painting high solvent paint in a poorly ventilated cellar. 
 
Table 1.6 Occupation with exposure to solvents (including n-hexane). 
 
Occupation 
 
  
Intensity of solvent exposure 
Dry cleaning, screen printing, rotogravure printing, industrial 
painting, manufacture of glass reinforced plastic, tile fixing 
 High exposure 
House painting, mechanic, assembly processes using solvents, paint 
making, industrial degreaser 
 Moderate exposure 
Petrol pump attendant, joiner/carpenter, chemical process operator, 
laboratory technician, cleaner using polishes 
 Low exposure 
(Adapted from: Dick, 2006) 
 
 
In the occupational health context, atmospheric levels should be kept below the recommended 
occupational exposure limits by suitably designed work processes and engineering controls 
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including ventilation. Suitable protective clothing and respiratory protection should be readily 
available for use in enclosed spaces, in emergencies, and for certain maintenance operations. The 
use of a supplied-air respirator or a self-contained breathing apparatus in continuous flow mode 
for n-hexane concentrations up to 8 800 mg/m
3
 (2 500 ppm) is recommended. It should be fitted 
with a full face piece for concentrations between 8 800 mg/m
3 
(2 500 ppm) and 17 600 mg/m
3
 (5 
000 ppm). Although, protective gloves may resist to penetration by n-hexane, mixtures of n-
hexane with other solvents, such as methyl ethyl ketone, may permit the n-hexane to penetrate 
gloves and other protective clothing.  This factor should be considered when using n-hexane 
mixtures (IPCS 122, 1991).  
 
Environmental Exposure 
At the levels of n-hexane to which the general population is exposed, is unlikely to be any hazard 
except in the case of major spills or discharges where there could be transient local effects (IPCS 
122, 1991). 
 
1.6.1 CHEMICAL PROTECTION 
 
In a perspective of protection of human health, it is important to study protective agents and/or 
antagonists of n-hexane, which may interfere with the formation of 2,5-HD and/or of pyrrole 
adducts, due to environmental of occupational exposure as the occurrence of certain diseases. 
In this context, risk prevention against n-hexane neurotoxicity is a relevant issue towards the 
measures to be proposed in occupational toxicology. One of the approaches that could be applied 
in risk protection against n-hexane neurotoxicity is the development of a 2,5-HD antagonist that 
could interfere with its chemical mechanism of toxicity. 
 
1.6.1.1 Role of Zinc 
 
Zinc is a transition element that has the ability to form coordinating bonds with electronegative 
atoms (oxygen, sulphur and nitrogen) and Zn (II) is an essential ion and is required as cofactor 
for many metalloenzymes. It regulates metallothionein (MT) synthesis and can interact with 
radical chemical toxicity of several compounds (Bertini et al., 1994).  
GENERAL INTRODUCTION 
57 
Mateus and co-workers (2000, 2001, 2002), investigated the protective role of zinc against the 
neurotoxic effects of 2,5-HD using in vivo models, where two different routes of exposure (oral 
and ip) were tested rats exposed to 2,5-HD and rats co-exposure to 2,5-HD and zinc (2,5-
HD+Zn). They found a decrease in the excretion of pyrroles derivatives and free 2,5-HD as well 
as a recovery in motor activity performance was found in rats co-exposed to (2,5-HD+Zn) 
(Mateus et al., 2000, 2001). The mechanism of this interaction was also investigated applying 
chemical models simulating the in vivo synthesis of dimethylpyrroles using the reaction of 2,5-
HD with NAL in presence or absence of a zinc compound (Mateus et al., 2000). The prevailing 
mechanism of this interaction was also investigated in rats co-exposed and pre exposed to zinc 
acetate and it was concluded that on comparing the changes in pyrroles excretion, there was a 
similar decrease in urinary excretion of pyrroles in the two groups of rats exposed to the mixture 
as compared with the pyrroles excreted in rats exposed to 2,5-HD alone (Mateus et al., 2000, 
2002). The results obtained suggest that zinc coordinates mainly to amino groups inhibiting the 
formation of 2,5-HD lysine complexes (Mateus et al., 2001). However, the simultaneous 
depletion of free 2,5-HD does not exclude the possibility of a simultaneous coordination of zinc 
ion to 2,5-HD (Mateus et al., 2000). It is also feasible that this process is affected by other 
factors, such as the reversibility of metal complexes formation and the binding of zinc ion to 
other endogenous critical proteins (as MT), which could add new approaches to evaluate the 
definitive role of this metal ion in the overall process. 
More recently, it has also been reported that in certain degenerative diseases zinc may delay their 
progression (Gu et al., 2003; Jackson et al., 2000, 2010).  
 
Pfeiffer et al., (1974) performed a study with outpatient schizophrenics and found they had low 
levels in serum zinc. They also found approximately 50 percent of the patients had low in blood 
histamine (histapenic) and high in copper, while 20 percent were high in blood histamine 
(histadelic) and normal in serum copper.  
Zinc is needed by the mast cell in order to store histamine. The terminal vesicles of the mossy 
fibers of the hippocampus are high in zinc which may be needed to store histamine for 
histaminergic neurotransmission.  
With specific therapy based on changing low or excess tissue histamine, most problem patients 
improved. A group of 30 percent to 40 percent of patients was normal in their blood histamine 
and normal in serum copper levels. This was the group which excreted kryptopyrrole (KP) or the 
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"mauve factor." They also found that these patients respond to large doses of B6 and dietary 
supplements of zinc because the pyrrole combines with pyridoxal (Vit. B6) and then makes a 
complex with zinc and produces a combined disease deficiency. Some patients had both, the 
mauve factor and a histamine imbalance. The schizophrenias may truly be a series of three or 
more biochemical imbalances. 
According with Pfeifer et al., (1974) several authors have confirmed the original observations 
that abnormal mauve factor is excreted in greater frequency in the urine of schizophrenics. 
Recently, these authors have succeeded in isolating and identifying the mauve factor as 2,4-
dimethyl-3-ethylpyrrole (isomers), an observation confirmed subsequently by Brett Lambert 
(Director of Applied Analytical Laboratories, Australia, in “Overview of Urinary Pyrrole/Mauve 
Factor Analysis”, 2013).  
 
The dose of Vit. B6 needed by the KP-positive patient may be as high as 3000 mg per day to 
prevent Psychopathology and keep the urine free of KP. They found that KP combines with the 
aldehyde of pyridoxal phosphate to form a stable Schiff's base which is then excreted in the urine 
complexed with zinc. This results in a syndrome of Vit. B6 and zinc deficiency. Mauve-positive 
patients excrete in their urine significantly more zinc and coproporphyrin. 
In addition, they experimented in "schizophrenics" compared to "normals" an oral dose of 50 mg 
of Vit. B6 which result in the reduction of urinary zinc excretion. This 50 mg oral dose of Vit. 
B6 reduce urinary zinc excretion. Decrease in zinc excretion produced by the B6 is greater in 
schizophrenic patients, comparing the levels with “normal”.  
 
According with Jackson et al., (2010) patients with various types of physiological and 
psychological stress had high urine pyrrole levels. They reported that due to the chemical 
structure of the pyrrole molecule, certain patients excreting high levels of pyrroles also excrete 
excess amounts of zinc and vitamin B6 in their urine (Jackson et al., 2000). 
Pfeiffer et al., (1974) report another study with a female. She showed a syndrome of severe 
constipation and splenic pain. She also had seizure syndrome and some mental problems. They 
found her KP excretion urinary were very high, and found further that abnormalities decreased 
with zinc and B6 therapy. They referred that a therapy with vitamin B6 taken with zinc keeps all 
mental and abdominal symptoms away. 
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1.6.1.2 Role of GSH and NAC 
 
The central role of GSH 
The brain is among the major organs generating large amounts of reactive oxygen species and is 
especially susceptible to oxidative stress. The biological thiol, glutathione (GSH), plays a critical 
role as antioxidant, in protecting cells from oxidative stress, and xenobiotics, as well as 
maintaining the thiol redox state, most notably in the central nervous system (CNS). GSH also 
plays a critical role as enzyme cofactor, Cys storage form (the major redox buffer), a 
neuromodulator in the CNS, participates in synthesis of leukotrienes and prostaglandins and 
GSH deficiency has been implicated in neurodegenerative diseases.  
The tripeptide glutathione (GSH, γ-glutamyl-L-cysteinyl glycine) is nearly ubiquitous in cells 
and has been shown to participate in a multitude of cellular functions and many of these are 
associated with protection against reactive intermediates, such as, free radicals and electrophiles, 
which include metabolites resulting from activation or detoxification of exogenous and 
endogenous compounds. Thus, GSH contributes with protein thiols for the maintenance of a 
suitable thiol redox balance which is crucial for cellular homeostasis (De Flora et al., 2001; 
Townsend et al., 2003; Aoyama et al., 2008). Although GSH was seen for many years as a 
protective molecule against activated metabolites of xenobiotics and of normal oxidative 
products of cellular metabolism, it is now also known to play a role in bioactivation of certain 
molecules (Current Protocols in Toxicology, 1999). 
GSH is predominantly located intracellularly and its biosynthesis occurs in the cytosol of all 
cells, however the liver plays a particular role in its synthesis. Its biosynthesis involves a two-
step process, both of which are ATP dependent: 
 
L-glutamate + L-Cysteine +  ATP → L-γ-glumatyl-cysteine + ADP + Pi 
γ-glumatyl cysteine synthetase 
 
L-γ-glumatyl-cysteine + glycine + ATP → GSH + ADP + Pi 
glutathione synthetase 
 
γ-Glumatyl Cys synthetase (γ-GCS), and glutathione synthase are the two enzymes that catalyze 
the two reactions of biosynthesis of GSH. The rate-limiting step in GSH synthesis is the 
availability of Cys (10
−4
 M), because glutamine and glycine are present at higher concentrations 
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(10
−3
 M) (Griffith and Meister, 1979; Drigen, 2000; De Flora et al., 2001; Dickinson and 
Forman, 2002; Aoyama et al., 2008). 
Most mammalian cells can synthesize GSH, however is mainly the liver that takes up and 
removes the bulk of the dietary Cys (in the portal blood), mostly by converting it to GSH, which 
then is released mainly into the blood circulation (Stipanuk et al., 2006). Although Cys be 
necessary in other tissues for GSH synthesis it returns to the liver, which closes the GSH cycle.  
GSH is used for the functions described above and also can be exported. Export of GSH allows 
the cell to protect its membranes against oxidative or other forms of damage by keeping thiol 
groups and membrane components (e.g., vitamin E) in their reduced forms (Meister, 1994). 
 
GSH breakdown 
When GSH breakdown, plasma GSH derived from the liver can only be utilized by tissues that 
have considerable amounts of γ-glutamyl transpeptidase (GGT) activity (e.g., kidney, small 
intestine, and type 2 alveolar cells). Degradation of GSH begins at the cell surface and requires 
enzymes located both on the cell surface (GGT) as well as in the cytosol. GGT is located at 
kidney epithelial cells. The kidneys take up GSH from the plasma through breakdown of GSH 
via GGT activity. GSH, GSSG, and γ-glutamyl GSH react with GGT at the outer surface. Most 
plasma GSH, transported to the kidney, is degraded with a half-life of 1.5 sec (Dickinson and 
Forman, 2002; Forman et al., 2009). 
This salvage pathway for glutathione was proven through inhibition of GGT, which raised the 
plasma glutathione level significantly (Stipanuk et al., 2006). 
Glutathione, exists mainly in the reduced state (GSH), with <5-10% of the total existing as 
glutathione disulfide (GSSG) under normal physiologic conditions. The GSH/GSSG redox cycle, 
one of the major endogenous antioxidant systems, protects cells from injurious events resulting 
from exposure to toxic chemicals, as well as the normal oxidative products of cellular 
metabolism. 
 
 
Normal turnover of GSH  
The normal turnover of GSH in human adults has been estimated to be approximately 40 
mmol/day, which are slightly greater than Cys turnover in the body protein pool. Although, GSH 
turnover returns Cys to the Cys pool, and oxidized glutathione can be reduced back to GSH, 
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some Cys is irreversibly lost through excretion of glutathione or its metabolites (e.g., 
mercapturic acids). Thus, some GSH accumulated extracellularly is excreted with the urine. In 
addition to GSH, Cys moieties and glutamyl-cysteine are also excreted in the urine (Stipanuk et 
al., 2006). 
Extracellular degradation is the basis for considering glutathione a physiological reservoir for 
Cys. In mammals, glutathione is maintained at a high intracellular concentration (0.5 to 6 mM) 
and a very low extracellular concentration (0.25 to 50 μM), with a half-life in blood of 1 to 2 min 
(Yang et al., 1994; Rice and Russo-Menna, 1998; Chen et al., 2008).  
The concentration in the brain is in a range of 1 to 3 mM. The glutathione concentration in brain 
astrocytes appears to be higher than that in neurons. Extracellular GSH has been monitored in 
brain by microdialysis (Yang et al., 1994; Lada and Kennedy, 1997) and these studies indicate 
that brain cells are able to release glutathione. In brain slices, its release was induced by 
depolarization and it was concluded that neurons are the glutathione-releasing cell type in brain. 
Glutathione released by brain cells, may contribute to the maintenance of the glutathione levels 
in the cerebrospinal fluid (Rice and Russo-Menna, 1998; Drigen, 2000; Ghersi-Egea et al., 2006)  
 
Increasing Glutathione levels in brain 
If orally administered, GSH is hydrolyzed by dipeptidase in the gastrointestinal tract. 
Intravenously administered GSH is also rapidly eliminated, with a half-life of only 7 min, by 
reaction with γ-GT. Only 0.5% of radiolabeled GSH administered by intra-carotid injection was 
detectable in brain extracts. It is generally considered to be difficult for GSH to cross the blood-
brain-barrier, although there are some reports describing a so-called “GSH transporter” (Aebi et 
al., 1991; Jain et al., 1991; Kannan et al., 1996; Zeevalk et al., 2007). However, systemic 
administration of NAC can deliver Cys to the brain, thereby raising the GSH level in the CNS. 
There are, in fact, reports of systemic NAC administration being beneficial in animal models 
with neurological disorders (Aoyama et al., 2006, 2008).  
 
 
Role of NAC 
NAC is currently used in clinical medicine and was introduced as a mucolytic agent in the 1960s. 
Almost 50 years of experience in the prophylaxis and therapy of a variety of clinical conditions, 
mostly involving GSH depletion and alterations of the redox status, have established the safety 
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of this drug, even at very high doses and for long-term treatments. NAC has an impressive array 
of mechanisms and protective effects towards DNA damage and carcinogenesis, which are 
related to its nucleophilicity and antioxidant activity (which influence the toxicokinetics of 
xenobiotics) (De Flora et al., 2001). Apart from its medicinal use in patients with respiratory 
diseases, it also has found therapeutic use in the treatment of acetaminophen overdose (Ballatori 
et al., 1998) and in raising GSH levels in HIV patients (Bridgeman et al., 1991; Zafarullah et al., 
2003). 
NAC is not toxic to humans, the tl/2 for NAC in blood plasma is approximately 2 hours and the 
volume of distribution is 0.33 L/kg, indicating its distribution mainly to extracellular water 
(Ballatori et al., 1998). It is rapidly eliminated in urine, with approximately one-third excreted 
during the first 12 hr after administration (Borgstrom et al., 1986). In urine is present mostly as 
the symmetrical disulfide although may be present as the mixed disulfide with Cys, and as a free 
thiol. 
 
Regulation of Cysteine 
The mammalian liver tightly regulates its free Cys pool. Intracellular Cys in rat liver is 
maintained between 20 and 100 nmol/g (to vary about 5-fold), even when sulfur amino acid 
intakes are deficient or excessive, while regulating Cys degradation to maintain the plasma Cys 
concentration is within a 2.5-fold range (between 80 and 200 mmol/L). By keeping Cys levels 
within a narrow range and by regulating the synthesis of glutathione, which serves as a reservoir 
of Cys, the liver addresses 2 opposing homeostatic requirements: the need to have adequate Cys 
to support normal metabolism and the need to keep Cys levels below the threshold of toxicity, 
because high levels of Cys are known to present cytotoxicity. Elevated tissue Cys levels should 
be avoided because they may lead to autoxidation of Cys to form cystine and ROS, oxidation of 
protein thiol groups, neurotoxicity mediated by NMDA-type glutamate receptors or membrane 
cystine/glutamate exchanger activity, or excess production of H2S via desulfhydration reactions. 
Catabolism of Cys is also tightly regulated via regulation of Cys dioxygenase (CDO) levels in 
the liver, with the turnover of CDO protein being dramatically decreased when intracellular Cys 
levels increase. This occurs in response to changes in the intracellular Cys concentration via 
changes in the rate of CDO ubiquitination and, hence, degradation. Because the response hepatic 
CDO to an increase in Cys or methionine load is rapid (i.e., < 24 h to reach new steady-state in 
rats) and large (i.e., > 30-fold increase in CDO protein in rats), the liver provides a substantial 
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safeguard against intake of excess Cys via the oral dietary route, particularly if dietary changes 
are made gradually (Stipanuk et al., 2006). 
 
NAC as a potential chemopreventive agent 
The pyrrole ring of the formed pyrroles, is an electron-rich heterocyclic, and is readily oxidized 
photochemically, electrochemically, or by several oxidizing agents including molecular oxygen. 
After autoxidize may bind to other lysine amino groups inducing crosslinks in neurofilaments 
responsible by 2,5-HD neuropathogenic toxicity (Genter et al., 1988; Amarnath, et al., 1994; 
LoPachin and Lehning, 1997). However, the inhibition of pyrroles autoxidation may be 
promoted by thiol compounds, knowing the high affinity of pyrroles for the sulfhydryl groups in 
proteins, peptides or aminoacids. NAC, a thiolic antioxidant, acts as a precursor of the natural 
antioxidant GSH, by direct reaction between its reducing thiol group and oxygen free radicals. 
GSH acts as hydrogen donor for free radicals since the S-H bond is relatively weak, and may 
also protect against oxidant damage in vitro and in vivo (Zhu et al.,  1995; Banaclocha et al., 
1997; Aoyama et al., 2008). 
In vitro and in vivo models demonstrated the formation of stable secondary pyrrole adducts with 
sulfhydryl groups of Cys which may inhibit pyrrole-pyrrole crosslinking (Zhu et al., 1994, 1995, 
1997; Torres et al., 2010, 2012a,b; Mateus et al., 2012).  
The biological thiol GSH could exert protective effects against γ-diketone neuropathy by 
interrupting the cross-linking process, however, as mentioned earlier, when orally administered 
is hydrolyzed in the gastrointestinal tract and concerning the intravenously administration, GSH 
has an half-life of only 7 min, by reaction with γGT. Finally, it is generally considered to be 
difficult for GSH to cross the blood-brain-barrier (Jain et al., 1991; Zeevalk, et al., 2007) and the 
precise mechanism underlying GSH transport from blood to the brain remains unknown 
(Aoyama et al.,  2008).  
 
Systemic administration of NAC can deliver Cys to the brain, thereby raising the GSH level in 
the CNS. There are, in fact, reports of systemic NAC administration being beneficial in animal 
models with neurological disorders. Therefore, NAC is the simplest Cys pro-drug that can be 
systemically administered to deliver Cys to the brain, acting as a precursor for glutathione 
synthesis as well as a stimulator of the cytosolic enzymes involved in glutathione regeneration. 
Systemic administration of NAC reduces markers of oxidative damage and increases brain levels 
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of glutathione in mice (Banaclocha, 2001). Increasing the neuronal GSH level, through the 
administration of NAC, would prevent the progression of some neurodegenerative diseases by 
protecting against oxidative stress and ROS (Schulz et al., 2000; Aoyama et al., 2008). 
 
NAC and neurodegenerative diseases 
The mechanisms of NAC action at the cellular level, and the usefulness of this antioxidant are 
very important for the treatment of age-associated neurodegenerative diseases.  
This thiol can act i) as a precursor for glutathione synthesis as well as a stimulator of the 
cytosolic enzymes involved in glutathione regeneration ii) by direct reaction between its 
reducing thiol group and reactive oxygen species. iii) preventing programmed cell death in 
cultured neuronal cells iv) increasing mitochondrial complex I and IV specific activities both in 
vitro and in vivo in synaptic mitochondrial preparations from aged mice. Systemic administration 
of NAC reduces markers of oxidative damage and increases brain levels of glutathione in mice 
(Banaclocha, 2001). 
 
All pharmacological agents proposed for any therapeutic or prophylactic use in humans, 
including prevention of cancer and other mutation-related diseases, should possess some general 
requisites, regarding cost, practicality of use, safety and efficacy (Pendyala and Creaven, 1995). 
In this domain, it is noteworthy that NAC preparations have a low cost and are of practical use, 
being stable for years in dry form. Moreover, oral administration is compatible with long-term 
use. At variance with other novel molecules that are candidate chemopreventive agents, for 
which phase I studies are needed in order to evaluate pharmacokinetics and tolerability, the 
pharmacokinetics and bioavailability of NAC have been extensively investigated (Pendyala and 
Creaven, 1995; De Flora et al., 2001). The safety of NAC has been well established after almost 
50 years of clinical experience.  
 
 
1.7 METHODS FOR ASSESSING NEUROTOXICITY  
 
To assess the neurotoxicity of a product is necessary to take measurements at different levels, 
which may include morphological, biochemical, electrophysiological and behavioral disorders 
(Markel et al., 1989; Kulig et al., 1996; Moser et al., 1997).  
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Neurobehavioral and pathological evaluations of the nervous system are additional components 
of basic research and toxicity testing of different neurotoxic products. They may express its 
neurological and behavioral effect in different ways and with varying specificity due to the high 
heterogeneity of the nervous system (Moser, 2011). 
 
The selection of the most appropriate methods depends on the purpose of the study. Although, 
none of the methods allow complete information of the action of compounds on the nervous 
system, behavioral tests show a number of advantages that make them very useful for studying 
the effects of exposure to a neurotoxic product.  
One of the advantages of behavioral methods is that the behavioral assays are not invasive, and 
can be used in long-term studies. Furthermore, is considered that changes in the behavior can be 
very sensitive and early indicators in chronic exposure to neurotoxic agents (Tilson, 1993a,b, 
1998). 
 
It is important to note that there is no one single functional observation battery protocol. 
Guidelines rather describe more general aspects and experimental tests that should be included. 
Over the years several protocols for behavioral assessments have been published (e.g., Kulig, 
1996; Moscardo et al., 2007; O’Donoghue, 1996; Moser, 2011), and each testing laboratory 
generally uses its own version.  
 
1.7.1 NEUROBEHAVIORAL TESTS IN ANIMALS 
 
The behavioral study consists of the direct observation of animal behavior after exposure to a 
chemical agent being one of the more direct means of documenting the changes of clinical signs 
(neurological and behavioral) and enabling investigate the potential neurotoxic effects of a 
compound. 
Observations take place in the home cage and an open field arena, during which time the 
subject’s movements, physical appearance, and reactions to various stimuli are evaluated.  
Often also included are manipulations including grip and landing foot splay (Moser, 2011). An 
advantage to this type of screening is that a single animal may be repeatedly assessed to 
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determine the onset, progression, duration, and reversibility of a neurotoxic injury, in a non-
invasive way.  
 
Behavioral tests comprise of a set of observations called functional observation battery (FOB) 
(Sette, 1989; Moser, 2011). FOB includes numerous physiological tests, neuromuscular (i.e., 
weakness, incoordination, gait, and tremor), sensory (i.e., audition, vision, and somatosensory) 
and motor tests, autonomic (i.e., pupil response, salivation) and thermoregulatoy functions, and 
activity and excitability of the CNS (Tilson, 1993a,b; Tilson et al., 1996; Cory-Slechta et al., 
2001). Neurobehavioral end points are frequently used in conjunction with other measures of 
neurotoxicity (Hattis et al., 1996) such as neuropathology and neurochemistry in an integrated 
approach to assess chemicals for possible neurotoxicity (Hattis et al., 1996). 
 
At the first-tier, simple, rapid, inexpensive methods are typically used to detect the presence of 
neurotoxicity. Methods are also called of screening or first-tier testing and typically consist of 
simple or quick tests of behavior that may be used to identify whether a chemical acts on the 
nervous system, and at what dose levels. Most sensory testing available for use in this screening 
include simple measures of locomotor activity, sensorimotor reflexes, and neurological signs. 
They either involves testing simple reflexes (e.g., grasping, pinna reflex) or evaluation of the 
motor response to a variety of sensory stimuli (e.g., auditory, nociceptive, somatosensory). 
Activity and/or reactivity measures may be automated or observed as part of the open field 
evaluations (e.g., rearing, arousal). Other behavioral evaluations including clinical signs of 
tremor, convulsions, or other motor abnormalities (Tilson, 1993a,b; Moser 2011). 
 
Second-tier testing involves more complex tests that provide a more complete description of the 
effects and dose-response relationships (Tilson, 1993a,b, 1998; Tilson et al., 1996), since they 
are more time- and resource-intensive. Learned or conditioned behaviors require training of the 
test subject and are focused on specific aspects of behavior (e.g., short- vs. long-term memory). 
The behavior is under procedural control, and since experimental variables may be altered to 
increase the specificity of the test, the data may be less variable and easier to interpret. Examples 
of second-tier tests include discriminated conditioned response methodologies to assess specific 
sensory or motor dysfunction and procedures to measure chemical-induced alterations in 
cognitive function (Tilson, 1998). Studies concerning biological mechanism(s) of action or those 
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intended to determine a no observable adverse effect level (NOAEL) or lowest observed adverse 
effect level (LOAEL) typically employ more sensitive tests. Specificity and sensitivity of effect 
are more desirable test attributes if the chemical is known to produce weakness, for example, and 
a second tier test is used to characterize the effect and to determine a no-observed adverse effect 
level (NOAEL), i.e., distinguish between diminished ability to exert high forces versus ataxia 
(Cory-Slechta et al., 2001; Moser, 2011). 
 
With the evolution of tiered testing strategies in which each stage of evaluation incorporates 
decision points as to whether available information is sufficient for determining the neurotoxicity 
of a chemical (Tilson et al., 1996). Evans and Weiss (Tilson, 2000) outlined a three-tier testing 
scheme, including hazard identification, characterization, and assessment of human 
susceptibility. They suggested assessing human susceptibility to chemicals, using methods 
analogous to those employed in animal studies. In 1992, the National Research Council (NRC) 
published a book on environmental neurotoxicology describing a three tier-testing scheme 
similar to that of Evans and Laties. Its included mechanistic rather than human studies in the 
third tier. A three-tier testing strategy was recently endorsed by the European Chemical Industry 
Ecology and Toxicology Centre (ECETOC, 1992; Tilson, 2000).  
 
The behaviors measured in FOB procedures may be sorted by domains of neurological functions, 
although there is often overlap since many tests tap more than one domain and these domains do 
not necessarily map to specific regions of the nervous system (Moser, 2011). Some autonomic 
endpoints may be assessed by observation (e.g., salivation, lacrimation, pupil size), while others 
(e.g., respiration, heart rate) may require specific instrumentation. Neuromuscular ability and 
coordination may be measured using any number of tests ranging from evaluations of gait and 
posture, to palpations of muscle tone or extensor strength, to instrumental tests of hindlimb and 
forelimb grip strength, to monitoring of righting or proprioceptive responses. Most sensory 
testing available for use in first-tier screening involves either testing simple reflexes (e.g., 
grasping, pinna reflex) or evaluation of the motor response to a variety of sensory stimuli (e.g., 
auditory, nociceptive, somatosensory). Activity and/or reactivity measures may be automated, or 
observed as part of the open field evaluations (e.g., rearing, arousal). Other behavioral 
evaluations including clinical signs of tremor, convulsions, or other motor abnormalities are an 
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important aspect of neurological testing. Comparisons of chemical effects on multiple FOB 
endpoints and across functional domains aid in data interpretation. 
 
1.7.1.1 Neurobehavioral screening in rodents 
 
Neurobehavioral evaluations are an important of testing for the neurotoxic potential of 
chemicals. Observations during toxicity studies or specialized neurotoxicity studies can provide 
information important for identifying and/or characterizing neurotoxic effects. A 
neurobehavioral test battery can be composed of a variety of endpoints, usually chosen to asses 
an array of neurological functions, including autonomic, neuromuscular, sensory, and 
excitability. 
The protocols can be then divided into observational assessments and manipulative tests. Each is 
further subdivided into specific tests or endpoints (Table 1.7).  
 
These various endpoints may be combined into a battery of tests for neurobehavioral screening 
and should be used in the context of a broad neurobehavioral test battery. 
For all these screening batteries, clearly defined protocols are critical to good experimentation 
(Moser, 2011). The use of rating scales also allows semi-quantitative assessment of the data that 
would otherwise have subjective evaluation (Weiss, 1988). This approach to the behavior is 
often more sensitive than a simply listing behaviors as ‘‘normal’’ or ‘‘abnormal’’ in which case 
it is critical to have working definitions of what is ‘‘normal’’. Likewise, detailed descriptions of 
behaviors are more informative than colloquial or nonspecific terms. Researchers conducting 
these tests must be ‘‘blind’’ or unaware of the animal’s treatment, so as not to introduce bias, 
however unintentional, into the data.  
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Table 1.7 Endpoints in a Neurobehavioral Screening Battery. 
Observational Assessments  Manipulative Tests 
Activity levels: 
Home-cage observations 
Open-field observations 
Rearing 
Reactivity/excitability: 
Reactivity 
Arousal 
Gait and postural characteristics: 
Gait descriptions 
Postural descriptions 
Involuntary/abnormal motor movements: 
Tremors 
Fasciculations 
Clonus 
Tonus 
Stereotypy 
Bizarre behaviors 
Clinical signs: 
Lacrimation 
Salivation 
Hair coat 
Palpebral closure 
Ocular abnormalities 
Muscle tone/mass 
 Neurologic reflexes/reactions: 
Pupil response 
Palpebral reflex 
Pinna reflex 
Extensor thrust reflex 
Neuromuscular test and postural reactions: 
Grip strength 
Landing food splay 
Hopping 
Righting reaction 
Sensory responses: 
Visual test: approach response 
Visual test: visual placing 
Somatosensory test: touch response 
Auditory test: click response 
Nociceptive test: tail/toe pinch 
Nociceptive test: flexor reflex 
Proprioceptive positioning test 
Olfactory test 
(Adapted from: Moser V.C. Current Protocols in Toxicology, John Wiley & Sons, Inc, 1999). 
 
 
These various endpoints may be combined into a battery of tests for neurobehavioral screening 
and should be used in the context of a broad neurobehavioral test battery. 
 
Training is also extremely important, including careful study of the protocols and considerable 
practice. Observers must be taught the basics of experimental design and good laboratory 
techniques, understand normal behavioral repertoires and factors that can alter behaviors, be at 
ease handling laboratory animals, and be certified with tests using positive controls (Slikker et 
al., 2005; Moser, 2011). 
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1.7.2 STUDIES IN HUMANS  
 
Solvents are ubiquitous in industrial societies in a wide range of processes. Clinicians are 
therefore likely, in daily practice, to see patients who are exposed to these agents either 
occupationally or through contaminated environments since the assessment of neurotoxicity 
begins with a clinical evaluation of the patient, including medical history and a standard 
neurological examination (White and Proctor, 1997; Bull, 2007). 
 
The associated symptoms after contact with these agents are generally related to the functioning 
of the central (CNS) or peripheral nervous system (PNS). In many cases, such symptoms are 
fleeting and resolve after cessation of exposure. However, long-term chronic exposure or high-
dose acute exposures can produce longer-lasting effects characterized by cognitive and 
behavioral changes. In some cases, the symptoms may fully or largely resolve with time, 
whereas in others, permanent CNS or PNS damage may occur (Chang et al., 1993). 
Many studies have demonstrated the neurotoxicity of organic solvents through the use of 
neuroimaging, neurophysiological and neuropsychological assessment techniques (Baker and 
Seppäläinen, 1986; Baker, 1994). These techniques reveal neurotoxicant effects in workers who 
are not clinically ill. The effects have been referred to as latent, subclinical, or preclinical 
(Hänninen, 1971; Baker et al., 1985; Feldman and White, 1996). 
 
1.7.2.1 Clinical assessment 
 
When the doctor suspects that possible nervous-system disorder as a result of solvent exposure, 
several special clinical examinations may be useful in defining the patient’s condition (Table 
1.8). As in any investigation, these examinations are most helpful if done by clinical specialists 
who have experience in examining patients with disorders related to occupational or 
environmental exposure to neurotoxicants. 
 
The CNS depression and psychomotor or attentional deficits are generally resulted of exposure 
to organic solvents. The patient may present with complaints of fatigue, irritability, confusion, or 
depression, and may describe memory difficulties (Baker et al., 1985; Feldman and White, 1996; 
White and Proctor, 1997).  
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When PNS function is affected, initially the patient may exhibit the following symptoms: 
intermittent tingling and numbness, with progression to an inability to perceive sensation and 
muscle weakness (Yokoyama et al., 1990; Smith and Albers, 1997). 
 
Neurological examinations can be used to define solvent-related neurological abnormalities of 
CNS or PNS function and to exclude other neurological explanations for the patient’s symptoms. 
Laboratory tests of nervous-system function can be useful in confirming clinical evidence of 
CNS or PNS disease. For example, nerve-conduction studies and electromyelography 
(Seppalainen et al., 1978) can help to confirm a suspected solvent-induced peripheral 
neuropathy. Computed tomography (CT) and magnetic resonance imaging (MRI) can be used to 
detect the atrophic changes in the frontal lobes and cerebellum as well as white-matter lesions 
that have been described after exposure to certain solvents (Yamanouchi et al., 1995; Ridgway et 
al., 2003). Neuropsychological testing can also be helpful in defining any intellectual and 
affective deficits that may be associated with exposure (Hänninen et al., 1976; Chang, 1987). 
 
Questionnaires and biological monitoring are generally the most feasible approaches for the 
clinician. In biological monitoring for specific solvents, the solvents themselves or metabolites 
can sometimes be measured in the patient’s blood, urine, hair, fat, or breath. This approach is the 
most accurate in assessment of internalized dose, but its use can be limited by the expense of 
sampling and measurement and concern about the accuracy of the measure (Thorne, 2008). 
 
Chronic exposure can be associated with permanent cognitive changes (Baker and Seppäläinen, 
1987; Hänninen et al., 1976). Typically, these changes in adults are limited to specific behavioral 
domains, including attentional capacity, executive function (the ability to deploy strategies for 
problem-solving and to organize responses to novel stimuli), visuospatial skills (analysis and 
integration of visual arrays), short-term memory, and mood/affect (White and Proctor, 1997). 
 
 
In the following Chapter it is presented the main and specific objectives to be achieved in this 
thesis.  
  
CHAPTER 1 
72 
 
 
  
 
 
73 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
OBJECTIVES 
 
 
  
CHAPTER 2 
74 
  
OBJECTIVES 
75 
 
Control and prevention of human exposure to neurotoxic chemicals is an important area of 
research that certainly contributes to the promotion of human health. Thus, it is important to 
control the exposure to neurotoxicants and to study protector agents and/or antagonist agents, 
which may reduce the pathologies due to environmental/occupational exposure. 
 
In this context, this thesis aims to implement measures to control and prevent the neurotoxicity 
induced by 2,5-hexanedione studying alternative biomarkers of exposure and effect. 
 
 
Main Objective 
 
To select biomarkers to control cumulative exposure to n-hexane and predict the neurotoxic 
effects induced by its neurotoxic metabolite 2,5-HD. 
 
 
Specific objectives 
 
 To identify the pyrroles compounds excreted in urine in rats exposed to 2,5-HD. 
 
 To determine which of the identified and quantified pyrroles can be used as indicators of 
cumulative exposure to 2,5-HD exposure. 
 
 To investigate if the formed pyrrole adducts may be proposed as predictive biomarkers of 
2,5-HD neurotoxicity. 
 
 To study the mechanism of interference of NAC in 2,5-HD neurotoxicity. 
 
 To investigate the presence of the identified pyrroles in human urine of an healthy and 
patients with neurodegenerative diseases.  
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To achieve these objectives we performed the following experiments: 
 
 
In Chapter 3 
Synthesis and characterization of standard pyrrole compounds, identification and 
quantification of aminopyrrole adducts and aminopyrroles thiol conjugates in rat urine by 
ESI-LC-MS/MS. 
 
In Chapter 4 
An in vivo model was used to investigate if the identified pyrroles could be selected as 
predictive biomarkers of effect by correlating the changes in urinary 2,5-HD and selected 
identified pyrroles with the changes in motor activity assays in rats treated with 4 doses of 
2,5-HD and 2,5-HD+NAC. 
 
In Chapter 5  
A new in vivo assay was performed treating the rats with 12 doses of 2,5-HD and 2,5-
HD+NAC to evaluate the protector/toxicity binomium induced by NAC on 2,5-HD 
neurotoxicity. 
Along the 12 doses treatment was determined the changes on selected urinary biomarkers 
and the motor activity performance.  
At the end of the experiment was studied the mechanism of interference of NAC on 2,5-HD 
neurotoxicity by measuring Cysteine and GSH in rat brain. 
 
In Chapter 6  
We performed a preliminary study to investigate the presence of the identified pyrroles in 
human urine of an healthy and a sick populations. 
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3.1 INTRODUCTION 
 
Biologic monitoring of occupational exposure to n-hexane has been routinely evaluated by 
determining the urinary levels of total 2,5-HD (Perbellini et al., 1990). More recently the 
determination of free 2,5-HD has been used as an alternative or complementary biomarker of n-
hexane exposure (Manini et al., 2004, 2006). However, as urinary 2,5-HD can only be a measure 
of recent exposure and the most common situation is the chronic exposure to this solvent 
(Toxicological review n-hexane, EPA, 2005), the study of other biomarkers is of great interest. 
In vitro and in vivo models demonstrated that 2,5-HD forms pyrrole adducts with amino groups 
in proteins, and pyrrole derivatives (PLS) were quantified in urine, hair and serum using the 
Ehrlich’s reagent, until now the most used method to quantify pyrroles compounds (Kessler et 
al., 1990; Johnson et al., 1995; Santos and Batoréu, 1991, 1993; Yin et al., 2013a,b). However, 
this colorimetric method quantifies all the compounds that have the pyrrole ring (Mattocks and 
White, 1970; DeCaprio et al., 1982) thus, it is not a specific method to analyze only the pyrroles 
resulting from 2,5-HD exposure. On the other hand, previous studies (Graham et al., 1995; 
Costa, 1996; Mateus et al., 2001) indicate that PLS could be a good indicator of cumulative 
exposure to 2,5-HD. Therefore, it was imperative to develop a method to determine the specific 
pyrroles formed after n-hexane exposure. 
 
In this chapter, our goal was to identify and quantify the pyrrole compounds excreted in urine to 
be used as biomarkers of repeated exposure to n-hexane. To achieve this objective we performed 
the following experiments: 
 
i) Synthesis and identification of one aminopyrrole compound and its thiol conjugates, to 
be used as standards;  
ii) Identification of pyrrole compounds excreted in urine of rats treated with 3 doses of 
2,5-HD; 
iii) Quantification of identified compounds. 
 
The synthesis of target pyrrole compounds and their identification by ESI-LC-MS/MS was based 
on previous work (Zhu et al., 1994, 1995, 1997; Torres et al., 2010, 2012a,b, 2014; Mateus et al., 
2012). 
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The compounds synthesized were DMPN, DMPN NAC and DMPN GSH (Fig. 3.1). The 
synthesis of these standards was essential for the development of our work, since by now they 
are not commercialized. 
 
 
 
 
 
Figure 3.1 Chemical structure of the pyrrole derivatives synthesized: Nα-Acetyl-6-(2,5-dimethylpyrrol-1-
yl)norleucine (DMPN), Nα-Acetyl-6-[3-(N-acetylcystein-S-yl)-2,5-dimethylpyrrol-1-yl]norleucine (N-
acetylcysteine conjugate of DMPN or DMPN NAC) and 2-Acetylamino-6-{3-[2-(4-amino-4-carboxy-
butyrylamino)-2- (carboxymethyl-carbamoyl)-ethylsulfanyl]-2,5-dimethyl-pyrrol-1-yl}-hexanoic acid 
(GSH conjugate of DMPN or DMPN GSH). 2,5-HD, NAL, NAC and GSH are reagents. 2,5-DMP is a 
pyrrole compound standard. 
 
 
The experimental work includes the synthesis and chemical characterization of the products 
formed upon incubation of 2,5-HD with Nα-acetyl-L-lysine (NAL) in the presence or absence of 
Nα-acetyl-L-cysteine (NAC) or glutathione (GSH).  
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The synthesis of pyrrole compounds was firstly followed through the formation of a 
chromophore (Fig. 3.2) between the pyrrole ring and 4-dimethylaminobenzaldheyde (Ehrlich's 
reagent). Despite the lack of method specificity, it is still widely used due to its high sensitivity, 
low cost, easy and quick to perform. 
 
 
 
Figure 3.2 Scheme reaction of 2,5-DMP with p-DMAB. (Adapted from Ogata et al., 1991). 
 
 
After an Ehrlich positive reaction, HPLC combined with diode array and electrospray ionization 
mass spectrometric detection was used to identify the different synthesized pyrrole compounds. 
 
 
3.2 EXPERIMENTAL PROTOCOL 
 
3.2.1 SYNTHESIS OF STANDARD COMPOUNDS 
 
For each synthesis, preliminary studies were performed with different concentrations of reagents, 
different reaction times and under different atmosphere conditions, to select conditions which 
had the highest performance.  
The following experiments describe the conditions selected for each synthesis. All synthesis 
were monitored during 48 h. 
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3.2.1.1 DMPN 
 
Nα-acetyl-6-(2,5-dimethylpyrrol-1-yl)norleucine, (DMPN), was synthesized by incubating Nα-
acetyl-L-lysine (100 mM) with 2,5-HD (100 mM), reaction I, in a two-necked flask immersed in 
a thermostatic bath.  
The reaction mixture was kept at 37 °C, with stirring, in the absence of air (under nitrogen) and 
of light. Hereafter these conditions will be referred as standard incubation conditions. 
 
3.2.1.2 DMPN NAC CONJUGATE 
 
Nα-acetyl-6-[3-(N-acetylcystein-S-yl)-2,5-dimethylpyrrol-1-yl]norleucine (N-acetylcysteine  
conjugate of DMPN) was synthesized by incubating Nα-acetyl-L-lysine (100 mM) and Nα-
acetyl-L-cysteine (10 mM) with 2,5-HD (100 mM), reaction II. The resulting mixture was kept 
under standard incubation conditions. 
 
3.2.1.3 DMPN GSH CONJUGATE 
 
The pyrrole compound, 2-Acetylamino-6-{3-[2-(4-amino-4-carboxy-butyrylamino)-2- 
(carboxymethyl-carbamoyl)-ethylsulfanyl]-2,5-dimethyl-pyrrol-1-yl}-hexanoic, (GSH conjugate 
of DMPN), was synthesized by incubating Nα-acetyl-L-lysine (100 mM) and GSH in reduced 
form (10 mM) with 2,5-HD (100 mM), reaction III. The resulting mixture was stirred under the 
same standard incubation conditions referred before. 
 
 
3.2.2 INSTRUMENTAL METHODS 
 
3.2.2.1 Spectrophotometric Method 
 
A Hitachi U-2000, UV–Vis spectrophotometer was used to detect the synthesized pyrrole after 
reaction of one aliquot (0.1 mL) of the product of reaction under study, with 1.9 mL of Ehrlich’s 
reagent (3% 4-dimethylaminobenzaldheyde in 40 mL of methanolic 14% boron trifluoride and 
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60 mL of ethanol) (Mattocks and White, 1970). Absorption values were measured at 526 nm (i.e. 
at the wavelength corresponding to spectrum maximum absorption) (Mateus et al., 2001). Each 
pyrrole was quantified using 2,5-DMP calibration curves.  
 
3.2.2.2 Liquid Chromatography and Mass Spectrometry Method 
 
A Waters Alliance 2695 (Waters®, Ireland) LC system equipped with a quaternary pump, 
solvent degasser, auto sampler, column oven and a Micromass® Quattro Micro triple quadrupole 
(Waters®, Ireland) with an electrospray ionization source (ESI), was used to obtain structural 
information for the identification of pyrrole derivatives.  
The ion source temperature was kept at 120ºC and capillary voltage was 3.5 kV. Argon was used 
as collision gas. In addition, a Photodiode Array Detector Waters 996 PDA (Waters®, Ireland) 
was used to scan wavelength from 210 to 600 nm. Data acquisition, processing and instrument 
control was performed by Micromass MassLynx version 4.1 Software. 
The LC separation was performed on a reversed-phase column (LiChrospher® RP18, 125 × 4; 
5.0  µm; Merck®) at 35ºC using an injection volume of 5 µL.  
The mobile phase consisted of ammonium acetate buffer 0.02 M (pH 5.2) (A) and acetonitrile 
(B) at a flow rate of 0.30 mL/min. A gradient of eluents was used for analysis, starting at 100% 
of A, and down to 30% A for 15 min. The conditions were kept during 1 min at 30% A and after 
the column were equilibrated with 100% eluent A for 5 min. 
The identification and characterization of pyrrole compounds was performed on a system LC 
Waters Alliance 2695 (Waters®, Ireland) equipped with the following elements: Quaternary 
pump, Solvent degasser, Auto sampler, Column oven and a Micromass® Quattro Micro triple 
quadrupole (Waters®, Ireland). Photodiode Array Detector Waters 996 PDA (Waters®, Ireland). 
Micromass MassLynx version 4.1 software. 
 
Individual solutions of each standard compound (2,5-HD, NAL, NAC and 2,5-DMP), and the 
solutions with the synthesized compounds (DMPN, DMPN conjugates: DMPN NAC and DMPN 
GSH) were infused into the mass spectrometer and scanned in the positive ion mode in order to 
achieve the best conditions of analysis (cone and capillary voltage) corresponding to higher 
signal/noise ratio to detect the molecular ion. 
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A spectrum for each compound was obtained in the m/z range from 40 to 600. After, Daughter 
Scan mode was used in order to choose the best collision energy, adequate to obtain a 
fragmentation spectra characteristic of each compound, to maximize the two main product ions 
signals. For the quantification, the mass spectrometer was operated in multiple reactions 
monitoring (MRM) mode. In this work one transition (MRM1) was used for quantification and 
another one (MRM2) for confirmation. The use of two transitions gives 4 identification points, 
corresponding to one precursor (1 point) and two product ions (3 points). The specificity of the 
method of analysis was guaranteed based on the comparison of: (1) the retention time variation 
of the standards and the target analytes in the samples, and (2) MRM1/MRM2 ratios. For peaks 
detected in samples, this ratio should not be outside the ±20% range, considering results obtained 
with the standards analyzed in the same conditions. These criteria are according to the 
Commission Decision 2002/657/EC. 
 
Matrix effect during analyte ionization may cause suppression or enhancement of the analyte 
signal. This effect was evaluated for 2,5-DMP commercial standard, by comparing the signal 
obtained from the calibration curves prepared using water as solvent or urine from control rats. 
The ion suppression (expressed in percentages) was quantified as 1 minus the ratio between the 
slope of the curve obtained with H2O and the slope of the curve with urine from control rats. If 
the result is positive, we have an ion suppression of the analyte signal. If it is negative, we have 
an ion enhancement. 
 
Previously published work describing in vitro assays allowed a comparative study with the 
chromatograms of the synthesized compounds (Zhu et al., 1994, 1995, 1997). 
 
 
3.2.3 ANIMALS 
 
Male Wistar rats (220 ± 25 g) from Charles River Laboratories® (Barcelona), were housed at 
controlled temperature, humidity and a 12-h light/dark cycle. Throughout the one week 
acclimatization period, and during the exposure, the general conditions of the animals were 
checked daily. Animals had free access to water and rat standard food (Letica Ref. IPM-R20). 
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All experiments were carried out in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. 
 
 
3.2.4 EXPOSURE OF RATS AND URINE COLLECTION 
 
After the acclimatization period, the animals were randomly assigned to two groups (n=7): 
Group I – 400 mg 2,5-HD/kg bw/48-h (ip injection); Group II – saline solution (ip injection in 
the same days of Group I).  
2,5-HD was made ip administrated due to the ease of administration compared with other 
parenteral routes. The γ-diketone was dissolved in a sterile saline solution and was administered 
to the animals with a 48-hour interval.  
The concentration of the 2,5-HD solution was calculated in order that the volume of the 2,5-HD 
by ip administration, was approximately 1 mL. In Table 3.1 is shown the experimental design of 
animal assay. 
 
(a) All treatment solutions were prepared freshly on a daily basis. 2,5-HD and saline were administered via ip 
injection (7 animals/group).  
 
 
During the 24 hours urine collection, animals were kept in metabolic cages provided with urine-
feces separator. All urine samples were collected over ice and out of light. All urines were 
centrifuged to remove particulate matter and stored at –80ºC until analysis. 
Before analysis by ESI-LC-MS/MS the urine samples were filtered on a 0.20 µm membrane 
(CHROMAFIL® Xtra) (Moriwaki et al., 2000; Manini et al., 2004).  
 
  
Table 3.1 Animal assay protocol. 
Group Treatment solution
a
 Doses 
HD  (I) 400 mg 2,5-HD/kg bw/48-h 3 (HD) 
Control  (II) Sterile saline/48-h 3 (saline) 
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3.3 RESULTS 
 
3.3.1 DETECTION OF PYRROLE COMPOUNDS BY SPECTROPHOTOMETRIC 
METHOD 
 
As previously stated, all reactions were followed by Ehrlich’s reaction, to confirm the formation 
of pyrrole compounds. 
Figure 3.3 shows pyrrole concentrations expressed in equivalent of 2,5-DMP synthesized in 
reaction I and II in function of reaction time. The presence of NAC increases markedly the 
detection of levels of equivalents of 2,5-DMP.  
 
 
Figure 3.3 Total pyrrole concentrations, reactions I and II. Reaction I: 2,5-HD+NAL and reaction II: 2,5-
HD+NAL+NAC, analyzed by spectrophotometric method. The concentration of pyrrole compounds is 
expressed as equivalent of 2,5-DMP (mg/L). Values are expressed as mean values (n=3). 
 
 
3.3.2 IDENTIFICATION OF STANDARDS: DMPN, DMPN NAC, DMPN GSH AND 2,5-
DMP, BY ESI-LC-MS/MS 
 
3.3.2.1 Optimization of MS Conditions  
 
The optimum conditions of analysis for each standard were selected, in order to have a higher 
signal of the precursor ion (see Table 3.2). Cone Voltage was 20 V to DMPN NAC, and 30 V to 
other compounds. Collision energy was 15 eV to 2,5-DMP and 20 eV to other compounds. 
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This study was performed by direct infusion of individual solutions of standards in the ion 
source. For all the compounds, the mass of the precursor ion corresponds to the mass of the 
corresponding protonated molecule [M+H]
+
.  
 
The molecular structure of the synthesized compounds was confirmed from the analysis of the 
mass spectra and fragmentation pattern obtained for each compound. The proposed chemical 
structures of each product ion are presented in figures 3.4, 3.5 and 3.6 and their structures are 
according to other authors Zhu et al., (1994, 1995). The following figures also show the mass 
spectra obtained after fragmentation of the precursor ions, using the Daughter Scan acquisition 
mode, as well as the MS/MS spectrum of the commercial standard for the 2,5-DMP (Fig. 3.7). 
 
MS/MS spectrum of DMPN 
 
In Fig. 3.4 is shown the fragmentation of the precursor ion [M+H]
+
 at m/z 267 corresponding to 
pyrrole compound DMPN. 
 
 
 
Figure 3.4 MS/MS spectrum of synthesized pyrrole compound, DMPN, obtained after the fragmentation 
of the molecular ion m/z 267. 
 
Fragmentation of DMPN at m/z 267 originated several fragments: an ion fragment at m/z 225 
corresponding to the loss of N-acetyl group [M─((C═O)CH3)]
+
, another at m/z 180 
corresponding to the loss of both groups, carboxylic acid and N-acetyl, 
[M─(CO2H)─((C═O)CH3)]
+
, and also m/z 162 corresponding to the loss of carboxylic acid and 
ethanamide derived group, [M─(CO2H)─(NH(C═O)CH3)]
+
. This product ion at m/z 162 is the 
CHAPTER 3 
88 
one with higher intensity. The ion at m/z 108 results from the cleavage of the bond between the 
two carbons of the lysine near N-pyrrole. 
 
For quantification of this compound the transition 267>162 (MRM1) was used as the transition 
of quantification, and 267>225 (MRM2) as transition of confirmation as presented in Table 3.2. 
 
MS/MS spectrum of DMPN NAC 
 
The mass spectrum of DMPN NAC is shown in Fig. 3.5. The fragmentation of the precursor ion 
[M+H]
+
 at m/z 428 originated several fragments, among them mention should be made to m/z 
299 and m/z 410. 
 
 
 
Figure 3.5 MS/MS spectrum of synthesized pyrrole compound, DMPN NAC, obtained after the 
fragmentation of the molecular ion m/z 428. 
 
 
The fragment at m/z 299 corresponds to the cleavage of the bond between the sulfur and carbon 
of Cys. This fragment is the one with greater intensity. The ion at m/z 410 results from loss of 
water molecule from the molecular ion [M─H2O]
+
. For m/z 368 we propose that protonated 
molecule loss the derivated carbamic acid [M─(NHCO2H)]
+
. Ions at m/z 194 and m/z 267 were 
also originated from the cleavage of the two C─S bonds. 
 
For quantification of DMPN NAC the transition 428>299 (MRM1) was used as the transition of 
quantification, and 428>410 (MRM2) as transition of confirmation, as presented in Table 3.2. 
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MS/MS spectrum of DMPN GSH 
 
Figure 3.6 presents the mass spectra of the synthesized compound, DMPN GSH. From the 
fragmentation of the precursor ion [M+H]
+
 at m/z 572, fragments m/z 443 and m/z 297 were the 
main obtained. The first results from the cleavage at N atom and 2-amino-5-oxo-pentanoic acid 
group, [M─((C═O)(CH2)2CH(NH2)CO2H)]
+
. Fragment at m/z 297 was obtained from the 
cleavage at C─S bond furthest from the pyrrole ring, led to the formation of thiol-pyrrole adduct. 
This fragment ion is similar to those of DMPN NAC, suggesting that thiol group of GSH and 
NAC was directly bound to the pyrrole ring. 
 
 
 
 
Figure 3.6 MS/MS spectrum of synthesized pyrrole compound, DMPN GSH, obtained after the 
fragmentation of the molecular ion m/z 572. 
 
 
MS/MS spectrum of Commercial Standard Compound 2,5-DMP 
 
In Fig. 3.7 is shown the fragmentation of the precursor ion [M+H]
+
 at m/z 96, corresponding to 
pyrrole compound 2,5-DMP (2,5-dimethylpyrrole).  
 
Fragmentation of 2,5-DMP at m/z 96 originated several fragments: an ion fragment at m/z 81 
corresponding to the loss of methyl group [M─CH3)]
+
, another at m/z 80 corresponding to the 
loss of a hydrogen atom, [M─(H)CH3)]
+
. When the precursor ion loses two methyl groups yields 
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the fragment mass m/z 67. The product ion at m/z 81 is the one with higher intensity. For 
quantification of this compound transitions 96>80 (MRM1) and 98>81 (MRM2) were chosen as 
the transition of quantification and confirmation as presented in Table 3.2 
 
 
Figure 3.7 MS/MS spectrum of standard pyrrole compound, 2,5-DMP, obtained after the fragmentation 
of the molecular ion m/z 96. 
 
 
In Table 3.2 are presented the principal ion intensity values obtained in the MS/MS spectra of 
pyrrole compounds synthesized and 2,5-DMP standard. 
 
Table 3.2 Optimized conditions for studied compounds. 
Rt
 
(min) 
Compound 
Precursor 
ion (m/z), 
[M+H]
+
 
Products ions, 
m/z (relative intensity) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
MRM1 
transition 
MRM2 
transition 
MRM1/MRM2 
(8<n<10; RSD) 
10.7 DMPN GSH 572 
443(28), 97(100), 350(13), 
265(11) 
30 20 572>297 572>443 2.29 (4.9%) 
11.1 DMPN NAC 428 
410(12), 351(19),  
299(100), 97(36), 194(6) 
20 20 428>299 428>410 2.23 (6.0%) 
13.6 DMPN 267 
225(19), 180(37), 162(100), 
108(37), 96(65) 
30 20 267>162 267>225 2.34 (3.4%) 
18.7 2,5-DMP 96 96(100), 95(37), 80(73), 
81(40), 79(15), 68(36) 
30 15 96>80 96>81 3.42 (9.0%) 
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3.3.2.2 Detection of the synthesized compounds using MRM 
 
DMPN 
 
Figure 3.8 shows the detection of the compound at the studied conditions. This compound was 
detected at 13.7 min. 
 
 
 
 
 
 
 
Figure 3.8 Chromatograms obtained, in MRM mode of compound DMPN: (A) 24 hours and (B) 48 hours 
of incubation reaction. 
 
The formation of the compound DMPN was followed at the beginning and monitored at 2 
different reaction times, 24 and 48 hours of incubation (Fig. 3.9) using Diode Array.  
 
Figure 3.9 Chromatograms obtained by LC with Diode Array detection (210 to 600 nm) for the synthesis 
of compound DMPN: (─) 24 h and (─) 48 h of incubation reaction. The blak line corresponds to 
incubation reaccion time, for t=0 min. 
DMPN
Time
2,5-HDNAL
 
 
 
 
A 
B 
24 h 
48 h 
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It can be seen in the resulting chromatograms the increase in the peak area of the compound as 
the time of reaction increases, so the incubation time selected for the DMPN synthesis was 48 
hours.  
 
DMPN NAC 
 
At the studied conditions, the compound DMPN NAC is detected at Rt=11.1 min as can be seen 
in Fig. 3.10.  
 
Figure 3.10 Chromatograms obtained in MRM mode, for the compound DMPN NAC: (A) 24 h and (B) 
48 h of incubation reaction.  
 
 
As for DMPN, the formation of the DMPN NAC compound was followed at the beginning and 
monitored at 2 different reaction times by Diode Array (Fig. 3.11).  
 
As can be seen in the chromatograms, the peak area of DMPN NAC increases with the time of 
reaction (Fig. 3.11), and the incubation time selected for the compound synthesis was 48 hours.  
  
A
B
A 
 B 
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Figure 3.11 Chromatograms obtained by LC with Diode Array detection (210 to 600 nm), for compound 
DMPN NAC. (─) 24 h and (─) 48 h of incubation reaction.  
 
 
DMPN GSH 
 
Using the optimized conditions and the transitions chosen for the compound, we confirmed that 
DMPN GSH is detected at Rt=10,6 min, (Fig. 3.12). 
 
 
 
Figure 3.12 Chromatograms obtained in MRM mode for the pyrrole compound synthetized, DMPN 
GSH: (A) 24 hours and (B) 48 hours of incubation reaction. 
  
NAL 
 NAC 
2,5-HD 
DMPN NAC 
Time (min) 
24 h 
 
48 h 
A 
B 
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Figure 3.13 Chromatograms obtained by LC with Diode Array detection (210 to 600 nm), for the 
synthesis of compound DMPN GSH: (─) 24 h and (─) 48 h of incubation reaction.  
 
 
The formation of DMPN GSH was monitored using Diode Array, at two different reaction times 
and it was observed that the GSH conjugate peak area increases with time of reaction (Fig. 3.13). 
 
The following figure (Fig. 3.14) shows the chromatograms of each reaction obtained with LC 
and Diode Array detection (210 to 600 nm), at the incubation time period selected for the study 
of all synthesized compounds.  
 
The chromatograms of the incubation reactions at 48 h presented here correspond to reactions in 
aqueous media under N2, for the three compounds: for DMPN with Rt at ~13.7 min, DMPN 
NAC with Rt at ~11.1 min and DMPN GSH with Rt at ~10.6 minutes. 
 
 
  
GSH (Rt= 4.1 min) 
NAL (Rt= 4.4 min) 
2,5-HD 
DMPN GSH 
Time (min) 
24 h 
48 h 
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Figure 3.14 Chromatograms obtained by LC with Diode Array Detection (210 to 600 nm) for the pyrrole 
compounds synthetized: DMPN, DMPN NAC and DMPN GSH, at the standard incubation conditions 
(37°C, N2 atmosphere, in the dark) at 48 hours of incubation. (Peaks at Rt= 9.51 min and Rt=5.98 min are 
presented in the blank). 
 
 
3.3.3 IDENTIFICATION OF PYRROLE COMPOUNDS IN URINE OF RATS EXPOSED 
TO 2,5-HD 
 
The chromatogram obtained by MRM mode using the analytical conditions previously 
described, allowed us to identify for the first time the following pyrrole compounds in urine of 
exposed rats: DMPN, DMPN NAC and DMPN GSH. 
Eluent, Blank (H
2
0) 
2,5-HD + NAL → 2,5-DMPN 
2,5-HD + NAL + NAC → (2,5-DMPN NAC) 
2,5-HD + NAL + GSH → (2,5-DMPN GSH) 
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In Figure 3.15 is presented the chromatogram profile corresponding to DMPN, DMPN NAC and 
DMPN GSH detected in urine of rats exposed to 2,5-HD. DMPN GSH, exhibit a Rt of 10.7 min, 
DMPN NAC exhibit a Rt of 11.1 min and DMPN a Rt of 13.7 min. Peak area of DPMN is much 
higher than the peak area of DMPN NAC and DMPN GSH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Chromatogram obtained in MRM mode of urine of rat exposed to 3 doses of 2,5-HD (400 
mg/kg bw) for derived pyrrole compound DMPN GSH (Rt=10.6 min), DMPN NAC (Rt=11.1 min) and 
DMPN (Rt=13.7 min).  
 
 
In order to confirm that the compounds detected in urine of the exposed animals corresponded to 
the synthesized ones and to evaluate the specificity of the method, MRM1/MRM2 transitions 
ratio were determined for each derived compound pyrroles in standard solutions and in urine 
samples. 
 
Figure 3.16 shows the two most important transitions for pyrrole compound DMPN, existing in 
the aforementioned urine: MRM1, 267>162 (quantification) and MRM2, 267>225 (confirmation) 
transitions, as well as the value of their intensities (5.35x10
6
 and 2.72x10
6
 respectively).  
 
 
DMPN 
DMPN NAC 
enlarged x24 
compared to  
DMPN 
13.71 
 
 
DMPN GSH 
enlarged X36 
compared to 
DMPN NAC 
ALTERNATIVE BIOMARKERS OF n-HEXANE EXPOSURE 
97 
  
 
Figure 3.16 Chromatograms in MRM mode of the two most important transitions for pyrrole compound 
DMPN detected in urine of one rat exposed to 3 doses of 2,5-HD. 
 
 
In Figure 3.17 are presented the two most important transitions for DMPN NAC, found in urine 
of one rat exposed to 2,5-HD (3 doses): MRM1, 428>299 (quantification) and MRM2, 428>410 
(confirmation) transitions, as well as the value of their intensities (1.85x10
4
 and 7.28x10
3
 
respectively).  
 
  
 
Figure 3.17 Chromatograms in MRM mode of the two most important transitions for derived pyrrole 
compound DMPN NAC detected in urine of one rat exposed to 2,5-HD (3 doses). 
 
According to the criteria of Commission Decision (2002/657/EC) this value should not be 
outside the range of RSD ± 20%, when comparing results obtained for samples with the ones 
obtained for standards. 
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In this work MRM1 transition was used for quantification and MRM2 for confirmation. The use 
of two transitions gives 4 identification points, corresponding to one precursor (1 point) and two 
product ions (3 points). This parameter fulfils the European Commission requirements for 
specificity (at least 3 identification points) for confirmation of target compounds. 
 
Table 3.3 Average MRM1/MRM2 ratio and relative standard deviation for 
each compound detected in urine of exposed rat.  
 
 
For each target pyrrole compound, RSD values of MRM1/MRM2 were lower than 20%, as 
shown in Table 3.3. Only DMPN GSH presents a value close to 20% for the RSD, due to the fact 
that the detection of this peak was near the LOD, though the variation was higher. From the 
results it was possible to conclude that the MRM ratios for the peaks detected in the urines can be 
attributed to the compounds studied DMPN, DMPN NAC, DMPN GSH and 2,5-DMP as these 
values are according to the criteria previously established. 
After identification of pyrrole compounds in rat urine, we proceeded to their quantification. 
 
 
3.3.4 QUANTIFICATION OF PYRROLE COMPOUNDS IN RAT URINE 
 
Due to the infeasibility of either obtaining commercial standards of pyrrole adducts or purifying 
those biosynthesized by rats exposed to 2,5-HD, a semi-quantitative approach, based on the use 
of structurally similar compounds as standards (2,5-DMP structure, Fig. 3.1), has been developed 
(Manini et al., 2004). When eluted with the same mobile phase composition, pyrrole derivatives, 
DMPN, DMPN NAC and DMPN GSH, showed similar ESI-MS/MS responses. 
Compound 
 Ratio MRM1/MRM2  
Samples 
 (n=21; RSD)  
DMPN  2.34 (4.1%)  
DMPN NAC  2.25 (4.9%)  
DMPN GSH  2.18 (18.1%)  
2,5-DMP  3.46 (8.6%)  
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Therefore, in order to quantify the data obtained from the identified pyrroles it was assumed that 
the responses for these compounds are independent of the conjugated part of 2,5-DMP. On this 
basis a calibration plot for 2,5-DMP was used to estimate the concentration of other identified 
pyrroles (Manini et al., 1998, 1999, 2004). 
 
From the S/N ratio of the respective MRM chromatograms, as derived from the analysis of 
standards, it was estimated the limit of detection and quantitation, LOD=17.5 nmol/mL and 
LOQ=52.6 nmol/mL for 2,5-DMP. The quantification of pyrrole compounds was expressed in 
terms of the concentration for 2,5-DMP. Under the optimized conditions, the calibration curve of 
2,5-DMP was linear in the ranges of 5–100 mg/L. Squared Correlation Coefficients were 0.999 
and 0.9993 with water and with control urine, respectively (Fig 3.18).  
 
 y = 72.621 x + 82.727, R² = 0.9993
X y = 63.338 x - 36.415, R² = 0.999
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Figure 3.18 Calibration curves for 2,5-DMP standard solutions in the concentrations range 5-100 mg/L.  
 
The repeatability of the method at LOQ is below 10% (RSD=3.4%). The value obtained for 
matrix effect of 2,5-DMP in urine solutions was 15%. This value indicates that there is a high ion 
enhancement. Large differences in matrix effect were observed between different bio-fluids 
(urine, oral fluid, and plasma) (Dams et al., 2003) and between different sample preparation 
techniques, including direct injection, (Bonfiglio et al., 1999; King et al., 2000; Muller et al., 
2002; Dams et al., 2003; Mallet et al., 2004). Although the mechanism and the origin of the 
matrix effect are not fully understood, signal suppression/enhancement is believed to result from 
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competition between matrix components and analyte ions in the sprayed solution for access to 
droplet surface for gas-phase emission (Constantopoulos et al., 1999; Annesley, 2003).  
 
Depending on the environment in which ionization and ion-evaporation take place, this 
competition may effectively increase (ion enhancement) the efficiency of formation of the 
desired analyte ion (Bonfiglio et al., 1999; Mallet et al., 2004).  
Several approaches have been proposed to compensate for such effect, such as the application of 
isotopically labeled internal standards (when available at the adequate isotopic purity) rather than 
analogue internal standards (ISs) (Matuszewski et al., 1998; Jemal et al., 2003), or the 
application of the standard addition method (Ito and Tsukada, 2002). 
According to Manini et al., 2004, one of the main advantages of LC–MS is the compatibility 
with aqueous matrices and the possibility to minimize or even eliminate sample preparation prior 
to analysis. However, one limitation is its susceptibility to matrix effect.  
 
Thereby, the results obtained for DMPN and DMPN NAC, after the quantification, are shown in 
Figure 3.19. 
This figure shows (A and B) shows a significant increase (p<0.01) of urinary DMPN and DMPN 
NAC as compared with control. The increase of DMPN levels is significant (p<0.01) over the 
three doses (Fig. 3.19 A) while the increase of DMPN NAC levels is not significant between the 
2
nd
 and 3
rd
 dose (Fig. 3.19 B). 
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Figure 3.19 Urinary concentration of DMPN (A) and DMPN NAC (B) expressed in nmol/mL, of control 
rats and rats exposed to 2,5-HD (400 mg/kg bw/48 h). Data represent mean ± SD (n=7). All groups were 
compared (by Mann–Whitney tests). (*) p < 0.01 for exposed animals vs. control; (#) p<0.01 for 1st dose 
vs. 2
nd
 and 3
rd
 dose and (ˆ) p < 0.01 for 2nd dose  vs. 3rd dose. 
 
 
In Figure 3.20 it is observed that both compounds have a dose dependent increase on their 
urinary levels and a linear correlation was established for DMPN (R
2
=0.9687) and for DMPN 
NAC (R
2
=0.9915). 
 
After the 3
rd
 administrated dose, the urinary levels of these two compounds are approximately 
twice (for DMPN), and three times (for DMPN NAC) higher, than their levels after the 1
st
 dose. 
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Figure 3.20 Comparison of urinary excretion of DMPN () and DMPN NAC () in rats exposed to 3 
(ip) doses of 2,5-HD (400 mg/kg bw/48 h). Each point is the (mean + SD) for DMPN, and (mean − SD) 
for DMPN NAC, for n=7. 
 
The other identified pyrroles, DMPN GSH and 2,5-DMP were detected, however their values 
were below LOQ. 
 
 
3.5 DISCUSSION AND CONCLUSIONS  
 
This work identifies for the first time DMPN and its thiol conjugates DMPN NAC and DMPN 
GSH in urine of rats exposed to 2,5-HD  using LC-MS/MS for their characterization.  
 
To achieve this goal, the first task was the synthesis and identification of DMPN and its thiol 
conjugates, to be used as standards in the identification of the target pyrroles in urine. In figures 
3.4, 3.5, and 3.6 it is shown the mass spectra of each synthesized compound after the 
optimization of instrumental conditions.  
The identification of pyrrole compounds in urine of all exposed rats was performed and based in 
two criteria: Rt and (MRM1/MRM2) ratio. Fig. 3.15 shows that the Rt of the more concentrated 
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target analytes (DMPN and DMPN NAC) in rat urine are in accordance with the Rt of the 
corresponding standards (Table 3.2). On the other hand, in Fig. 3.16 and Fig. 3.17 the two 
transitions, MRM1 and MRM2 (of quantification and confirmation), for the pyrroles, DMPN and 
DMPN NAC are shown.  
On comparing, the RSD of MRM1/MRM2 ratio of target analytes (Table 3.3), with the RSD of 
the corresponding standards (Table 3.2), a RSD less than 20% was found for all the calculated 
ratios. All together, the obtained results are in accordance with the requirements of the 
commission decision (Commission Decision 2002/657/EC) to identify a compound by LC-
MS/MS, thus, allowing us to identify, DMPN, DMPN NAC and DMPN GSH in rat urine. 
 
We suggest that the source of DMPN is due to the formation of primary (pyrrolylated N-
acetylysine) amino-pyrrole adducts and the source of Cys conjugates is due to the formation of 
secondary (pyrrolylated cysteine conjugates) thiol-pyrrole adducts. These two types of adducts 
may occur in most proteins. Our results confirm that the amino-pyrrole adducts are formed in 
much higher amounts which may be explained by the low level of free thiols present in most 
proteins limiting the relevance of thiol-to-pyrrole adducts, nevertheless the excretion of this 
thiol-pyrrole conjugated could be quantified in rat urine and may have a role in 2,5-HD 
detoxification process. 
Concerning DMPN GSH conjugate and 2,5-DMP these pyrroles were detected but their levels 
were below the LOQ (52.6 nmol/mL). 
 
The comparison of DMPN and DMPN NAC excretion (Fig. 3.19 A and B, and Fig 3.20) 
evidences (i) the high urinary DMPN excretion as compared with urinary DMPN NAC, (ii) the 
linear correlation between the DMPN or DMPN NAC levels at the administrated doses. 
 
In conclusion, DMPN is a strong candidate to be proposed as a new biomarker of exposure to 
2,5-HD and research is needed to study its role as a potential biomarker of neurotoxic effect. 
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4.1 INTRODUCTION 
 
Risk prevention against n-hexane neurotoxicity is a relevant issue towards the measures to be 
proposed in occupational toxicology. One of the approaches to be applied in protection against n-
hexane neurotoxicity is the development of antagonists that could reduce or eliminate its 
toxicity. 
It is well known that 2,5-HD is the metabolite responsible by n-hexane neurotoxicity and urinary 
levels of total 2,5-HD (free 2,5-HD + 4,5-dihydroxi-2-hexanone) have been used in routine 
analysis as a biomarker of occupational exposure to n-hexane (Perbellini et al., 1990a,b; 
Biological Exposure Values for Occupational Toxicants and Carcinogens, 1994). However, in 
2001, the ACGIH recommended the determination of “free” instead of “total” 2,5-HD, since 
“free” 2,5-HD, indicates the amount of 2,5-HD that escapes to the detoxification process, and 
probably is a better predictor of the neurotoxic risk than the conjugated metabolites that are 
rapidly excreted in urine (Manini et al., 1999, 2004; Mateus et al., 2001). On the other hand, this 
γ-diketone, may bind to amino groups of lysine in axonal proteins forming 2,5-DMP (2,5-
dimethylpyrrole) primary adducts or binds to free thiols in proteins forming secondary pyrrole 
adducts (Zhu et al., 1994, 1995, 1997; Torres et al., 2010; Torres et al., 2012a, 2012b; Mateus et 
al., 2012). However, the low levels of free thiols present in most proteins limit the relevance of 
thiol-to-pyrrole adducts. 
Several authors (Graham et al., 1995; Costa, 1996) have proposed the determination of Pyrrole 
Like Substances (PLS) as a biomarker of cumulative exposure to n-hexane, as it reflects the dose 
of free 2,5-HD that escapes detoxification and reaches its target proteins. The PLS have been 
detected in hen CNS tissues (DeCaprio et al., 1983), rat hair (Johnson et al., 1995; Lack et al., 
2002), rat and hen blood (DeCaprio et al., 1982, 1988; Graham et al., 1995) and rat and human 
urine (Kessler et al., 1990; Santos and Batoréu, 1991, 1993). To detect the PLS a simple and 
sensitive colorimetric assay with p-DMBA (Erhlich’s reagent) was used and was established 
(Kessler et al., 1990) a correlation between PLS and 2,5-HD urinary levels. However, this 
method does not identify the different pyrrole compounds excreted in urine, hindering the 
meaning of pyrroles excretion in several neurophysiologic conditions (Hidalgo et al., 1998) and 
in different exposure situations (Lamé et al., 1990). 
In Chapter 3, we described the synthesis and identification of pyrrole compounds by ESI-LC-
MS, and DMPN and DMPN NAC were also quantified in urine of rats exposed to 2,5-HD 
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(Torres et al., 2014). At this point, it was imperative to investigate the toxicological meaning of 
excretion of the identified pyrroles. 
 
 
4.2 NAC AS A POTENTIAL CHEMOPREVENTIVE AGENT 
 
The role of NAC in protecting CNS was  investigated by Banaclocha (2001), proposing its 
potential mechanism of action based on the assumption that NAC can cross the blood-brain 
barrier, and exert its beneficial effects at the level of CNS (Drigen, 2000).  
It is well known that NAC is a precursor of Cys and an excellent source of sulfhydryl (-SH) 
groups that restore the reduced cellular glutathione (GSH) and increases its pool (Zafarullah et 
al., 2003; Chen et al., 2008; Moschou et al., 2008; Circu and Aw, 2010). GSH plays a central 
physiological role in maintaining the body homeostasis and in protecting cells against oxidant 
toxicants, of either exogenous or endogenous source. Unfortunately, the large GSH molecule is 
not transported efficiently into cells. Furthermore, Cys, which is the rate-limiting amino acid in 
the intracellular synthesis of this tripeptide, is toxic to humans (De Flora et al., 2001). Thus, to 
obtain an increased amount of cellular GSH levels we selected NAC. It is an amino acid 
derivative with low toxicity which readily deacetylated in cells to yield Cys (Bridgeman et al., 
1991) and promotes intracellular glutathione (GSH) synthesis. Besides this activity as a GSH 
precursor, NAC is, per se, responsible for protective effects in the extracellular environment, 
mainly due to its nucleophilic and antioxidant properties, which influence the toxicokinetics of 
several xenobiotics (Schulz et al., 2000; Aoyama et al., 2008). 
 
NAC is an important antioxidant and a free radical-scavenging agent that increases intracellular 
GSH (Griffith and Meister, 1979), a major component of the pathways by which cells are 
protected from oxidative stress (Meister, 1988; De Flora et al., 2001; Arakawa et al., 2006). The 
efficacy of NAC in protecting cells from apoptosis has generally been interpreted within the 
context of a mechanism involving oxidative stress (Ferrari et al., 1995; Arakawa et al., 2006). 
NAC, at a concentration of 1 mM, became an excellent neuroprotective compound, causing 
almost 100% neuroprotection against metal-induced neurotoxicity which is mainly caused by the 
increase of reactive oxygen species (ROS) (Moschou et al., 2008). 
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It has been shown to exert survival promoting actions in several cell systems (Banaclocha et al., 
1997) and fluorescence studies revealed that neuronal death was suppressed by NAC (Ferrari et 
al., 1995). Cys is transported mainly by alanine-serine-cysteine (ASC) system, a ubiquitous 
system of Na
+
-dependent neutral amino acid transport, in a variety of cells (Arakawa et al., 
2006). However, NAC is a membrane-permeable Cys precursor that does not require active 
transport and delivers Cyst to the cell in this own unique ways (Sen, 1998; Aoyama et al., 2006).  
 
The aim of this work was to study the interference of NAC on 2,5-HD neurotoxicity and to 
investigate the toxicological meaning of urinary aminoderived pyrroles and thiol-pyrrole 
conjugates excretion.  
To achieve these objectives we analyzed urinary 2,5-HD, 2,5-DMP, DMPN, DMPN NAC and 
DMPN GSH levels, and performed behavioral assays in rats exposed to 2,5-HD and co-exposed 
to 2,5-HD and NAC. 
 
 
4.3 MATERIAL AND METHODS 
 
4.3.1 CHEMICALS 
 
2,5-Hexanedione (2,5-HD, 99%) was purchased from Fluka, 2,5-dimethylpyrrole (2,5-DMP, 
98%), Nα-acetyl-L-cysteine (NAC, 99%), Nα-acetyl-L-lysine (NAL, 98%), γ-L-glutamyl-L-
cysteinyl-glycine (GSH, 98%) and cyclohexanone (99,8%) were obtained from Sigma–Aldrich, 
4-dimethylaminobenzaldheyde (DMAB, 99%), boron trifluoride–methanol complex, ammonium 
acetate, acetonitrile Lichrosolv and ethanol p.a. were from Merck. Other reagents and solvents 
used were of analytical grade and were purchased from reliable commercial sources.  
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4.3.2 INSTRUMENTATION 
 
4.3.2.1 Gas Chromatography and Mass Spectrometry Method 
 
Quantification of 2,5-HD in urine was performed by GC-MS, Perkin Elmer, Clarus 500 Gas 
Chromatograph, Claurus 560D Mass Spectrometer, with a quadrupole detector in selected ion 
monitoring (SIM) mode and a DB-17 capillary column (30 m x 0,53 mm, 1µm). 
For GC-MS detection, an electron ionization system was operated in electronic impact (EI) mode 
with ionization energy of 70 eV, Helium gas (99.999%) was the carrier gas at a constant flow 
rate of 1 mL/min, and an injection volume of 1 μL was employed. The injector temperature was 
maintained at 225 °C, the ion-source temperature was 200 °C, and oven temperature was 
programmed from 70 °C (1 min), with an increase of 15 °C/min to 150°C (20 min). 
The mass-detector was the Turbo-Mass Gold-Perkin-Elmer, and the software adopted to handle 
mass spectra and chromatograms was a Turbo-Mass, version 5.2. 
Interpretation on mass-spectrum GC-MS was conducted using the database of National Institute 
Standard and Technology (NIST MS Search, version 2.0).  
 
4.3.2.2 Liquid Chromatography and Mass Spectrometry Method 
 
Urine was analyzed by ESI-LC-MS/MS, for pyrrole compounds determination. A Waters 
Alliance 2695 (Waters®, Ireland) LC system equipped with a quaternary pump, solvent 
degasser, auto sampler, column oven and a Micromass® Quattro Micro triple quadrupole 
(Waters®, Ireland) with an electrospray ionization source (ESI), already mentioned in Chapter 3. 
 
 
4.3.3 ANIMALS 
 
Male Wistar rats (223 ± 22 g) from Charles River Laboratories® (Barcelona), were housed at 
controlled temperature, humidity and a 12-h light/dark cycle. A preliminary week 
acclimatization period, and during the exposure, the general conditions of the animals were 
checked daily. Animals had free access to water and rat standard food (Letica Ref. IPM-R20). 
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All experiments were carried out in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals. 
 
 
4.3.4 EXPOSURE OF RATS AND URINE COLLECTION 
 
The selection of dose, time and frequency of exposure was based on previous experiments 
performed in our lab. (Mateus et al., 2001, 2002; Torres et al., 2010, 2012a, 2012b). 
Concerning the selection of NAC doses, it is reported that has a low toxicity in experimental 
animals, being its oral LD50 > 10 g/kg body weight in both rats and mice, and the LD50 after 
intravenous administration 4.6 g/kg in mice and 2.8 g/kg in rats (De Flora et al., 2001). 
After the acclimatization period, the animals were randomly assigned to four groups (n=7): 
Group I – 400 mg 2,5-HD/kg bw/48-h (ip); Group II – 400 mg 2,5-HD/kg bw/48-h (ip) + 200 mg 
NAC/kg bw/day (drinking water); Group III – 200 mg NAC/kg bw/day (drinking water); Group 
IV – saline solution (ip). The Group II was pre-exposed to NAC (200 mg/kg bw) in drinking 
water, one week before the co-exposure to 2,5-HD+NAC. The Group III was also pre-exposed, 
(see Table 4.1). 
 
 
Figure 4.1 Collection of 24-hour urine from rats kept in metabolic cages. A: metabolic cages provided 
with urine-feces separator. B: the collection of urine should be done protected from light to prevent 
degradation of pyrrole compounds. 
 
  
 
A B 
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During the 24 hours urine collection, animals were kept in metabolic cages provided with urine-
feces separator (Fig. 4.1). All urine samples were collected over ice and out of light, and then 
were centrifuged to remove particulate matter. Urine samples were stored at –80ºC until analysis. 
 
2,5-Hexanedione was dissolved in a sterile saline solution and was ip administered to the animals 
with a 48-hour interval. NAC was added to the drinkable water supplied to the animals. NAC 
solution concentration was calculated considering an average rat’s water intake, between 10 and 
20 mL (Ecobichon, 1997). In Table 4.1 is presented the experimental design of animal study.  
 
(a) All treatment solutions were prepared freshly on a daily basis. 2,5-HD was administered via ip injection and 
NAC was administered via oral in drinking water (7 animals/group). 
 
 
4.3.5 DETERMINATION OF 2,5-HEXANEDIONE 
 
4.3.5.1 Urine Sample Pre-Treatment 
 
Determination of Free 2,5-HD in urine  
To 5 mL of centrifuged urine, was added 100 mL of a 10.4 mM cyclohexanone solution in water 
(Internal Standard) and 1.5 g of NaCl. After addition of 1 mL of dichloromethane, samples were 
rotated and subsequently centrifuged. Organic phase was collected for analysis on the gas 
chromatography system. 
 
 
 
Table 4.1 Animal assay protocol. 
Group Treatment solution
a
 Doses 
HD  (I) 400 mg 2,5-HD/kg bw/48-h 4 (HD) 
(HD + NAC)  (II) 400 mg 2,5-HD/kg bw/48-h + 200 mg NAC/kg/day 4 (HD) + 15 (NAC) 
NAC  (III) 200 mg NAC/kg/day 15 (NAC) 
Control  (IV) Sterile saline/48-h 4 (saline) 
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Determination of Total 2,5-HD in urine  
Five mL of urine was hydrolyzed with HCl (pH 0.1) at 100 ºC, and the formed 2,5-HD was 
extracted and determined by the above procedure (Mateus et al., 2000).  
 
4.3.5.2 Gas Chromatography-Mass Spectrometry Analysis 
 
A 1-µL aliquot of the dichloromethane extract was injected onto the GC system (van Engelen et 
al., 1995; Mateus et al., 2000). 
Individual standard solution (100 ppm) of 2,5-HD, was injected into GC and analysed in the 
positive ion mode in order to achieve the best conditions of analysis.  
 
4.3.5.3 Validation parameters for GC-MS Method 
 
The calibration curves for quantitative analysis of 2,5-HD were calculated by the analysis of 
standard solutions. These were performed by spiking pooled control urines with 2,5-HD. They 
were also used to study the linearity of the method. To control the analytical conditions stability, 
standard solutions were frequently included during sample analysis. 
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Figure 4.2 Calibration curves for 2,5-HD standard solutions in urine of unexposed rats, obtained by GC-
MS for different concentrations. Each value is the average of three determinations. 
 
 
Under the optimized conditions, the calibration curves of 2,5-HD were linear in the 
concentration ranges of 10-100 ppm and 100-1000 ppm (Fig. 4.2). 
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The instrumental limit of detection (LOD) was estimated from the standard deviation of the 
response and the Slope. It can be expressed as LOD = 3.3 x σ / S, where σ is the standard error 
of the response B (intercept coefficient) and S is the slope of the calibration curve. The slope S 
was estimated from the calibration curve of 2,5-HD for concentrations between 10 and 100 ppm. 
The estimation of σ was also based on the calibration curve. The residual standard error of the 
regression line or the standard error of y-intercepts (B) of regression line was used as the 
standard error (ICH-Q2-R1). 
The instrumental limit of quantification (LOQ) is 3×LOD (Commission Decision 2002/657/EC; 
ISO 8466-1, 1990).  
By using SPSS SATISTICS® version 21, the following values were obtained for B, S and σ 
(Table 4.2). 
 
Table 4.2 Results for σ and S. 
 Unstandardized Coefficients 
  Std. Error 
Ratio (2,5-HD/IS) 1.335 (B) 0.233(σ) 
2,5-HD (ppm)  0.112 (S) 0.004 
 
 
Through the values of σ and S, it was obtained for 2,5-HD analyzed by GC-MS, the following 
results: LOD=6.8 mg/L (59.6 nmol/mL) and LOQ=20.6 mg/L (180.4 nmol/mL). 
 
The repeatability of the injection was determined by injecting consecutively, 10 times, the same 
solution of 2,5-HD (100 mg/L) in urine of unexposed rat. The value obtained had RSD=6.7%. 
In summary, the method described above proved to have adequate sensitivity and a good 
repeatability. Additionally, it was robust to small analytical conditions variation. 
 
 
4.3.6 DETERMINATION OF THE PYRROLE DERIVATIVES 
 
To confirm the presence of pyrrole compounds, prior to analysis by ESI-LC-MS/MS, we 
proceeded to a qualitative analysis of each urine sample, by a colorimetric method with Ehrlich’s 
reagent.  
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Liquid Chromatography and Mass Spectrometry Method  
Standard solutions of 2,5-DMP, or the synthesized compounds (DMPN, DMPN cysteine 
conjugates: DMPN NAC and DMPN GSH) were infused into the mass spectrometer and scanned 
in the positive ion mode in order to achieve the best conditions of analysis (cone and capillary 
voltage) corresponding to higher signal/noise ratio to detect the molecular ion, as it was referred 
in Chapter 3. 
The analytical procedure for analyzing pyrrole compounds obtained in this study is identical to 
that used in the previous chapter. 
 
4.3.7 BEHAVIORAL ASSAYS 
 
The behavioral tests were based on the sequential observation of locomotor animal acts when 
they were placed in a new environment (reviewed in exploratory activity). Observations took 
place in the home cage and on an open field arena (Fig. 4.3). During this time the different 
movements, physical appearance, and reactions to various stimuli were evaluated. 
Behavioral tests were repeated with the same procedure throughout the experiment for all 
animals, to eliminate other factors that could affect the reproducibility of the measured 
parameters.  
The behavioral assays were always performed at the same hour, just before the 2,5-HD ip 
treatment. 
To minimize the observer bias, the observations were performed without knowledge of the group 
to which the animal belonged (blind observation). 
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Figure 4.3 Open field test. 
 
The open field was placed in a restricted access room, separated from the rat room. The open 
field has an area of 90 cm x 60 cm, with walls to limit the field of 35 cm in height and divided 
into six equal-sized quadrants, as shown in Figure 4.3 (Ladefoged et al., 1994; Moser 1999). 
 
Traits recorded consisted of counting the number of rectangles traversed and the number of times 
the rats were placed on their hind legs supported or was supported by the side wall of the field. 
The count took place during the period of five minutes after placing the mouse in the center of 
the field. This placement was always made at the same place, i.e., in the same quadrant to all 
rats. 
 
4.4 RESULTS 
 
During the experiment were analysed urinary biomarkers and were performed motor activity 
assays in all four groups of rats. 
The determined urinary biomarkers were: 
 Free and total 2,5-HD determined by GC-MS,  
 Pyrrole compounds as pyrrole DMPN, DMPN NAC, DMPN GSH and 2,5-DMP 
determined by ESI-LC-MS/MS 
The performed motor activity assays were: 
 Rearing and ambulation in open field. 
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4.4.1 URINARY BIOMARKERS 
 
4.4.1.1 Free and Total 2,5-HD  
 
Identification of 2,5-HD in rat urine 
Gas chromatography analysis, allowed us to identify 2,5-HD in urine of all rats (Rt~4.38 min, for 
2,5-HD). Total ion chromatograms were performed in selected ion monitoring (SIM) mode. The 
chromatogram profile corresponding to 2,5-HD determined in urine of one rat exposed to 2,5-
HD is presented in Figure 4.4.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Total ion chromatogram obtained in selected ion monitoring mode (SIM) for 2,5-HD and IS, 
of urine of one rat exposed to 2,5-HD.  
 
 
In Figure 4.5 is shown the product-ions mass spectrum from molecular ion for 2,5-HD, m/z 114, 
obtained through an urine of an exposed animal to 2,5-HD. Multiple ion detection was used to 
obtain the molecular ion of 2,5-hexanedione, m/z 114, and the fragmentation ions, m/z 43, 71 and 
99. The ions m/z 71, 99 and 114 served as qualifiers to identify 2,5-hexanedione by their 
abundance relative to the base fragment ion m/z 43. 
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Figure 4.5 Product-ions mass spectrum from molecular ion of 2,5-HD, m/z 114, and the fragmentation 
ions m/z 43, 57, 71 and 99. Spectrum obtained through urine of an exposed animal to 2,5-HD.  
 
To confirm the results of fragmentation ions m/z 43, 57, 71, 99 and 114 for 2,5-HD and m/z 42, 
55, 69, 70 and 98 for cyclohexanone (IS), an interpretation on mass-spectrum GC-MS was 
conducted using the database of National Institute Standard and Technology (NIST MS Search, 
version 2.0).  
 
Quantification of Free and Total 2,5-HD in rat urine 
The quantification of free 2,5-HD is presented in Figure 4.6. It is shown a significant decrease 
(p< 0.01) of free 2,5-HD levels in rats co-exposed to 2,5-HD+NAC as compared with its values 
in rats exposed to 2,5-HD alone. In Figure 4.7 is shown the significantly higher levels (p<0.01) 
of total 2,5-HD in rats co-exposed to 2,5-HD+NAC when compared with the levels in rats 
exposed to 2,5-HD. The values obtained with control rats (Groups III and IV) are not represented 
as their values are below the limit of quantification (LOQ=20,6 mg/L). 
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Figure 4.6 Urinary excretion of free 2,5-HD (expressed as nmol/mL) in rats exposed to 2,5-HD (Group I) 
and co-exposed to 2,5-HD+NAC (Group II). Values represent means ± SD for n=7. (*) p<0.01 for Group 
I vs. II. Groups were compared by Mann–Whitney tests. 
 
 
0
2000
4000
6000
8000
10000
12000
14000
0 1 2 3 4 5
To
ta
l 2
,5
-H
D
 (n
m
o
l/
m
L)
Dose
2,5-HD (400 mg/kg bw)
2,5-HD+NAC ((400+200) mg/kg bw)
 
Figure 4.7 Urinary excretion of total 2,5-HD (expressed as nmol/mL) in rats exposed to 2,5-HD (Group 
I) and co-exposed to 2,5-HD+NAC (Group II). Values represent means ± SD for n=7. 
 
 
On comparing figures 4.6 e 4.7 it is evident that the higher values of urinary free 2,5-HD are 
found in Group I, and Group II present the higher values of total 2,5-HD. 
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4.4.1.2 Pyrrole compounds  
 
Identification of pyrrole compounds in rat urine 
Besides, the identification of urinary DMPN and of DMPN NAC already referred in Chapter 3, 
in this experiment it was possible to identify the other pyrrole cysteine conjugate, DMPN GSH, 
in urine of rats co-exposed to 2,5-HD+NAC. 
 
The fragmentation from precursor ion m/z 572 in fragments m/z 443 and m/z 294 was obtained 
through a urine of an exposed animal to 2,5-HD+NAC. In Figure 4.8, it is shown the two most 
important transitions for derived pyrrole compound DMPN GSH, in urine of rat exposed to 4 
doses (2,5-HD+NAC): MRM1, 572>297 (quantification) and MRM2, 572>443 (confirmation) 
transitions, as well as the value of their intensities. 
 
  
Figure 4.8 Chromatograms in MRM mode of the two most important transitions for derived pyrrole 
compound DMPN GSH detected in urine of rat exposed to 4 doses (2,5-HD+NAC): MRM1, 572>297 
(transition of quantification) and MRM2, 572>443 (transition of confirmation), as well as the value of 
their intensities. 
 
 
Quantification of pyrrole compounds in rat urine 
 
DMPN 
In Figure 4.9, are represented several chromatograms in MRM mode of pyrrole compound 
DMPN detect in urine of all groups of rats (after treatment with 4 doses of 2,5-HD). 
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In these chromatograms, the rats treated with 2,5-HD (chromatogram in red) have the higher 
urinary levels of DMPN. It is also evident that the animals co-exposed to 2,5-HD and NAC 
present lower urinary levels of DMPN, (chromatogram in green). The control groups (III and IV) 
(chromatograms violet and brown) present values near the detection limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Chromatograms obtained in MRM mode for pyrrole compound DMPN, of urine of rats 
exposed to 4 doses of 2,5-HD (─), co-exposed to 2,5-HD+NAC (─), exposed to NAC (─) and Control 
(─). (The lag between the baselines of several chromatograms is 2% relative intensity).  
 
 
Figure 4.10 shows the mean values of urinary levels of DMPN in 24 hours urine animals, for 
each administrated dose. Levels of urinary DMPN in rats exposed to 2,5-HD are significant 
(p<0.01) higher compared with its levels in control.  
 
The following figure (4.10) also shows that the urinary levels of DMPN decreases significantly 
in rats co-exposed to 2,5-HD+NAC as compared with its values in rats exposed to 2,5-HD alone. 
This difference is noticeable immediately after the 1
st
 dose of co-exposure. 
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Figure 4.10 Urinary excretion of pyrrole compound DMPN of Group IV, Group III, Group I and II. Data 
represents the mean ± SD (n=7). Groups were compared by Mann–Whitney tests. (*) p<0.01 for Group 
IV vs. I and II; (#) p<0.01 for Group III vs. Group II; (^) p<0.01 for Group I vs. Group II. 
 
 
 
DMPN NAC 
The chromatograms profile corresponding to DMPN NAC detected in urines of rats of: Group I 
(4 doses 2,5-HD), Group II (4 doses 2,5-HD + 15 doses NAC), Group III and Group IV is 
presented in Figure 4.11. It can be seen that rats exposed to 2,5-HD show an urinary excretion of 
DMPN NAC significantly higher than controls (saline treated (IV) and treated with NAC (III)), 
and significantly lower than those co-exposed to (2,5-HD+NAC). 
 
After the quantification of this pyrrole compound in all urines of Groups I, II, III and IV we 
represent the graph in Figure 4.12. In this figure it can be seen that rats co-exposed to 2,5-
HD+NAC show a significantly (p<0.01) higher urinary excretion of DMPN NAC when 
compared with 2,5-HD exposed rats. This significant difference between the two Groups is 
noticeable immediately after the 1
st
 dose. 
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Figure 4.11 Chromatograms obtained in MRM mode for pyrrole compound DMPN NAC, of urine of rats 
exposed to 4th dose of: 2,5-HD (─), co-exposed to (2,5-HD+NAC) (─), exposed to NAC (─) and Control 
(─).(The lag between the baselines of several chromatograms is 2% relative intensity).  
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Figure 4.12 Urinary excretion of pyrrole compound DMPN NAC of Group I and II. Data represents the 
mean ± SD (n=7). (^) p<0.01 for Group I vs. Group II. Groups were compared by Mann–Whitney tests. 
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We also try to determine the levels of 2,5-DMP in urine of animals. However, the values 
obtained for 2,5-DMP, although they were above the limit of detection for this method 
(LOD=17,7 nmol/mL), are beyond the limit of quantification (LOQ=52,6 nmol/mL) (Table 4.3). 
 
Concerning 2,5-DMP levels, the animals of Group II present a lower urinary excretion of this 
pyrrole than those of Group I. This decrease (Table 4.3) was only quantified after the 3
rd
 dose 
and follows the decrease of DMPN (Figure 4.10), being the levels of 2,5-DMP excretion much 
lower than those of DMPN. 
 
Table 4.3 Urinary excretion of pyrrole compound 2,5-DMP of 2,5-HD exposed rats and co-exposed rats 
(2,5-HD+NAC). Data represents the mean ± SD (n=7). 
 
Urinary excretion of 2,5-DMP (nmol/mL) 
Dose 2,5-HD  2,5-HD+NAC  
1
st
 < LOQ 
 (44.5 ± 7.4) 
< LOQ 
(30.9 ± 1.1) 
2
nd
 < LOQ 
(49.2 ± 7.2) 
< LOQ 
(20.3 ± 6.4) 
3
rd
 58.8 ± 5.6 < LOD 
4
th
 61.1 ± 16.7 < LOD 
 
 
 
4.4.2  LOCOMOTOR ACTIVITY ASSESSMENT 
 
Two parameters (Fig. 4.13), ambulation (horizontal activity and number of crossings to different 
quadrants) and rearing (vertical activity and number of times where both forelegs were raised 
from the floor) were analyzed at two different time points: at pre-exposure (immediately before 
the first 2,5-HD dose) and after the last administration. 
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AMBULATION 
 
 
REARING 
 
 
Figure 4.13 Animals motor activity recorded during 5 min in an open field, by alteration on motor 
activity counts of two behavioral end points: rearing and ambulation. 
 
 
In Figures 4.14 and 4.15 is represented the results of all groups. Dysfunction on ambulation and 
rearing in Group I are statistically significant (p<0.01) when compared with control group.  
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Figure 4.14 Support on hind legs in the open field (number of restraints on their hind legs for 5 minutes) 
of unexposed rats (control group), exposed to NAC, exposed to 2,5-HD and co-exposed to 2,5-HD+NAC. 
Data of 0 and 4 doses are expressed by the mean value + or - SD (n=7). 
 
 
Additionally, in the group exposed to (2,5-HD+NAC) a significant recovery of motor activity 
was observed as compared to the group exposed to 2,5-HD alone, being the obtained values 
nearly similar to control values. 
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Figure 4.15 Passages in the open field (number of times that the markings are crossed for 5 minutes) of 
unexposed rats (control group), exposed to NAC, exposed to 2,5-HD and co-exposed to (2,5-HD+NAC). 
Data of 0 and 4 doses are expressed by the mean value + or - SD (n=7). 
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These figures illustrate a causal relationship between 2,5-HD exposure and the decrease of motor 
activity. The results of rearing and ambulation for the animal groups in study, for the fourth dose, 
are shown in Figure 4.16.  
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Figure 4.16 Results of rearing and ambulation for I (2,5-HD), II (2,5-HD+NAC), III (NAC) and IV 
(Control) Groups, after the fourth dose treatment. 
 
 
4.4.3 CORRELATION BETWEEN URINARY BIOMARKERS LEVELS AND MOTOR 
ACTIVITY PERFORMANCE 
 
To explore the toxicological meaning of the analyzed urinary biomarkers 2,5-HD, DMPN and 
DMPN NAC, we calculated the best correlation against the behavioral changes.  
 
In Figure 4.17 it is observed a negative correlation between the urinary DMPN levels and motor 
activity, i.e., the higher is the amount of urinary excretion of DMPN, the lower is the motor 
activity performance. On the other hand, a positive correlation was found between the motor 
activity functions and the urinary levels of DMPN NAC (Fig. 4.18). 
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Figure 4.17 Correlation between ambulation and rearing, and pyrrole compound DMPN in the urine of 
rats treated with 4 doses of 2,5-HD and rats treated with (2,5-HD+NAC). For ambulation R
2
=0.9135, 
p<0.01, for rearing R
2
=0.905, p<0.01. 
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Figure 4.18 Correlation between the values of ambulation and rearing and DMPN NAC in the urine of 
rats exposed to 4 doses of 2,5-HD and group of rats co-exposed to (2,5-HD+NAC). For ambulation 
R
2
=0.8111, p<0.05, for rearing R
2
=0.8213, p<0.05. 
 
 
In Figure 4.19 it is shown a negative correlation between urinary 2,5-HD levels and motor 
activities changes.  
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Figure 4.19 Correlation between ambulation and rearing with free 2,5-HD in the urine of rats, treated 
with 4 doses of 2,5-HD and treated with (2,5-HD+NAC). For ambulation R
2
=0.8625, p<0.01, for rearing 
R
2
=0.8809, p<0.01. 
 
 
4.4.4 PHYSIOLOGICAL PARAMETERS 
 
Ongoing assessment was performed during the experiment. Thus, to check the changes in rats 
body weight due to 2,5-HD exposure and the interference of NAC on these potential changes, we 
determined at the beginning and at the end of the experiment the body weight of all rats . 
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Figure 4.20 Body weight of the control group, rats exposed only to 2,5-HD, NAC and co-exposed (2,5-
HD+NAC) to zero and fourth dose. Values are means ± SD (n=7). 
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Figure 4.20 shows no difference of body weight between controls Groups (III and IV). After the 
4 doses, the group exposed to 2,5-HD evidences a body weight decrease comparing with all 
other groups. The co-exposed group to 2,5-HD+NAC evidences a tendency to a body weight 
increase.  
 
 
4.5 DISCUSSION AND CONCLUSIONS 
 
In this study the correlation between 2,5-HD, DMPN and DMPN NAC urinary levels and the 
motor activity performance in rats exposed to 2,5-HD and co-exposed to 2,5-HD+NAC were 
determined to clarify their use as biomarkers and to investigate the role of NAC in protecting 
against 2,5-HD neurotoxicity. 
 
The interference of NAC on 2,5-HD neurotoxicity was evidenced by a significant decrease in 
urinary free 2,5-HD (Fig. 4.6) and DMPN levels (Fig. 4.10), a significant increase in urinary 
DMPN NAC (Fig. 4.12), and a significant recovery of neurobehavior motor activities in animals 
co-exposed (Fig. 4.16), when compared to their values in rats exposed to 2,5-HD alone. 
 
The choice of behavioral endpoints to predict 2,5-HD neurotoxicity was based on their frequent 
use to identify chemical-induced alterations in nervous system functions, and to the knowledge 
that motor dysfunctions, as rearing and ambulation, could be used as sensitive indicators of 2,5-
HD motor activity depression (Ladefoged et al., 1994; Kulig, 1996; Mateus et al., 2002). This 
preliminary finding indicates that for the 4 administrated doses of 2,5-HD, NAC protects against 
2,5-HD neurotoxicity. 
 
Figure 4.10 shows a significant increase of urinary DMPN in rats exposed to 2,5-HD as 
compared with control and a significant decrease of urinary excretion of DMPN in rats co-
exposed to 2,5-HD+NAC, when compared to the groups exposed to 2,5-HD alone.  
Based on the mechanism of 2,5-hexanedione neurotoxicity, it is established that 2,5-HD reacts 
with amino groups of lysine forming pyrrole adducts, thus, these results may be explained 
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considering that the formation of DMPN depends directly on the reaction between the γ-diketone 
and the ε-amino group of lysine in proteins. 
In fact, our results show that in rats co-exposed to 2,5-HD+NAC (Fig. 4.6) it is observed a 
significant decrease of urinary free 2,5-HD as compared with its urinary levels in rats exposed to 
2,5-HD alone. This finding is in accordance with the recovery of motor activity functions in the 
same co-exposed group (Fig. 4.16). It is well known that is the free 2,5-HD that reaches the 
target organs and is the responsible by its toxicity, thus, the decrease of free 2,5-HD levels 
probably explains the decrease of urinary DMPN levels and indicates the reduction of its 
neurotoxicity. 
 
Our hypothesis is that, in (2,5-HD+NAC) co-exposed animals, free 2,5-HD may partly react with 
thiol (-SH) residues of Cys of NAC or sulfhydryl groups of GSH, before reaching the ε-amino 
groups of lysine residues of NFs.  
Higher levels of urinary total 2,5-HD were found for the co-exposed group as compared with the 
group exposed to 2,5-HD (Fig. 4.7). This result may be explained considering that total 2,5-HD, 
corresponds mainly to the conjugated products of 2,5-HD biotransformation process suggesting 
that NAC may contribute to the 2,5-HD detoxification. 
 
Concerning the quantification of urinary DMPN NAC, the co-treated rats, show a significant 
increase on its urinary excretion, as compared with its excretion in 2,5-HD treated rats (Fig. 
4.12). Previous studies performed by Zhu and co-workers (1995), demonstrated that in the 
presence of biological thiols (GSH and cysteine) a mechanism of inhibition of auto-oxidative 
pyrrole-to-pyrrole cross-linking may occur, via thiol-to-pyrrole conjugation as well as through 
direct antioxidant action. Thus, the increase of DMPN NAC levels in urine of co-exposed 
animals may be associated with the inhibition of pyrroles auto-oxidation, remaining the DMPN 
free to adduct to NAC or GSH. In fact, since pyrrole formation itself is not sufficient to cause 
neuropathy, we suggest that NAC induces the increase of biological thiols which may contribute 
indirectly to prevent the progression of 2,5-HD induced neuropathy by promoting the 
detoxification of ROS, then reducing the probability of autoxidation of pyrroles, the subsequent 
pyrrolyl-pyrrole crosslinking and the development of neuropathies. This hypothesis may explain 
the recovery of motor activities in rats co-treated with 2,5-HD+NAC shown in Figs. 4.14 and 
4.15. 
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On observing Table 4.3 we suggest that a marked decrease of urinary excretion of 2,5-DMP in 
rats co-exposed to 2,5-HD+NAC, may occur, although the values for the 1
st
 and 2
nd
 doses were 
below LOQ. 
 
To understand the toxicological meaning of the urinary biomarkers excretion, in Figures 4.17, 
4.18 and 4.19 we plotted the variation of the levels of the studied biomarkers and the motor 
activity functions in treated and co-treated rats. The best correlation was found for DMPN and 
motor activity (R
2
=0.9135 for ambulation and R
2
=0.905 for rearing), suggesting that this pyrrole 
compound may be proposed as a new sensitive predictive biomarker of 2,5-HD neurotoxicity. 
Thus, the results suggest that at the studied conditions: 
 
i) NAC protects against 2,5-HD neurotoxicity and  
ii) DMPN may be selected as a new specific and sensitive biomarker of 2,5-HD 
neurotoxicity. 
 
Nevertheless, the role of NAC in protecting against 2,5-HD neurotoxicity requires further 
investigation, thus, in Chapter 5 we performed a longer repeated co-treatment of rats with 2,5-
HD+NAC. 
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5.1 INTRODUCTION 
 
In vitro and in vivo studies reported the interference of NAC on several chemicals bioactivity 
underlying its protector effects against their toxicity. 
Nevertheless, several authors refer different concentrations of NAC that induce toxicity using in 
vitro models. For example inhibitory effects on Na
+
 absorption in human nasal epithelia were 
observed at a concentration near 10 mM NAC (Moschou et al., 2008), at concentrations greater 
than or equal to 30 mM, were reported toxic effects on diaphragm muscles (Khawli and Reid, 
1994; Moschou et al., 2008) and at 5–10 mM concentrations, reductions in viability in rat and 
human aortic smooth muscle cells were documented (Tsai et al., 1996). 
In vivo experiments were also reported using NAC. For example, 50 mg NAC/kg/day was orally, 
administrated in the prevention and treatment of acute lead intoxication in rats and the results 
suggest a decrease of lead absorption in the blood and tissues (Pande et al., 2001). More recently 
Lasram et al., (2014) studied the effects of NAC, in vivo, against pathological changes induced 
by malathion and Altinoz and Turkoz (2014) studied the protective role of NAC (250 mg/kg bw, 
via gavage) against acrylamide-induced genotoxicity and oxidative stress in rats. 
Human studies were performed by Burgunder et al., (1989) to study the effect of oral 
administration of (2g) NAC in heathy volunteers after 2g of paracetamol administration and 
concluded that NAC induces glutathione synthesis and prevents the depletion of glutathione 
induced by paracetamol administration. 
 
 
The objective of this work was to pursue the study of NAC interference on the biological activity 
of 2,5-HD using as tools the changes on selected biomarkers levels and the alterations on motor 
activity performance in rats treated with 2,5-HD and co-treated with 2,5-HD+NAC. 
In Part I, we followed the same procedure of Chapter 4, extending the repeated co-treatment of 
rats with 2,5-HD+NAC and in the Part II we determined the levels of brain GSH and Cys in 
order to clarify the mechanism of NAC interference on 2,5-HD neurotoxicity. 
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PART I 
 
URINARY BIOMARKERS ANALYSIS AND LOCOMOTOR ACTIVITY 
ASSESSMENT 
 
 
5.2 MATERIAL AND METHODS 
 
5.2.1 CHEMICALS 
 
2,5-Hexanedione (2,5-HD, 99%) was purchased from Fluka, 2,5-dimethylpyrrole (2,5-DMP, 
98%), Nα-acetyl-L-cysteine (NAC, 99%), Nα-acetyl-L-lysine (NAL, 98%) and γ-L-glutamyl-L-
cysteinyl-glycine (GSH, 98%), were obtained from Sigma–Aldrich, 4-
dimethylaminobenzaldheyde (DMAB, 99%) and boron trifluoride–methanol complex, 
ammonium acetate, acetonitrile Lichrosolv and ethanol p.a. were from Merck. Other reagents 
and solvents used, were of analytical grade and were purchased from reliable commercial 
sources.  
 
 
5.2.2 INSTRUMENTATION 
 
In this chapter was applied the same methodology reported in Chapter 4 to detect, identify and 
quantify the pyrrole compounds. 
Thus, a Hitachi U-2000, UV–Vis spectrophotometer was used to confirm the presence of the 
pyrrole derivatives in rat urine after reaction with Ehrlich’s reagent.  
For the identification and quantification of pyrrole compounds, we used the ESI-LC-MS/MS 
instrumentation. The pyrroles analyzed were DMPN and DMPN NAC. In this Chapter, free 2,5-
HD was determined by ESI-LC-MS. 
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LC–MS is compatible for aqueous matrices which enable to minimize or even eliminate sample 
preparation prior to analysis. The simplification of pre-analytical work reduces the time and the 
cost of analysis and minimizes the target analytes losses (Andreoli et al., 1998; Manini et al., 
2004, 2006). 
 
 
5.2.3 ANIMALS 
 
Male Wistar rats (215 ± 20 g) from Charles River Laboratories® (Barcelona), were housed at 
controlled temperature, humidity and a 12-h light/dark cycle. As for the two previous studies, 
throughout the one week acclimatization period, and during all the in vivo assay, the general 
conditions of the animals were checked daily. Animals had free access to water and rat standard 
food (Letica Ref. IPM-R20). All experiments were carried out in accordance with the NIH Guide 
for the Care and Use of Laboratory Animals. 
 
 
5.2.4 RATS TREATMENT AND URINE COLLECTION 
 
The same procedure was used as performed for the in vivo sub-acute study (Chapter 4). Before 
analysis, all urines were centrifuged and filtered on a 0.20 µm membrane (CHROMAFIL® 
Xtra), to remove particulate matter. 
 
 
5.2.5 EXPERIMENTAL PROTOCOL 
 
Table 5.1 shows the experimental design of animal administration. 
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Table 5.1 Animals assay protocol.  
 (a) All treatment solutions were prepared freshly on a daily basis. 2,5-HD was administered via ip injection and 
NAC was administered via oral in drinking water (7 animals/group). 
 
 
The concentrations of the solutions administrated were weekly adjusted according to the 
variation of body weight and calculated taking into account that the volume of 2,5-HD solution   
to administrate via ip, was 1 mL. However, even within each group, the differences in rats body 
weigh were taken in to account when were calculated the levels of urinary biomarkers. 
 
 
5.2.6 DETERMINATION OF 2,5-HEXANEDIONE AND PYRROLE COMPOUNDS BY 
LC-MS/MS METHOD 
 
2,5-Hexanedione 
An individual standard solution of 2,5-HD (10 ppm), was infused into the mass spectrometer and 
scanned in the positive ion mode in order to achieve the best conditions of analysis (cone and 
capillary voltage) corresponding to higher signal/noise ratio to detect the molecular ion. The 
optimum conditions of analysis (cone voltage and the best collision energy) for 2,5-HD standard 
were selected, to obtain a fragmentation spectra characteristic of compound and to maximize the 
two main product ions signals (see Table 5.2). Mass of the precursor ion corresponds to the mass 
of the corresponding protonated molecule [M+H]
+
. In Table 5.2 are presented the principal ion 
intensity values obtained in the MS/MS spectra for 2,5-HD commercial standard. 
 
 
 
Group Treatment solution
a
 Doses 
HD  (I) 400 mg 2,5-HD/kg bw/48-h 12 (HD) 
(HD+NAC)  (II) 400 mg 2,5-HD/kg bw/48-h + 200 mg NAC/kg/day 12 (HD) + 31 (NAC) 
NAC  (III) 200 mg NAC/kg/day 31 (NAC) 
Control  (IV) Sterile saline/48-h 12 (saline) 
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Table 5.2 Optimized conditions for studied compound, 2,5-HD. . 
Rt  
(min) 
Precursor 
ion (m/z) 
[M+H]
+
 
Products ions, m/z 
 (relative intensity) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
MRM1 
transition 
MRM2 
transition 
MRM1/MRM2 
(8 < n < 10; RSD) 
12.4 115 
97(100), 79(27), 69(46), 
55(19), 43(76) 
30 10 115>97 115>69 13.60 (3.8%) 
 
 
Pyrrole Compounds 
The quantification of pyrrole compounds was performed as reported previously, using MRM1 
and MRM2 of each pyrrole compound (Chapters 3 and 4).  
In brief, the mass spectrometer was operated in multiple reactions monitoring (MRM) mode. We 
use transition (MRM1) for quantification and (MRM2) for confirmation. The specificity of the 
method of analysis was guaranteed based on the comparison of: (1) the retention time of the of 
2,5-HD standard solution and the target analyte in the urines (pyrrole compounds), and (2) 
MRM1/MRM2 ratios. For peaks of compound detected in samples, this ratio should not be 
outside the ± 20% range, considering results obtained with the standards analyzed in the same 
conditions. These criteria are according to the Commission Decision (2002/657/EC - Concerning 
the Performance of Analytical Methods and the Interpretation of Results). 
 
 
5.2.6.1 Validation parameters 
 
The calibration curves, for quantitative analysis, of 2,5-HD was calculated by the analysis of 8 
standard solutions (concentration range of 0.5–100 mg/L). These were performed by spiking 
pooled control urines (urine of animals of Group IV) with 2,5-HD, in order to eliminate a 
possible matrix effect. 
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Figure 5.1 Calibration curves of 2,5-HD standard solutions in the concentrations range: 0.5-100 mg/L for 
aqueous solutions and 1-150 mg/L for standard solutions in urine.  
 
 
Under the optimized conditions, the calibration curve of 2,5-HD was linear in the range of 0.5-
100 mg/L. Squared Correlation Coefficients were 0.9988 and 0.9991 with water and with control 
urine, respectively (Fig. 5.1). The value obtained for matrix effect in urine solutions was 3%. 
Thus, for 2,5-HD, matrix effect during analyte ionization may cause suppression of the analyte 
signal. 
 
The instrumental limit of detection for 2,5-HD, (LOD), was estimated considering the 
concentration of the compound that gives a signal that corresponds to three times the baseline 
noise (S/N≥3) and the instrumental limit of quantification (LOQ) as 3.3×LOD (S/N±10), as was 
calculated for 2,5-DMP (Chapter 3).  
The limit of detection and quantification obtained for 2,5-HD, were LOD=14.6 nmol/mL and 
LOQ=43.8 nmol/mL. These values were estimated from S/N ratio of the respective MRM 
chromatograms, as derived from the analysis of standards. 2,5-HD quantification in urine of 
exposed and control rats was expressed in terms of nmol of 2,5-HD/mL.  
The method presents a good repeatability at LOQ. Its value is below 10% (RSD=3.3%). 
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5.3 RESULTS 
 
Analysis of urinary biomarkers and motor activity assays were performed in control, treated and 
co-treated animals. 
 
 
5.3.1 IDENTIFICATION OF 2,5-HD IN RAT URINE 
 
The ESI-LC-MS/MS analytical conditions described previously, allowed us to identify 2,5-HD 
in urine of rats treated and co-treated.  
A chromatogram profile corresponding to 2,5-HD (retention time of 12.4 min) detected in MRM 
mode in urine of rat of Group I, is presented in Fig. 5.2. 
 
 
Figure 5.2 Chromatogram in MRM mode obtained after analysis of urine of a 2,5-HD exposed rat, for 
2,5-HD compound (Rt=12.4 min). 
 
 
The two most important transitions, existing in urine, for 2,5-HD: MRM1, 115>97 
(quantification) and MRM2, 115>69 (confirmation), as well as the value of their intensities are 
shown in Fig. 5.3. 
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Figure 5.3 Chromatograms in MRM mode of the two most important transitions for 2,5-HD detected in 
urine of rat of Group I: MRM1, 115>97 (transition of quantification) and MRM2, 115>69 (transition of 
confirmation), as well as the value of their intensities, 4.57x105 and 3.68x104 respectively.  
 
 
The product-ions mass spectrum from molecular ion of 2,5-HD, m/z 115, obtained through a 
urine of an exposed animal to 2,5-HD is presented in Fig. 5.4.  
 
 
 
Figure 5.4 Product-ions mass spectrum from molecular ion of 2,5-HD, m/z 115, and the fragmentation 
ions m/z 43, 55, 69, 79 and 97. Spectrum obtained through an urine of an exposed animal to 2,5-HD.  
 
 
 
2,5-HD
[M+H]+
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5.3.2 QUANTIFICATION OF 2,5-HEXANEDIONE IN RAT URINE 
 
The results obtained for free 2,5-HD are represented in Figure 5.5. It is shown a significant  
decrease (p<0.01) in urinary 2,5-HD levels in the co-treated rats (Group II) as compared with its 
levels in rats treated with 2,5-HD (Group I) after the 1
st
, 4
th
 and 8
th
 doses treatment. However, 
after the 12
th
 dose, 2,5-HD levels for Group II are lower but no significant differences are found 
between the treated and co-treated rats. 
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Figure 5.5 Urinary excretion of free 2,5-HD (expressed as nmol/mL) in rats treated with 2,5-HD (Group 
I), co-treated with 2,5-HD+NAC (Group II), treated with NAC (Group III) and saline treated (Group IV). 
Values represent means ± SD for n=7. All groups were compared by Mann–Whitney tests. (*) p<0.01 for 
Group I and II vs. Group IV; (^) p<0.01 for Group II vs. Group III and (#) p<0.01 for Group I vs. Group 
II. 
 
 
5.3.3 QUANTIFICATION OF D PYRROLE COMPOUNDS IN RAT’S URINE 
 
Detection by Colorimetric Method  
The colorimetric test (Ehrlich’s reagent) was also used to control the presence of pyrrole 
compounds in analyzed samples of urines of animals treated with 2,5 HD and co-treated 2,5-
HD+NAC for repeated study.  
This test allowed us to confirm that all animals exposed to 2,5-HD or co-exposed to 2,5-
HD+NAC, presented in their urine pyrrole compounds. 
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5.3.3.1 Quantification of pyrrole compounds 
 
The urinary levels of DMPN, along the 12 doses treatment is shown in Figure 5.6. In Group II 
the animals co-treated with 2,5-HD+NAC present a significant decrease (p<0.01) of DMPN, 
when compared with its levels in animals treated with 2,5-HD. However, this decrease is not 
significant after 12 doses of treatment. DMPN urinary values of control animals are not 
presented graphically as they are below the LOQ of the method. 
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Figure 5.6 Urinary excretion of the pyrrole compound, DMPN, in 2,5-HD treated rats, (2,5-HD+NAC) 
co- treated rats and NAC treated rats. Data represents the mean ± SD for n=7. All groups were compared 
by Mann–Whitney tests. (^) p<0.01 for Group II vs. Group III, and (#) p<0.01 for Group I vs. Group II. 
 
 
The urinary DMPN NAC levels along the study were also determined. In Figure 5.7 it is shown a 
significant  increase (p<0.01) of urinary excretion of DMPN NAC in rats co-treated as compared 
with rats treated with 2,5-HD alone. The results for Group III (NAC treated) and Group IV 
(control) are below the detection limit of the method. 
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Figure 5.7 Urinary excretion of the pyrrole compound DMPN NAC in 2,5-HD treated rats and (2,5-
HD+NAC) co-treated rats. Data represents the mean ± SD for n=7. The two groups of results were 
compared by Mann–Whitney tests. (#) p<0.01 for Group I vs. Group II. 
 
 
 
5.3.4 LOCOMOTOR ACTIVITY ASSESSMENT 
 
Motor activity performance in an open field, was evaluated through the assessment of two 
parameters: ambulation (horizontal activity) and rearing (vertical activity) which were obtained 
at different time points: at pre-exposure (before the first 2,5-HD dose) and after 4
th
, 8
th
 and 12
th
 
administration. 
After the 1
th
 dose a significant (p<0.01) recovery of ambulation and rearing was found in Group 
II, (2,5-HD+NAC),  as compared to the reduction of motor activities observed in Group I (2,5-
HD). In addition, after the 8
th
 dose a significant decrease (p<0.01) on motor activities in Group I 
and II when compared with Groups III (NAC) and IV (Control) was observed (Fig.5.8 and 
Fig.5.9).  
In the same figures it is also shown after the 4
th
 dose, co-treated animals (Group II), 
progressively approximate the behavioral performance of rats treated with 2,5-HD alone (Group 
I), being more evident after the 12 doses treatment. 
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Figure 5.8 Support on hind legs in the open field (number of restraints on their hind legs for 5 minutes) 
of rats treated with 2,5-HD, co-treated with (HD+NAC), treated with NAC and untreated rats (control 
group). The results are expressed by the mean ± SD values, for n=7, and refer to the exposure of 0, 4, 8 
and 12 doses. Groups (I+II) and (III+IV) of results were compared by Kruskall Wallis tests and are only 
statistically significant for 4
th
, 8
th
 and 12
th
 doses. 
 
 
-10
0
10
20
30
40
50
0 4 8 12
N
u
m
b
e
r 
o
f c
ro
ss
in
gs
  
/ 
5 
m
in
u
te
s.
Dose
Ambulation in open field
2,5-HD (400 mg/kg bw)
2,5-HD+NAC ((400+200)
mg/kg bw)
NAC (200 mg/kg bw)
Control
 
Figure 5.9 Passages in the open field (number of times that the square markings are crossed during 5 
minutes) of rats treated with 2,5-HD, co-treated with (HD+NAC), treated with NAC and untreated rats 
(control group). The results are expressed by the mean ± SD values, for n=7, and are referred to the 
exposure of 0, 4, 8 and 12 doses. Groups (I+II) and (III+IV) of results were compared by Kruskall Wallis 
tests and are only statistically significant for 8
th
 and 12
th
 doses. 
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5.3.5 PHYSIOLOGICAL PARAMETERS 
 
Ongoing assessment was performed along the study through a daily observation of animals in 
cages and through the determination on changes of rat’s body weight in the 4 groups of rats. 
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Figure 5.10 Difference of body weight from control group (%): rats treated only with 2,5-HD (Group I), 
co-treated with (2,5-HD+NAC) (Group II) and treated with NAC (Group III), for 4, 8 and 12 doses. Data 
represents the mean ± SEM for n=7. Results were compared by Mann-Whitney tests. (*) p<0.01 for 
Group II vs. Group III and (#) p<0.01 for Group I vs. Group II. 
 
 
During the 4 weeks experiment, Group I evidences a tendency to a weight loss along the 
treatments. Group II evidences a tendency to a weight body increase over the 4
th
 dose, a slight 
decrease on the 8
th
 dose and a marked decrease in body weight at 12
th
 doses. 
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5.4 DISCUSSON AND CONCLUSION 
 
The role of NAC in protecting against 2,5-HD neurotoxicity was further investigated by 
increasing the number of administrated doses (12), in rats treated with 2,5-HD and co-treated 
with 2,5-HD+NAC. 
To achieve this objective we applied the same methodology used in Chapter 4. Thus, 
determining the changes in free 2,5-HD, DMPN and DMPN NAC urinary levels and assessing 
the motor activity performance in rats treated with 2,5-HD (Group I), co-treated with 2,5-
HD+NAC (Group II), treated with NAC (Group III) and saline treated (Group IV). 
The interference of NAC on 2,5-HD neurotoxicity was evidenced by a significant decrease in 
urinary free 2,5-HD and DMPN levels until 8th dose in Group II as compared with Group I. 
However, this decrease was no longer significant after 12 doses treatment. A significant increase 
of urinary DMPN NAC in Group II as compared with Group I for all the administrated doses it 
was also observed.  
 
In this experiment, the behavioral data reported in Chapter 4 was confirmed because it was also 
observed a significant recovery on motor activity performance in Group II until the 4
th
 dose 
administration. However, it is evident that this protector effect is decreasing progressively over 
the time of co-treatment and from the 8
th
 dose there isn’t any significant difference in behavioral 
performance between the Group I and Group II. Moreover, at the 12
th
 dose it appears that there is 
a reversal of the NAC effect likely producing an increase of toxic effect. 
 
Concerning the observed significant decrease (p<0.01) of urinary free 2,5-HD and DMPN levels 
(Figs. 5.5 and 5.6), in the previous chapter we justified the protective role of NAC against the 
neurotoxicity of 2,5-HD until the 4 doses administration. In brief the decrease of urinary DMPN 
levels in rats treated with the mixture may be a consequence of the observed reduction of free 
2,5-HD that may be partly due to its higher probability to react with cysteine thiol (SH) residues 
of NAC or sulfhydryl groups of GSH, before reaching the amino groups of lysine in NFs. In fact, 
the formation of DMPN depends directly on the reaction between the γ-diketone and the ε-amino 
group of lysine in proteins. In particular, the chemical adduction of proteins that are critical to 
the neuronal functions may be dictated by the position of the aforementioned amino residues 
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within (neuro)-protein sequences and their active/catalytic sites (Tshala-Katumbay et al., 2009a). 
The interactions of the hard electrophile 2,5-HD, with the hard nucleophile, ε-amino groups on 
lysine residues of axon cytoskeletal proteins is based on HSAB theory, which may also explain 
the interference of NAC on 2,5-HD neurotoxicity. In fact, the decrease in urinary concentration 
of DMPN in co-treated animals must also take into account the low nucleophilicity of ε-amino 
group of lysine (+1) at physiological pH, which means that the formation of adducts with 2,5-
HD is very slow. Meanwhile, the reaction between 2,5-HD or pyrrole compound and cysteine 
sulfhydryl protonated (0) thiol may occur, as this thiol is present at higher levels in co-treated 
animals. 
 
Figures 5.8 and 5.9 evidence that until the 4
th
 dose of co-treatment, NAC presents a protector 
effect against 2,5-HD neurotoxicity. However after the 4
th
 dose, there is an attenuation of 
protector effect and possibly emerges a toxic effect which is shown after 12 doses co-treatment.  
 
This toxicity is evidenced by motor activity assessment as well as by the decrease of body 
weight of co-treated animals. Ongoing assessment was performed to determine the changes on 
rats body weight along the 4 weeks study. In Fig. 5.10 it is shown that at 4 doses there is an 
increase on the body weight of animals of Group II, as compared with Group I, where it is 
observed a marked decrease of rat body weight as compared with Groups III and IV. 
At 12 doses, the Groups I and II have a significant decrease (p<0.01) of their body weights, 
which is an alert to the potential toxicity induced by 2,5-HD as well as by the 2,5+NAC 
treatment. 
 
In Figs. 5.8 and 5.9 it is also shown that at 12 doses the two groups (I and II) show significant 
motor activity dysfunctions. It is well known that 2,5-HD induces neurotoxicity which confirm 
our results in Group I. The same is not true for the Group II where no data is reported concerning 
the interaction between 2,5-HD and NAC at any dose. Our results show that after the 4
th
 dose, 
there is a progressive reduction of protection effect and a slight increase of neurotoxicity in rats 
co-treated with 2,5-HD+NAC (Group II). In fact, through the behavioral tests (ambulation and 
rearing), we also verified that the animals exposed to 12 doses of 2,5-HD exhibited hind limb 
muscle weakness due to gait abnormality and decrease in grip strength and the extensor thrust 
response. Moreover, co-treated animals, for the same time of exposure, exhibited gait 
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abnormalities (ataxia, splayed hind limbs), in conjunction with increased landing hind foot 
spread and decreased hind limb grip strength and extensor thrust, i.e., hindlimb landing foot 
spread was not affected by 2,5-HD treatment. On the other hand, the group treated with NAC 
alone (Group III) did not present any toxicity which may suggest that the toxicity of Group II is 
induced by the formation and/or accumulation of a new neurotoxic compound. 
Taking this into account, we also determined the changes on urinary excretion of DMPN NAC 
and it was found that in Group II (co-treated with NAC), there is a significant increase (p<0.01) 
on its levels as compared with the excretion in Group I (treated with 2,5-HD alone). 
Additionally, in Group II, there is a dose dependent increase on its excretion along the 12 doses 
treatment (Fig. 5.7). According with Zhu et al., (1995, 1997) DMPN NAC, a non-cross-linked 
product, is a more stable compound than other compounds resulting from 2,5-HD action treated 
with amino acids, peptides and proteins, and more recently it was referred (LoPachin and Gavin, 
2012) that due to its great stability, adducts formed between electrophile DMPN and sulfhydryl 
thiolate may be irreversible. In this context, knowing that DMPN NAC, is a more stable 
compound than DMPN, we may wonder if it may accumulate in nervous system, inducing 
delayed toxicity in animals co-treated with 2,5-HD+NAC.  
 
This suggestion is supported by LoPachin and Gavin (2012), that investigated acrylamide 
adducts with thiolate group, and concluded that CNS nerve terminal dysfunction occurs at a 
cumulative adduct level of 350–500 pg Cys adduct/μg protein. As intoxication continues and 
adduct formation exceeds this threshold, the pool of dysfunctional proteins increases 
proportionately and the related presynaptic processes are progressively disabled, leading to the 
characteristic cumulative neurotoxicity of acrylamide (LoPachin et al., 2006).  
However, neurotransmission is a complex process that is highly regulated by NO signaling being 
NO a biological electrophile that forms reversible adducts with sulfhydryl thiolate groups (S-
nitrosylation) on proteins. NO signaling transiently decreases synaptic strength by reversibly 
inhibiting the function of several proteins involved in the synaptic vesicle cycle (Kiss, 2000; Kiss 
and Vizi, 2001; LoPachin and Barber, 2006; Vincent, 2010; LoPachin and Gavin 2012). 
Consequently, other hypothesis is that the electrophilic neurotoxicant DMPN, selectively adducts 
NO-receptor thiolates in catalytic triads which results in loss of neurotransmission, having 
substantial implications for protein function and subsequent presynaptic toxicity. 
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On the other hand, a large number of structurally diverse chemicals are electrophiles and cause 
synaptic dysfunction by unknown mechanisms. Highly nucleophilic Cys thiolate groups within 
synaptic proteins represent targets for electrophilic neurotoxicants that share the ability to adduct 
or otherwise modify nucleophilic sulfhydryl groups. Thus, electrophilic neurotoxicants may 
produce synaptic toxicity by modifying these thiols since most proteins contain Cys residues. 
These sulfhydryl thiolate sites regulate protein activity by playing a direct role in the enzymatic 
catalytic process and a broad spectrum of synaptic activities by acting as acceptors for nitric 
oxide (NO), and other redox modulators (H2O2) that transiently regulate enzyme function 
(LoPachin et al., 2008b, 2009a,b; Jones, 2010; LoPachin and Gavin, 2014). 
 
In conclusion, we hypothesize that the co-treatment of rats with 2,5-HD+NAC have a dual 
opposite dose dependent effect: firstly inhibiting the formation of DMPN crosslinks in axonium 
neurofilaments and protecting against 2,5-HD neurotoxicity, secondly accumulating the stable 
DMPN NAC adducts which after reaching a threshold value may induce neurotoxicity by 
unknown mechanisms. 
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PART II 
 
DETERMINATION OF THIOLS IN URINE AND IN BRAIN TISSUE 
 
 
5.5 INTRODUCTION 
 
The brain has a large potential oxidative capacity, however a limited ability to counteract 
oxidative stress (Calabrese et al., 2003; Poon et al., 2004a; Halliwell, 2007). Within the cell, 
reactive oxygen species (ROS) are physiologically present at minimal concentrations, in normal 
conditions, and there is a steady-state balance between pro-oxidants and antioxidants which is 
necessary to ensure optimal efficiency of antioxidant defenses (Calabrese et al., 2004a,b;  
Forman et al., 2004; Poon et al., 2004b). However, when the rate of free radicals generation 
exceeds the capacity of antioxidant defenses, oxidative stress ensues with consequential severe 
damage to proteins and lipids, and has been implicated in mechanisms leading to neuronal cell 
injury in various pathological states of the brain, including neurodegenerative disorders 
(Calabrese et al., 2008).  
 
The neurotoxicity of 2,5-HD was previously described (1.2.1 of Chapter 1) and the formation of 
pyrroles which readily autoxidize may bind to other lysine amino groups inducing crosslinks in 
neurofilaments, the responsible by 2,5-HD neuropathogenic toxicity (Genter et al., 1988; 
Amarnath et al., 1994; LoPachin and Lehning, 1997). In this context, the inhibition of pyrroles 
autoxidation may be promoted by thiol compounds, knowing the high affinity of pyrroles for the 
sulfhydryl groups in proteins, peptides or aminoacids. NAC, a thiolic antioxidant, acts as a 
precursor of the natural antioxidant glutathione that acts as hydrogen donor for free radicals 
since the S-H bond is relatively weak, and may also protect against oxidant damage (Zhu 1995; 
Banaclocha et al. 1997; Ayoama et al., 2008). 
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The main objective of this part of the work was to evaluate the effect of NAC in the levels of 
reduced glutathione (GSH) and Cys in brain of rats treated (Group I) and co-treated (Group II) in 
order to clarify the mechanism of interaction of NAC with 2,5-HD. 
 
 
5.6 MATERIALS AND METHODS  
 
5.6.1 ANIMALS  
  
Experiments were performed according to the NIH Guide for the Care and Use of Laboratory 
Animals as stated in the beginning of Part I. 
The experimental protocol of animals study was presented previously in Table 5.1. 
 
5.6.1.1 Tissue collection 
 
Animals were anesthetized 24 h after the last dose with diethyl ether. Immediately after, brain 
was removed, weighed and stored at −80°C, until analysis. 
 
 
5.6.2 CHEMICALS 
 
2,5-Hexanedione (2,5-HD, 99%) was purchased from Fluka, 2,5-Dimethylpyrrole (2,5-DMP, 
98%), Nα-acetyl-L-cysteine (NAC, 99%), L-cysteine (L-Cys, ≥97%), Nα-acetyl-L-lysine (NAL, 
98%), Cysteamine (98%), Tri-n-butylphosphine (TBP, 97%), N,N-dimethylformamide (MDF, 
≥99,9%), 7-Fluorobenzofurazan-4-sulfonic acid ammonium (SBD-F, 98%) and Glutathione, in 
reduced form (GSH, 98%),  were obtained from Sigma-Aldrich. Other reagents and solvents 
used were of analytical grade and were purchased from reliable commercial sources. 
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5.6.3 INSTRUMENTATION 
 
To analyze thiol compounds in brain tissue, liquid chromatography (HPLC) with fluorescence 
detection was performed.  
The HPLC system (Agilent 1100 Series) consisted of a G1311A Pump, a G1328B Injector, a 
spectrofluorophotometer (FLD) G1321A operating at an excitation wavelength of 385 nm and an 
emission wavelength of 515 nm and a UV-Vis Detector G1314A. The LC separation was 
performed on a reversed-phase column (LiChrospher® RP18, 125 × 4; 5.0m; Merck®) using 
an injection volume of 20 L and a 0.1 N (pH 2.1) potassium dihydrogen phosphate buffer 
solution, as mobile phase at a flow rate of 1.0 mL/min, on isocratic elution.  
Acquisition and quantification of the peaks from the HPLC system was performed by data 
acquisition programme software ChemStation®. 
 
 
5.6.4 DETERMINATION OF THIOLS 
 
The quantification of thiols in brain samples was performed using the internal standard method 
(0.58 mM cysteamine). 
 
Derivatization, prior to chromatographic analysis, was performed to render thiols specifically 
detectable for fluorescence, which is a more sensitive tool for compounds detection. Thiols 
reacted with SBD-F (7-Fluorobenzo-2-Oxa-1,3-Diazole-4-Sulfonic Acid) in controlled 
conditions, allowing to transform them into fluorescent compounds. 
 
Low levels of GSSG need to be accurately determined, thus, oxidation of GSH to GSSG has to 
be prevented during sample preparation and derivatization. This is particularly important since 
an alteration in the GSH/GSSG ratio is an indicator of oxidative stress. 
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5.6.4.1 Brain Tissues 
 
Tissues samples were homogenized and weighed in individual samples of about 50 mg for an 
eppendorf. One mM of borate buffer, 2 mM EDTA (pH 9.5) in a volume 10 times greater than 
the weight of the sample brain, was added. Thereafter, each sample was subjected to sonication 
(30 cycles; Condition: Cycle 0.5, range 100). Withdrew 100 µL of each sample and proceeded to 
the technical derivation. 
 
5.6.4.2 Derivatization reaction 
 
To 100 µL of sample or standard were added 10 µL of internal standard (Cysteamine) and 10 µL 
of TBP in DMF (extemporaneous solution). It was placed at 4°C for 30 min. To the mixture, a 
100 µL of 10% TCA (1 mM EDTA) was added and then was centrifuged at 25 000 x g for 10 
min. A 50 µl was removed from the supernatant. 
To ensure an alkaline pH, necessary to facilitate the derivatization reaction, a 10 µL of NaOH, 
1.55 M was added. After that, 100 µL of borate buffer, 125 mM (4 mM EDTA, pH 9.5) and 50 
µl of SBD-F (extemporaneous solution) were added to supernatant. The mixture was heated at 
60°C. After one hour, the samples showed a yellowish color and were placed on ice until 
injection. 
 
After sample preparation, we proceeded to its analysis by HPLC to determine thiols brain 
content.  
 
5.6.4.3 Validation parameters for HPLC Method 
 
The calibration curves for quantitative analysis, of thiol compounds in brain tissue, were 
obtained by the analysis of standards solutions, (n=7), of GSH and Cys in the concentration 
range between 0.05 mM and 0.5 mM. These standard solutions were prepared from stock 
solutions diluted with 1 mM borate buffer (2mM EDTA, pH 9.5). 
For reduced GSH the coefficients, R
2
, ranged between 0.9982 and 0.9977 and for L-Cys between 
0.9979 and 0.9964. Under the optimized conditions for quantitative analysis of thiol compounds, 
calibration curves were linear in the ranges of concentrations utilized. 
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Instrumental limit of detection (LOD) and quantification (LOQ) of the assay for Cys and GSH 
was estimated from the standard deviation of the intercept response and the Slope, of calibration 
curves, exactly in the same way that was explained in 4.3.6.3 for 2,5-HD (Chapter 4). Results are 
presented in Table 5.3. 
 
Table 5.3 LOD and LOQ values for GSH and Cys for HPLC method.(σ and S were obtained by SPSS 
SATISTICS® version 21). . 
  LOD LOQ 
Compound Values 
(µM) 
GSH 
S=7.636771 
σ=0.061406 
26.53 79.60 
Cys 
S=1.897216 
σ=0.016616 
28.90 86.70 
 
 
In every analytical run were included some calibration standards. All of the derivatized samples 
were kept in sample vials and reinjected periodically onto the HPLC system until significant 
changes in peak areas were noticed. 
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5.7 RESULTS 
 
The chromatogram obtained with standard solutions of GSH and L-Cys (0.1 mM) and internal 
standard (IS) cysteamine (0.58 mM) is shown in Figure 5.11. It is possible to see peaks 
corresponding to L-Cys (Rt=3.030 min), and GSH (Rt=15.449 min) standards and for the 
cysteamine (Rt=4.064 min).  
 
 
 
 
 
  
 
 
 
 
Figure 5.11 Chromatogram obtained with standard solutions of GSH, L-Cys (0.1 mM), and cysteamine 
(IS). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12 Chromatogram obtained for a sample of brain tissue analyzed, referring to the group co-
exposed to 2,5-HD+NAC (400+200) mg/kg bw. 
 
L-Cys 
IS 
GSH 
L-Cys 
IS 
GSH 
CHAPTER 5 
158 
In Figure 5.12 is shown the chromatogram obtained with a sample of brain tissue analyzed, 
referred to the Group II. 
 
 
5.7.1 DETERMINATION OF THIOLS  
 
In Figure 5.13 Group IV (control) presents the lowest values of Total GSH and Reduced GSH. 
However, this group doesn’t present the lowest values for Cys. The lowest levels of Cys are seen 
in Groups II and III (co-treated with NAC and treated with NAC). 
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Figure 5.13 Concentration of Total GSH (GSHt), Reduced GSH (GSH) and Cys, determined in tissues 
from the brains of rats treated with 2,5-HD (Group I), co-treated with 2,5-HD+NAC (Group II), treated 
with NAC (Group III) and control (Group IV). (Columns are mean ± SD, n=7).  
 
In the same figure it is shown that Group I presents the highest value of total GSH (GSHt) due to 
the highest value of GSSG as compared with the other groups 
 
The concentration of Total GSH, Reduced GSH (GSHred) and Oxidized GSH (GSSG), 
determined in tissues from the brains of rats treated with 2,5-HD (Group I), co-treated with 2,5-
HD+NAC (Group II), with NAC (Group III) and Control (Group IV) are shown in Fig. 5.14. 
Group I presents the highest values of Total GSH and GSSG. The lowest levels are seen in 
Group IV. 
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Figure 5.14 Concentration of Total GSH (GSHt), Reduced GSH (GSHred) and Oxidized GSH (GSSG), 
determined in tissues from the brains of rats treated with 2,5-HD (Group I), co-treated with 2,5-HD+NAC 
(Group II), with NAC (Group III) and Control (Group IV). (Columns are mean ± SD, n=7).  
 
 
 
5.8 DISCUSSION AND CONCLUSION 
 
In this work, we investigated the mechanism of interaction of NAC with 2,5-HD through the 
determination of brain GSH and Cys levels in rats treated with 12 doses of 2,5-HD+NAC. 
 
NAC has antioxidant potential and its main metabolite, Cys, a precursor in the biosynthesis of 
reduced glutathione, is an extremely important intracellular and extracellular antioxidant 
(Bridgeman et al., 1991). Several authors, referred that Glutathione found in mammalians cells 
exists mainly in the reduced state (GSH), with <5-10% of the total existing as glutathione 
disulfide (GSSG) under normal physiologic conditions. 
 
In Figures 5.13 and 5.14 it is shown that, Group II, Group III and Group IV present brain 
glutathione disulfide (GSSG) levels near 10, 15.4 and 15.0% of Total GSH respectively, being 
the highest brain GSSG concentrations found in Group I, approximately 42% of Total GSH. In 
addition, in Fig. 5.13 both groups exposed to NAC (II and III) have a lower value for Cys which 
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is probably due to its conversion to cystine. In fact, elevated tissue Cys levels should be avoided 
because they may lead to autoxidation of Cys to form cystine and ROS (Aoyama et al., 2008). 
 
 
Figure 5.15 Ratio between GSH in reduced form and GSSG, in brain tissues of Groups I (2,5-HD) Group 
II (2,5-HD+NAC), Group III (NAC) and Group IV (Control).  
 
 
In Figure 5.15, the lowest ratio of GSH/GSSG is observed in Group I, whereas in Group II the 
highest ratio of GSH/GSSG was found, suggesting that NAC induces GSH recovery. 
 
In conclusion, our results didn’t clarify how NAC interferes on 2,5-HD neurotoxicity as the 
increase of brain GSH/GSSG ratio in rats co-treated with 12 doses of 2,5-HD+NAC(Group II), 
only confirms its brain antioxidant function. However, NAC doesn’t induce the recovery of 
neurobehavioral dysfunctions in the same rats (Group II), which means that its antioxidant 
properties are not correlated with its protector effects against 2,5-HD neurotoxicity after 12 
doses of co-treatment. Moreover, the levels of brain Cys are not a good indicator to evaluate the 
role of NAC in 2,5-HD toxicity . 
Other in vivo and in vitro experiments are programmed to clarify the mechanism of NAC 
interaction with 2,5-HD. 
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6.1 INTRODUCTION 
 
In this thesis we proposed to select biomarkers to control cumulative n-hexane exposure and 
predict its induced neurotoxic effects. 
In the previous chapters, we identified and quantified several urinary pyrrole compounds in rats 
treated with 2,5-HD  and co-treated with 2,5-HD+NAC. By analyzing the results obtained it was 
possible to select DMPN and DMPN NAC as specific biomarkers of 2,5-HD exposure. 
 
In this Chapter 6 we propose to investigate if the selected biomarkers could be identified in 
A - An healthy population 
B - Patients with neurodegenerative diseases 
 
Several studies support this experimental proposal: 
 
 
A - Healthy population 
 
The endogenous production of n-hexane, may explain the appearance of low levels of 2,5-
hexanedione in the urine of subjects unexposed to this solvent (Fedtke and Bolt, 1986a). 
Bavazanno et al., (1998) also refer the presence of 2,5-HD in subjects who have not been 
occupationally exposed to the above-mentioned solvent. For this purpose they postulated both an 
exogenous origin related to n-hexane micropollution and an endogenous source based on the 
hypothesis that 2,5-HD can act as an intermediate catabolite in some biochemical physiological 
processes. Perbellini et al., (1993), report results regarding physiological aspects of 2,5-HD 
excretion in subjects not occupationally exposed to n-hexane, proposing that it is a product of 
intermediate metabolism in the human body and only a minimal part could derive from n-hexane 
as a ubiquitous micropollutant. Finally, Persson et al., (2013), reviewed the urinary 2,5-HD 
levels in the general population and concluded that is detected in low concentrations (Table 6.1). 
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Table 6.1 Urinary levels of 2,5-hexanedione (2,5-HD) in general population. 
Country (men:women) 2,5-HD mean ± SD mg/L 2,5-HD range mg/L Method Reference 
Germany 8:4 0.45 ± 0.20 0.12-0.78 GC-MS Fedtke and Bolt, 1986a 
Italy 10 0.49 ± 0.14 0.32-0.64 GC-FID Perbellini et al., 1986 
Japan 55:0 1.47 ± 0.60 - GC-FID Kawai et al., 1990 
Japan 53:0 0.33 ± 0.47 - GC-FID Kawai et al., 1991 
Italy 20:20 0.47 ± 0.21 0.10-1.00 GC-FID Bavazzano et al., 1998 
 
 
Kessler et al., (1990), reported that endogenous and exogenous 2,5-HD originates pyrrole 
substances that were identified as PLS “pyrrole-like substances” and the total pyrrole values in 
urine of rat and man exposed and not exposed to n-hexane were detected by Ehrlich’s reagent. 
 
 
B - Patients with neurodegenerative diseases 
 
The etiology of most neurodegenerative disorders is multifactorial and it is general consensus 
that a convergence of factors (e.g., genetic, environmental and age related), possibly specific to 
each disease, culminate in a common pathophysiological cascade involving oxidative stress and 
lipid peroxidation (LoPachin et al., 2008b). Damage to tissue biomolecules, including lipids, 
proteins and DNA, by free radicals is postulated to contribute importantly to the pathophysiology 
of oxidative stress (Migliore and Coppedè, 2009; Persson et al., 2013). 
Concerning lipid peroxidation it is primarily initiated with hydrogen capture of a fatty acid by 
radical oxygen, followed by the formation of hydroperoxides. The degradation of these 
hydroperoxides results in a chain reaction producing various compounds including carbonyl 
groups mainly aldehydes and ketones (Yin and Chen, 2005). One of the carbonyl compounds 
which may be formed during lipid peroxidation is γ-diketone, 2,5-HD (Fedtke and Bolt 1986a). 
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In this context, we propose the identification of urinary γ-diketone derivative pyrroles in health 
individuals and in patients with neurodegenerative diseases, to investigate their use as one of the 
biomarkers of neurodegenerative diseases.  
 
6.2 MATERIAL AND METHODS 
 
The study was approved by the Research Ethics Committee of Casa de Saúde das Irmãs 
Hospitaleiras da Idanha, where the subjects were inpatients, and the patients’ family members 
signed an informed consent form for their participation (Annex I of this chapter).  
 
The study included 11 patients: 2 men and 9 women. The average age was 78.8±7.6 years. 
In the group of patients 5 had Alzheimer Disease (AD), 4 had Vascular Dementia (VD), 1 had 
Parkinson Disease (PD) and another had Lewy Body Dementia (LBD). 
The control group included a population with an average age of 71.3±5.4 years (n=10, 5 men and 
5 women) an were form. 
The urine was collected over the night and out of light. Urine samples were stored at –80ºC until 
analysis. Before analysis, all urine samples were centrifuged and filtered as described above. 
 
The analytical methodology was the same as previously described in Chapter 3 (for DMPN and 
DMPN NAC) and Chapter 5 (for 2,5-HD). 
In brief, a rapid and easy urinary pyrroles detection (Ehrlich’s reagent) followed by identification 
of 2,5-HD, DMPN and DMPN NAC by LC-MS/MS were performed. 
 
However, due to unexpected problems (disassembly of the LC-MS/MS system, as a consequence 
of rehabilitation works in the building and a fire in the nearby laboratory) was not possible to 
quantify the target analytes. 
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6.3 RESULTS 
 
The presence of pyrrole compounds was detected in all analyzed urines using Ehrlich’s reagent 
by a spectrophotometric method. 
 
 
6.3.1 IDENTIFICATION OF 2,5-HD AND PYRROLE COMPOUNDS BY LC-MS/MS 
 
After urines pretreatment, all samples were analyzed by LC-MS/MS. 
 
The ESI-LC-MS/MS analytical conditions described previously in Chapter 3 and in Chapter 5, 
allowed us to identify DMPN, DMPN NAC and 2,5-HD in urine of patients and healthy subjects. 
 
 
Table 6.2 Conditions obtained for studied compounds (see Chapter 3 and 5). 
Rt
  
(min) 
Compound 
Precursor 
ion (m/z), 
[M+H]
+
 
Product ions,  
m/z (relative intensity) 
MRM1 
transition 
MRM2 
transition 
12.4 2,5-HD 115 43(76), 55(19), 69(46), 79(27), 97(100) 115>97 115>69 
11.1 DMPN NAC 428 410(12), 351(19),  299(100), 297(36), 194(6) 428>299 428>410 
13.6 DMPN 267 225(19), 180(37), 162(100), 108(37), 96(65) 267>162 267>225 
18.7 2,5-DMP 96 96(100), 95(37), 80(73), 81(40),79(15), 68(36) 96>80 96>81 
 
 
The same analytical conditions described previously were used to detected 2,5-HD and 2,5-DMP 
in standard solutions (100 ppm). These were performed by spiking pooled human healthy urine 
with 2,5-HD or 2,5-DMP. 
 
As can be seen in the chromatograms (Fig. 6.1 A and B), 2,5-HD is detected at Rt=11.7 min and 
2,5-DMP is detected at Rt=18.1 min. 
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Figure 6.1 Chromatograms in MRM mode for standard solutions (100 ppm) of 2,5-HD (A) and 2,5-DMP 
(B). TIC obtained for the most important transitions for 2,5-HD and 2,5-DMP, in human healthy urine. 
 
 
Chromatograms profile corresponding to 2,5-HD detected in urines are presented in Figure 6.2. 
 
 
 
Figure 6.2 Chromatograms in MRM mode for 2,5-HD. TIC obtained for the most important 
transitions for 2,5-HD: MRM1, 115>97 and MRM2, 115>69. Detection in urines of healthy 
person and patient with Alzheimer Disease (AD).  
 
These chromatograms were obtained in MRM mode of the two most important transitions for 
2,5-HD detected in urine: MRM1, 115>97 (transition of quantification) and MRM2, 115>69 
A B
2,5-HD, patient with AD
2,5-HD, healthy person
2,5-HD  
standard  
solution in  
human healthy 
urine 
2,5-DMP standard 
solution in human 
healty urine 
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(transition of confirmation). In this figure are presented two of the MRM chromatograms of 2,5-
HD identified in the urines of one healthy person and one patient with Alzheimer Disease (AD). 
The 2,5-HD in urine of rat had a Rt=12.4 min, however in human urine has a Rt=11.7 min. There 
was a decrease in the retention time (less 0.7 min). 
 
The same analytical conditions described previously in Chapter 3, were applied to the 
identification of pyrrole compounds in urine of patients and healthy subjects. 
For analytical conditions used, the compound 2,5-DMP was not detected in the urine of patients 
and healthy people. 
However, for identification of DMPN, compound at m/z 267, chromatograms were obtained, in 
MRM mode choosing the most important transitions 267>162 (MRM1) and 267>225 (MRM2) 
(Figs. 6.3 and 6.4). 
In Figure 6.3 are presented chromatograms in MRM mode of urine of patients: one with 
Alzheimer Disease and two with Vascular Dementia (VD). 
 
 
 
Figure 6.3 Chromatograms in MRM mode for DMPN, detected in urines of patients with Alzheimer 
Disease and with Vascular Dementia. TIC obtained for the most important transitions: 267>162 (MRM1) 
and 267>225 (MRM2).  
 
DMPN  in patient 
with AD
with VD
with VD
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Chromatograms in MRM mode, selecting the same transitions MRM1 and MRM2, to identify 
DMPN in urines of healthy people are presented in Figure 6.3. 
 
 
 
Figure 6.4 Chromatograms in MRM mode for DMPN, detected in urines of healthy people. TIC obtained 
for the most important transitions 267>162 (MRM1) and 267>225 (MRM2).  
 
 
The pyrrole compound, DMPN, in urine of rat had a Rt=13.6 min, however in human urine has a 
Rt=12.1 min. There was also a decrease in the retention time (less 1.5 min). 
 
 
DMPN in healhty people
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Figure 6.5 Chromatograms in MRM mode for DMPN NAC, detected in urines of patients with VD and 
with AD. TIC obtained for the most important transitions 428>299 (MRM1) and 428>410 (MRM2).  
 
 
The precursor ion [M+H]
+
 at m/z 428 of DMPN NAC originated fragments m/z 299 and m/z 410 
(Chapter 3). Chromatograms were obtained, in MRM mode choosing the most important 
transitions 428>299 (MRM1) and 428>410 (MRM2) (Fig. 6.5). However as can be see through 
the chromatograms only trace amounts of DMPN NAC were found. For this compound the 
variation of Rt was minimal (more 0.2 min). 
 
In a pH balanced human body, urine is slightly acid in the morning, (pH = 6.5 - 7.0). However, 
generally becomes more alkaline (pH = 7.5 - 8.0) by evening in (healthy) people primarily 
because no food or beverages are consumed while sleeping. During the day the body buffers the 
pH of the food and beverages consumed by releasing electrolytes and the pH level goes up.  
To facilitate the procedure for collecting the urines of patients, they were collected overnight. 
For rats, urine pH range is 5-7, and urine is collected for 24 h.  
 
This difference between the pH of human urine and the pH of the urine of rats may perhaps 
explain the difference of retention times. 
 
DMPN NAC  in patient 
with VD
with AD
with AD
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This difference, which is found between the various retention times, may be related to ionization 
of the compounds in human urine.  
In this case, the basic pH of human urine will cause, in the more ionizable compounds, 2,5-HD 
and DMPN, a shift of peak area and in human urine these compounds exhibit a lower Rt. 
 
In conclusion, in all the analyzed urines (9 +10), was possible to identify 2,5-HD and DMPN, 
and in all patients urines (9) was also identified trace amounts of DMPN NAC. 
 
 
6.4 DISCUSSION AND CONCLUSION 
 
The objective of this preliminary human study was to apply the studied biomarkers in two aged 
populations: one healthy (Group I) and one sick with neurodegenerative diseases (Group II).  
Our first results show that 2,5-HD and the pyrrole compound DMPN were identified in the urine 
of all healthy and patients individuals (Figs. 6.2 to 6.4) and, in urine of patients was also 
identified DMPN NAC (Fig. 6.5).  
 
The first step of this study was to confirm the presence of total urinary pyrroles in the 2 groups. 
The Ehrlich’s reaction was found positive in all the urines and these results are in accordance 
with others authors which refer the presence of pyrroles in not n-hexane exposed populations 
(Kessler et al., 1990; Ogata et al., 1991).  
 
Subsequently was applied LC-MS/MS analysis, to search for the studied target analytes: urinary 
2,5-HD and the previously identified pyrrole compounds DMPN and DMPN NAC.  
Figures 6.2, 6.3 and 6.4, show that DMPN and 2,5-HD were detected in both Groups of Humans 
(I and II).  
 
The presence of 2,5-HD in urines may be explained by the involuntary exposure to n-hexane by 
the general population, as is an ubiquitous micropollutant, and by the endogenous production of 
n-hexane and 2,5-HD, through reactions of metabolism and/or lipid peroxidation in human body 
as referred by several authors (Fedtke and Bolt 1986a; Perbellini et al., 1986, 1993; Brugnone et 
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al., 1991; Bavazanno et al., 1998; Tondel et al., 2011). Both hypothesis might explain the 
appearance of levels of 2,5-HD in all analyzed urines.  
 
Concerning, the urinary DMPN identified in all the urines, its origin is probably due to the 
endogenous 2,5-HD production and its subsequent reaction with amino groups of lysine. 
Certainly, we need to perform a new study with a larger healthy population, where it is 
quantified 2,5-HD and DMPN to confirm these preliminary results. 
 
The other target pyrrole, DMPN NAC, was not detected in control urines. This is an interesting 
result considering that also in rats control and not co-treated with NAC was not possible to 
quantify DMPN NAC. However, in all nine patient urines DMPN NAC was detected.  
Obviously, it is very difficult to interpret the source of DMPN NAC found in a few samples of 
patients with different neurodegenerative diseases.  
 
Human brain studies suggest that oxidative stress has an important role in neuronal degeneration 
in elder patients and a convergence of several factors (genetic, age related and environmental) 
initiate a common pathophysiological cascade involving oxidative stress, lipid peroxidation and 
the subsequent generation of products in disease-specific brain regions (LoPachin et al., 
2008a,b): e.g., the hippocampus and neocortex of AD brain in these patients.  
Thus, the increase of electrophilic products resulting from lipid peroxidation in elder individuals 
could produce synaptotoxicity through their adduction to protein nucleophilic with sulfhydryl 
groups which have the role of intermediate mediators of synaptotoxicity in many 
neurodegenerative diseases.  
In conclusion, it is likely, that in part the urinary DMPN and DMPN NAC, detected in patients 
may be due to the increase formation of pyrrole adducts with amino and sulfhydryl groups in 
proteins which may contribute to the neurological effects observed in neurodegenerative 
diseases.  
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ANNEX I: 
CONSENTIMENTO INFORMADO, LIVRE E ESCLARECIDO PARA PARTICIPAÇÃO EM INVESTIGAÇÃO 
 
Por favor, leia com atenção a seguinte informação. Se achar que algo está incorrecto ou que não está claro, não 
hesite em solicitar mais informações. Se concorda com a proposta que lhe foi feita, queira assinar este documento. 
 
Título do estudo:  
Desenvolvimento e validação de biomarcadores para avaliação e prevenção de efeitos neurotóxicos 
 
Enquadramento:  
Trabalho a realizar na Faculdade de Farmácia da Universidade de Lisboa  
 
Explicação do estudo:  
Este estudo enquadra-se numa parte do doutoramento correspondente à recolha de urinas de pacientes de idade 
avançada com doenças neurodegenerativas. A recolha e o estudo dessas urinas irá permitir fazer um estudo no 
âmbito de biomarcadores preditivos de efeitos neurotóxicos, uma vez que podem ser considerados uma 
importante ferramenta para a prevenção e promoção da saúde pública.  
 
A caracterização de determinados compostos (derivados pirrólicos) e o estudo do mecanismo de interacção com 
agentes antagonistas ou protectores da formação dos aductos pirrólicos poderá ajudar a esclarecer o mecanismo 
de protecção ou antagonismo que reduz o desenvolvimento de alterações moleculares e celulares e 
eventualmente identificar a origem de algumas doenças neurológicas de origem desconhecida. Nesta faixa etária 
as doenças neurodegenerativas representam um factor importante no agravamento das condições de saúde. 
Assim, a prevenção destas doenças através do controlo e prevenção da exposição a xenobióticos neurotóxicos 
e/ou indutores do stress oxidativo, contribuirá decisivamente para um melhoramento da qualidade de vida das 
populações expostas ou geneticamente predispostas ao seu desenvolvimento. 
Após a recolha e análise das urinas dos pacientes, as respectivas urinas serão destruídas. 
 
Confidencialidade e anonimato:  
Garante-se a total confidencialidade e o uso exclusivo dos dados recolhidos para o presente estudo. 
 
Expressamos o nosso reconhecimento pela sua disponibilidade em colaborar. 
 
Orientador:   
Professora Doutora Maria Luisa Lopes Maio Ribeiro de Andrade Mateus  
Prof. Auxiliar, Faculdade de Farmácia da Universidade de Lisboa; Av. Prof. Gama Pinto, 1649-019 Lisboa; 
Phone: +351 217946400 /+351 217946413; Fax: +351 217946470; lmateus@ff.ul.pt 
 
Aluna de doutoramento:  
Mestre Maria Edite da Silva Oliveira Torres  
Faculdade de Farmácia da Universidade de Lisboa; Av. Prof. Gama Pinto, 1649-019 Lisboa;  
TM 91 823 07 57;  etorres@ff.ul.pt 
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The work presented in this thesis is inserted in the area of Toxicology, and is a contribution to 
the selection of specific biomarkers to be applied in control and prevention of neurotoxicity in 
risky populations. 
An analytical and one toxicological approach were used to develop this research project: 
 
 
In Chapter 3 an analytical approach was applied to study alternative biomarkers of n-hexane 
exposure. 
To achieve this goal we performed: 
the synthesis of standard pyrrole compounds, 
the identification of DMPN, DPMN NAC and DMPN GSH in standards and in urine of 
rats treated with 2,5-HD by LC-MS/MS, 
the quantification of DMPN and DMPN NAC in rats treated with 3 doses of 2,5-HD by 
the same method. 
 
In Chapter 4 and Chapter 5 a toxicological approach was used to investigate if the identified 
pyrroles could be selected as biomarkers of 2,5-HD neurotoxicity and to clarify the role of NAC 
in its toxicity. 
To achieve this goal were performed 2 in vivo assays with repeated dose treatments of 2,5-HD 
and 2,5-HD+NAC. 
 
 In Chapter 4 was evaluated the correlation between 2,5-HD, DMPN and DMPN NAC 
urinary levels and the motor activity performance in rats treated with 4 doses of 2,5-HD 
and co-treated with 4 doses of 2,5-HD+NAC. 
 In Chapter 5 the protection versus toxicity effects of NAC on 2,5-HD neurotoxicity was 
investigated increasing the number of administrated doses. Along the four weeks assay, 
motor activity performance, 2,5-HD, DMPN and DMPN NAC levels were evaluated, and 
after rats’ sacrifice, brain GSH and Cys levels were determined in all rats. 
 
Finally, in Chapter 6 a preliminary study was performed in human urine of an healthy and a sick 
population to investigate the presence of the identified pyrroles. 
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The results obtained in the experimental work of this thesis allowed us to synthesize the 
following final conclusions: 
 
FINAL CONCLUSIONS 
 
 DMPN, DMPN NAC and DMPN GSH were identified, for the first time by LC-MS/MS, 
in urine of rats treated with 2,5-HD. 
 
 In rats treated with 2,5-HD were quantified DMPN and DMPN NAC being DMPN 
presented in much higher levels than DMPN NAC in all analyzed urines, thus, DMPN 
may be suggested as an specific and sensitive biomarker of 2,5-HD exposure. 
 
 NAC decreases the excretion of urinary levels of 2,5-HD and DMPN and increases the 
excretion of DMPN NAC in rats co-treated with 2,5-HD+NAC as compared with their 
levels in rats treated with 4 doses of 2,5-HD alone. 
 
 NAC interferes on the reduction of motor activity performance observed in rats treated 
with 2,5-HD: until the 4 doses of co-treatment, NAC promotes the recovery of rearing 
and ambulation, with a progressive attenuation of motor activities recovery after 8 and 12 
doses of co-treatment. 
 
 The mechanism of NAC interference on 2,5-HD neurotoxicity may be suggested as a 
biphasic process: 
i) along the first 4 doses of co-treatment, a significant reduction of urinary free 
2,5-HD and DMPN levels may be an indicator of  DMPN decrease formation 
in axonium proteins, decreasing the probability of neurofilaments 
crosslinking which could explain the observed recovery of motor activities;  
ii) after the 4 doses co-treatment a progressive attenuation of motor activity 
recovery was observed with decrease of  DMPN excretion. This fact probably 
induces an accumulation of DMPN in axonium proteins with the subsequent 
increase of motor activity dysfunctions. 
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 The increase of DMPN NAC along the study in treated and co-treated rats, suggests that 
this pyrrole is a specific biomarker of 2,5-HD exposure. However, this compound is 
excreted in much lower levels than DMPN.   
 
 The well known persistence of DMPN NAC adducts, indicates that along the experiment, 
this aminopyrrole thiol conjugate may accumulate in axonal cytoskeletal proteins which 
in part contributes to the progressive increase of neurobehavior dysfunctions. 
 
 Finally the first results obtained in human urine of healthy and sick individuals suggest 
that DMPN may be detected in human urine in elder healthy and sick populations. 
 
 
FUTURE PERSPECTIVES 
 
In vivo models with Wistar rats at a longer period (8 weeks) of co-treatment with 2,5-HD+NAC 
to determine  DMPN and DMPN NAC  in urine, erythrocytes, sciatic nerve and brain.  
 
New battery of behavioral assays to accurately correlate the levels of determined pyrroles in 
biological samples with the changes in behavioral performance (for each dose). 
 
In vitro models to evaluate the mechanism of interaction of NAC with 2,5-HD using the human 
neuroblastoma line SK-N-SH to clarify the NAC threshold levels in protecting against 2,5-HD 
neurotoxicity. 
 
Identification and quantification of DMPN, DMPN NAC, and other pyrroles namely kripto-
pyrroles in urine of a larger group of individuals, patients (environmental or occupational 
exposed), with neurodegenerative diseases and in healthy individuals. 
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ANNEX 
 
STUDY OF STABILITY OF 2,5-DMP AND DMPN IN RAT URINE 
 
Before identifying the different pyrroles in urine we performed a preliminary study to investigate 
their stability in urine.  
Urine of animals of first in vivo study, rats treated with 3 doses of 2,5-HD. 
In the presence of oxidizing agents, or on account of their low stability, 2,5-DMP, may lead to 
formation of dimers and trimmers. Although they have not been synthesized, its presence was 
confirmed by the Daughters Scans of its precursor ions. 
 
 
MS/MS spectra of dimer and trimmer of 2,5-DMP 
 
In Figure 1 are shown the 2,5-DMP structures, dimer and trimmer. The molecular form and 
molecular weight is C12H16N2 and 188.27 g/mol for dimer, and C18H23N3 and 281.40 g/mol for 
trimmer. 
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Figure 1. Structures of dimer (A) and trimmer (B) of 2,5-DMP. 
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In Figure 2 (A and B) is shown the fragmentation of the precursor ion [M+H]
+
 at m/z 
corresponding to dimer and trimmer of pyrrole compound. In these mass spectra are presented 
the daughters scans of precursor ion m/z 189 for dimer (A) and the daughter scans of precursor 
ion m/z 282 for trimmer (B). 
 
 
 
Figure 2. MS/MS spectra of dimer and trimmer of the standard pyrrole compound, 2,5-DMP, obtained 
after the fragmentation of the molecular ion (m/z 189) (A) and (m/z 282) (B). 
 
 
Fragmentation of dimer and trimmer of 2,5-DMP at m/z 189 and m/z 282 originated several 
fragments, some common. For 2,5-DMP dimer, an ion fragment at m/z 174 corresponding to the 
loss of methyl group [M─CH3)]
+
, another at m/z 94 corresponding to the 2,5-dimethylpyrrole 
fragment. For precursor ion m/z 282, an ion fragment at m/z 267 corresponding to the loss of 
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methyl group [M─CH3)]
+
, another at m/z 187 corresponding to the fragment of dimer of 2,5-
dimethylpyrrol and at m/z 94 corresponding to the 2,5-dimethylpyrrole fragment. 
These compounds, dimers and trimmers of 2,5-DMP were detected in urine however were not 
quantified. 
 
 
Standard 2,5-DMP Solution in Control Urine 
 
The stability of 2,5-DMP in urine matrix was studied knowing that this compound easily 
undergoes dimerization and trimmerization reactions (Zhu et al., 1995, 1997). 
 
Thus, we used a pool of urines of control rats added of 2,5-DMP standard solution which were 
analyzed over time by LC-MS/MS. In Figure 3 is shown the TIC chromatogram of 2,5-DMP 
with a concentration of 100 ppm in a pool of urine of a control group (II) of rats. It was found 
that after 32 h, the peak of 2,5-DMP (Rt~18.7 min) decreases nearly for half height.  
 
In Figure 4 it is observed the overlapping of the peaks resulting from the analysis of the test 
solution, over the time. It is noted a significant decrease in the peak with Rt=18.67 minutes and 
an increase of the peak at Rt=15.66 min. No change in signal intensity, relative to the compound 
with a retention time at Rt=13.54 min, was found. 
 
The decrease of 2,5-DMP was also tested with other urine pools using a lower concentration of 
2,5-DMP solution. After 32 hours, for a 10 ppm solution of 2,5-DMP in a pool of urine rats of 
group II a decrease of ~50% in 2,5-DMP concentration was found. 
 
In Figure 5 it is shown the peaks of the 10 ppm 2,5-DMP solution, under N2 atmosphere, over 
the time. It is noted a relative decrease in the peak with Rt~18.6 minutes, and an increase of the 
peak at Rt~15.5 min. There seems no change in signal intensity, relative to the compound with a 
retention time at 13.9 min.  
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Figure 3. TIC chromatograms of pyrrole compound with a concentration of 100 ppm in a pool of urine of 
a group of control rats, over the time. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Overlapping of the peaks resulting from TIC chromatograms of pyrrole compound with a 
concentration of 100 ppm in a pool of urine of a group of control rats, over the time. 
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Figure 5. TIC chromatograms of pyrrole compound with a concentration of 10 ppm in 2,5-DMP (in N2) 
in a pool of urine of a group II of rats, over the time. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Overlapping of the peaks resulting from TIC chromatograms of pyrrole compound with a 
concentration of 10 ppm of 2,5-DMP, under N2 atmosphere, in a pool of urine of a group of control rats 
over the time. 
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In Figure 6 we can observe the overlapping of the peaks, over the time. Now, it can be seen a 
significant decrease in the band with Rt~18.6 minutes. The band at Rt~15.5 min there seems no 
change in signal intensity. 
 
DMPN in Urine of Exposed Rat 
 
Unlike the compound 2,5-DMP, the pyrrole DMPN presents itself as a stable compound over 
time. The study was conducted using a pool of urines of rats exposed to 3 doses (400 mg 2,5-
HD/kg/48-h) which was analyzed by LC-MS/MS. 
 
In Figure 7 is shown the TIC chromatogram of DMPN in a pool of urine of rats of Group I (for 3 
doses). It was found that after 48 h, the peak of DMPN (Rt~13,7 min) don’t decreases and 
continues to present the same intensity presented at time 0 h. 
 
 
 
Figure 7. TIC chromatograms of pyrrole compound DMPN in a pool of urine of group I of rats, over 
time. 
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Conclusion: 
 
Unlike the compound 2,5-DMP, the pyrrole DMPN presents itself as a stable compound over 
time. 
It is shown the peaks of the 10 ppm DMP solution, under N2 atmosphere, over the time. It is 
noted a relative decrease in the peak with Rt~18.6 minutes, and an increase of the peak at 
Rt~15.5 min (Fig. 4). Even under N2 atmosphere, DMP may form others compounds, probably 
dimmer and/or trimmers. 
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